LINC Complex Inhibiting Polypeptides

By developing a polypeptide encoding LINC complex inhibition, including specific SUN domain sequences and endoplasmic reticulum retention motifs, delivering using AAV vectors, successfully destroying the LINC complex at the cellular level, solving the development of LINC complex inhibitors in the prior art The problem of this problem provides an effective gene therapy solution.

CN118922436APending Publication Date: 2024-11-08AGENCY FOR SCI TECH & RES +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280090577.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2021-12-01
Filing Date
2022-11-30
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In the prior art, it is unclear whether the truncated variant of the SUN protein can effectively destroy the LINC complex, and its mechanism of action at the cellular level is unknown, making it difficult to develop effective LINC complex inhibitors.

Method used

Provides a LINC complex inhibitory polypeptide encoding an LINC complex containing amino acid sequences corresponding to the alpha 3 helical and SUN domains of the CC2 region and includes an endoplasmic reticulum retention motif delivered as gene therapy using these polypeptides to destroy LINC at the cellular level Complex.

Benefits of technology

Effective destruction of LINC complexes in vivo provides a new gene therapy strategy suitable for the treatment of laminosis and other related diseases, especially for medium-packing vector systems.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922436A_ABST
    Figure CN118922436A_ABST
Patent Text Reader

Abstract

The present invention relates to a nucleic acid encoding a dominant SUN domain inhibitory polypeptide comprising a CC2 region a3 helix and a SUN domain-containing protein, capable of inhibiting LING complexes. Particular embodiments relate to polypeptides of different lengths derived from amino acids 404-812 of SUN1 having a KDEL signal sequence. The invention also relates to a method for identifying inhibitors of the LING complex and to the use of the polypeptides for the treatment and prevention of laminopathy and diseases characterized by hyperlipidemia.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to SG 10202113391P filed on December 1, 2021, the contents and elements of which are incorporated herein by reference for all purposes. Technical Field

[0002] The present disclosure relates to the fields of molecular and cellular biology, and also to methods of medical treatment and prevention. Background Art

[0003] Lamin A / C is a component of the nuclear lamina located beneath the inner nuclear membrane and is thought to provide mechanical support to the nucleus (Burke and Stewart, 2013). Mutations in LMNA, encoding lamins A and C, lead to a number of diseases known as laminopathies. Disruption of the nucleoskeleton and cytoskeletal linker (LINC) complex is a recently proposed strategy for treating laminopathies. The LINC complex consists of SUN domain proteins at the inner nuclear membrane and KASH domain proteins at the outer nuclear membrane (Lee and Burke, 2018). Paralogs Sun1 and Sun2 are the major SUN domain proteins that are widely expressed in mammalian tissues. Among the KASH domain proteins, Nesprin-1, Nesprin-2, and Nesprin-3 are the most widely expressed.

[0004] Crisp et al., 2006 described disruption of the LINC complex by overexpression of a dominant negative form of the mouse Sun1 (DNSun1) protein. DNSun1 includes the entire luminal domain of Sun1, the N-terminal signal sequence, and the C-terminal Golgi to ER retention sequence KDEL. It is thought to act by disrupting the SUN-KASH interaction within the LINC complex, perhaps by competing with endogenous SUN domain-containing proteins (such as Sun1 and Sun2) for binding to KASH domain-containing proteins. Unlike wild-type Sun1, DNSun1 is not anchored to the nuclear lamina, so forces from the cytoskeleton transmitted to the KASH domain proteins are not further transmitted to the nuclear interior through DNSun1. A humanized version of DNSun1 is described in WO 2019 / 143300A1.

[0005] The coding sequence of DNSUN1 is relatively large (~1.5 kb), which poses a challenge to its delivery (e.g., as gene therapy). For example, in the self-complementary adeno-associated viral vector (scAAV) system, the entire transgene, including the viral inverted terminal repeats (ITRs), the promoter and other regulatory sequences, and the coding sequence itself, cannot exceed 2.3 kb.

[0006] The C-terminal SUN structure of SUN domain-containing proteins has been shown to be necessary but not sufficient for interaction with KASH domain-containing proteins, and trimerization of the SUN domain mediated by upstream helical and coiled regions is thought to be required for interaction with KASH (Sosa et al., 2012; Wang et al., 2012; Zhou et al., 2012, Jahed et al., 2018b; Nie et al., 2016; Xu et al., 2018).

[0007] Zhou et al., 2012 and Sosa et al., 2012 demonstrated that lumenal SUN constructs truncated before the start of the CC1 domain were able to bind to KASH domain proteins. Zhou et al., 2012, Wang et al., 2012, Jahed et al., 2018b and Nie et al., 2016 showed that constructs containing CC1-CC2-SUN were able to form trimers in gel filtration assays or interact with the KASH domain in pull-down assays. Zhou et al., 2012 and Jahed et al., 2018b further showed that truncations starting in the middle of the CC1 domain and containing CC2 and SUN did not interact with KASH in pull-down assays and formed monomers in gel filtration assays. Wang et al., 2012 and Nie et al., 2016 showed that CC2-SUN constructs also did not interact with KASH in vitro and only formed monomers in gel filtration assays.

[0008] While most studies have focused on SUN2, there is a high degree of sequence conservation between SUN1 and SUN2, particularly in their lumenal domains, and in studies conducted on SUN1 itself, there is significant conservation between SUN1 and SUN2 at the structural level (Xu et al., 2018; Gurusaran and Davies, 2021).

[0009] Importantly, there are conflicting reports on whether certain truncated SUN protein variants that include the lumenal domain are able to form trimers and interact with KASH domain proteins (Jahed et al., 2018a).

[0010] In the studies of Zhou et al., 2012 and Wang et al., 2012, a Sun2 truncation variant consisting of sites G522 to H717 was able to interact with KASH domain-containing proteins (determined by co-immunoprecipitation analysis), and a Sun2 truncation variant consisting of sites V520 to H717 was able to form trimers and was used to solve the SUN trimer structure by X-ray crystallography (SUN trimer formation is considered to be required for binding to KASH domain-containing proteins). Nie et al., 2016 determined that removal of the α1 (α2-α3-SUN) or α1 and α2 (α3-SUN) helices from CC2-SUN abolished the autoinhibitory function of CC2, and the resulting Sun2 constructs could interact with KASH domain proteins. Interestingly, while α2-α3-SUN formed trimers in gel filtration assays, α3-SUN was a mixture of monomers and trimers.

[0011] In contrast, Sosa et al., 2012 reported that while a SUN2 truncated variant consisting of positions 507 to 717 (corresponding to α2-α3-SUN) was able to bind to the KASH domain, further truncations resulted in weak (in the case of the SUN2(514-717) truncated variant) or negligible (in the case of the SUN2(521-717) truncated variant, which corresponds to α3-SUN) binding to the KASH domain. Although the literature has investigated how truncations of the lumenal domain of SUN proteins affect binding to KASH, it is unclear whether trimer formation and in vitro KASH domain binding can predict the ability to disrupt the LINC complex at the cellular level.

[0012] Therefore, it is unclear which truncations of the SUN lumenal region can serve as agents for LINC complex disruption. Summary of the invention

[0013] In a first aspect, the present disclosure provides a nucleic acid encoding a LINC complex inhibitory polypeptide, wherein the LINC complex inhibitory polypeptide comprises: (i) an inhibitory region comprising an amino acid sequence corresponding to the α3 helix of the CC2 region and the SUN region of a protein containing a SUN domain, and (ii) an endoplasmic reticulum retention motif; and wherein the LINC complex inhibitory polypeptide does not comprise the amino acid sequence of any one of SEQ ID NO:43, 45 or 58.

[0014] In some embodiments, the inhibitory region of the LINC complex inhibitory polypeptide does not consist essentially of the amino acid sequence of SEQ ID NO: 44 or 46. In some embodiments, the inhibitory region of the LINC complex inhibitory polypeptide does not consist essentially of the amino acid sequence of SEQ ID NO: 49, 50, 51, 52, 53, 54, 55, 56, 57, 59, 60, 61, or 62.

[0015] In some embodiments, the inhibitory region of a LINC complex inhibitory polypeptide consists essentially of:

[0016] (i) an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 66;

[0017] (ii) an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO:94; or

[0018] (iii) an amino acid sequence that has at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 65; or

[0019] (iv) an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 63; or

[0020] (v) an amino acid sequence that has at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO:64; or (vi) an amino acid sequence that has at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO:67.

[0021] In some embodiments, the LINC complex inhibitory polypeptide comprises or consists essentially of:

[0022] (i) an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 72;

[0023] (ii) an amino acid sequence that has at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO:95; or

[0024] (iii) an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 71; or

[0025] (iv) an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 69; or

[0026] (v) an amino acid sequence that has at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO:70; or (vi) an amino acid sequence that has at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO:73.

[0027] In some embodiments, the LINC complex inhibitory polypeptide includes a signal peptide. In some embodiments, the nucleic acid is a vector suitable for delivering a nucleic acid encoding a LINC complex inhibitory polypeptide as a gene therapy. In some embodiments, the vector is an adeno-associated virus (AAV) vector.

[0028] The present disclosure also provides a LINC complex inhibitory polypeptide, comprising: (i) an inhibitory region comprising an amino acid sequence corresponding to the α3 helix of the CC2 region and the SUN domain of a protein containing a SUN domain, and (ii) an endoplasmic reticulum retention motif;

[0029] And the LINC complex inhibitory polypeptide does not comprise the amino acid sequence of SEQ ID NO: 43 or 45.

[0030] In some embodiments, the inhibitory region of the LINC complex inhibitory polypeptide does not consist essentially of the amino acid sequence of SEQ ID NO: 44 or 46. In some embodiments, the LINC complex inhibitory polypeptide of claim 9 or claim 10, wherein the inhibitory region of the LINC complex inhibitor polypeptide does not consist essentially of the amino acid sequence of SEQ ID NO: 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61 or 62.

[0031] In some embodiments, the inhibitory region of a LINC complex inhibitory polypeptide consists essentially of:

[0032] (i) an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 66;

[0033] (ii) an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO:94; or

[0034] (iii) an amino acid sequence that has at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 65; or

[0035] (iv) an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 63; or

[0036] (v) an amino acid sequence that has at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 64; or

[0037] (vi) an amino acid sequence having at least 80% amino acid sequence identity with the amino acid sequence of SEQ ID NO:67.

[0038] In some embodiments, the LINC complex inhibitory polypeptide comprises or consists essentially of:

[0039] (i) an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 72;

[0040] (ii) an amino acid sequence that has at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO:95; or

[0041] (iii) an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 71; or

[0042] (iv) an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 69; or

[0043] (v) an amino acid sequence that has at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO:70; or (vi) an amino acid sequence that has at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO:73.

[0044] In some embodiments, the LINC complex inhibitory polypeptide includes a signal peptide.

[0045] The present disclosure also provides a method for identifying a LINC complex inhibitory polypeptide, comprising:

[0046] introducing a nucleic acid encoding a candidate LINC complex inhibitory polypeptide comprising an amino acid sequence corresponding to a SUN domain of a SUN domain-containing protein; and

[0047] The cells were then analyzed to determine the subcellular localization of the interacting partners of the SUN domain-containing proteins;

[0048] Wherein, when a change in the subcellular localization of an interacting partner of a SUN domain-containing protein is detected, the candidate LINC complex inhibitory polypeptide is identified as a LINC complex inhibitory polypeptide.

[0049] The present disclosure also provides a method for identifying a LINC complex inhibitory polypeptide, comprising:

[0050] introducing a nucleic acid encoding a candidate LINC complex inhibitory polypeptide comprising an amino acid sequence corresponding to a KASH domain of a KASH domain-containing protein; and

[0051] The cells were then analyzed to determine the subcellular localization of the interacting partners of the KASH domain-containing proteins;

[0052] Wherein, when a change in the subcellular localization of an interacting partner of a KASH domain-containing protein is detected, the candidate LINC complex inhibitory polypeptide is identified as a LINC complex inhibitory polypeptide.

[0053] In some embodiments, when an increase in the proportion of interacting partners of a SUN / KASH domain-containing protein localized in the endoplasmic reticulum is detected, the candidate LINC complex inhibitor polypeptide is identified as a LINC complex inhibitor polypeptide.

[0054] The present disclosure also provides LINC complex inhibitory polypeptides identified by the methods according to the present disclosure.

[0055] The present disclosure also provides nucleic acids encoding the LINC complex inhibitory polypeptides of the present disclosure.

[0056] The present disclosure also provides a vector comprising the nucleic acid of the present disclosure, which is suitable for delivering the nucleic acid encoding the LINC complex inhibitory polypeptide as a vector for gene therapy.

[0057] In some embodiments, the vector is an adeno-associated virus (AAV) vector.

[0058] The present disclosure also provides cells comprising the nucleic acid, LINC complex inhibitory polypeptide or vector of the present disclosure.

[0059] The present disclosure also provides a pharmaceutical composition comprising the nucleic acid, LINC complex inhibitory polypeptide, vector or cell of the present disclosure.

[0060] The present disclosure also provides a method for using the nucleic acid, LINC complex inhibitory polypeptide, vector, cell or pharmaceutical composition of the present disclosure for drug treatment or prevention.

[0061] The present disclosure also provides a method for using the nucleic acid, LINC complex inhibitory polypeptide, vector, cell or pharmaceutical composition of the present disclosure for treating or preventing laminopathy.

[0062] The present disclosure also provides use of the nucleic acid, LINC complex inhibitory polypeptide, vector, cell or pharmaceutical composition of the present disclosure in the preparation of a medicament for treating or preventing laminopathy.

[0063] The present disclosure also provides a method for treating or preventing laminopathy, comprising administering to a subject a therapeutically effective amount or a preventively effective amount of a nucleic acid, a LINC complex inhibitory polypeptide, a vector, a cell or a pharmaceutical composition of the present disclosure.

[0064] In some embodiments of various aspects of the present disclosure, the laminopathy is characterized by one or more of myopathy, cardiomyopathy, dilated cardiomyopathy, muscular dystrophy, cardiac myodystrophy, skeletal muscular dystrophy, progeria, neuropathy, lipoatrophy, skeletal dysplasia, lipodystrophy, leukodystrophy, or skin disease. In some embodiments, the laminopathy is associated with a mutation in LMNA. In some embodiments, the laminopathy is selected from: Hutchinson-Gilford Progeria Syndrome; Dilated Cardiomyopathy; Muscular Dystrophy, Congenital, Lmna-Associated; Emery Dreifuss muscular dystrophy type 2, autosomal dominant; muscular dystrophy; mandibular dysplasia with lipodystrophy type a; dilated cardiomyopathy, 1a; Charcot-Marie-Tooth disease; limb girdle muscular dystrophy; dilated cardiomyopathy with hypogonadism; Emery Dreifuss muscular dystrophy type 3, autosomal recessive; lipodystrophy, familial partial, type 2; Emery Dreifuss muscular dystrophy; Charcot-Marie-Tooth disease, axonal type, type 2b1; heart-hand syndrome, Slovenian type; senescence; Familial partial lipodystrophy; restrictive skin disease, lethal; arrhythmogenic right ventricular cardiomyopathy; dental disease; heart disease; Werner syndrome; hypertrophic cardiomyopathy; left ventricular nonfilling; atrioventricular block; calcifications; acroosteolysis; autosomal dominant acromuscular dystrophy; diabetes mellitus, non-insulin-dependent; osteoporosis; atrial fibrillation; atrial standstill 1; acanthosis nigricans; cardiac conduction defects; catecholaminergic polymorphism ventricular tachycardia; mandibular dysplasia, deafness, prodromal features, and lipodystrophy syndrome; sick sinus syndrome; Pelger Huet anomaly; Charcot-Marie-Tooth disease, axonal type, type 2e; congenital generalized lipodystrophy; restrictive cardiomyopathy; congenital dysproportion of fiber type; lipodystrophy, congenital generalized, type 1; myofibrillar myopathy; lipodystrophy, familial partial, type 1; axonal neuropathy; atypical Werner syndrome; ovarian cystadenoma; Fanconi anemia, complement group a; body mass index quantitative trait locus 11; skin diseases; myotonic spinal muscular dystrophy 1 case; neuromuscular diseases; craniofacial dysmorphism syndrome;

[0065] Bethlem myopathy 1; acquired generalized lipodystrophy; dilated cardiomyopathy, 1e; lipodystrophy, congenital generalized, type 4; undifferentiated pleomorphic sarcoma; lipodystrophy, familial partial, type 3; muscular dystrophy, congenital carnosine deficiency, 1a; proximal cord muscular atrophy; muscular dystrophy polysaccharide disorder, type B, 5; congenital muscular dystrophy, 1b; Reynolds syndrome; Wiedemann-Rautenstrauch syndrome; Emery Dreifuss muscular dystrophy 1, X-linked; lipodystrophy, congenital generalized, type 2; monogenic diabetes mellitus; dilated cardiomyopathy, 1d; myopia, proximal and ophthalmoplegia; muscle tissue disease; lipodystrophy, familial partial, type 4; dilated cardiomyopathy, 1h; second degree atrioventricular block; median neuropathy; intrinsic cardiomyopathy; female genital organ prolapse; complete generalized lipodystrophy; myotonic spinal muscular dystrophy; emergency; ulnar nerve injury; limb muscular dystrophy type 1b;

[0066] Lmna-related dilated cardiomyopathy; pelvic muscle wasting; generalized lipodystrophy-related progestogen syndrome; muscle disease; dilated cardiomyopathy, 1b; autosomal genetic disorders; familial isolated arrhythmogenic ventricular dysplasia, right dominant; familial isolated arrhythmogenic ventricular dysplasia, biventricular type; familial isolated arrhythmogenic ventricular dysplasia, left dominant; Lmna-related premature carpel syndrome; and autosomal semidominant severe lipodystrophy laminopathy.

[0067] The present disclosure also provides a method for using the nucleic acid, LINC complex inhibitory polypeptide, vector, cell or pharmaceutical composition of the present disclosure to treat or prevent a disease characterized by hyperlipidemia.

[0068] The present disclosure also provides use of the nucleic acid, LINC complex inhibitory polypeptide, vector, cell or pharmaceutical composition of the present disclosure in the preparation of a medicament for treating or preventing a disease characterized by hyperlipidemia.

[0069] The present disclosure also provides a method for treating or preventing a disease characterized by hyperlipidemia, comprising administering to a subject a therapeutically effective amount or a preventively effective amount of the nucleic acid, LINC complex inhibitory polypeptide, vector, cell or pharmaceutical composition of the present disclosure.

[0070] In some embodiments of various aspects of the present disclosure, the disease characterized by hyperlipidemia is selected from atherosclerosis, cardiovascular disease, stroke, and familial hyperlipidemia.

[0071] describe

[0072] The present disclosure is based on the unexpected discovery of the inventors that, although it has been reported in the prior art that various truncated variants of the lumenal domain of SUN domain-containing proteins cannot bind to KASH domain-containing proteins and are therefore believed not to function as LINC complex inhibitors, a wide range of such truncated variants actually function as LINC complex inhibitors.

[0073] Using a cell-based assay to determine LINC complex disruption by observing disruption of the normal subcellular localization of endogenous KASH domain-containing proteins (specifically, where KASH domain-containing proteins localize to the endoplasmic reticulum rather than the nuclear membrane following LINC complex disruption), the inventors demonstrated that various truncations corresponding to the lumenal domain of SUN domain-containing proteins, as well as polypeptides comprising different structural motifs thereof (i.e., coiled-coil regions, alpha helices thereof) were able to affect LINC complex disruption. The inventors further demonstrated that various dominant negative LINC complex-inhibiting polypeptides delivered by AAV as gene therapy reduced the pathology of dilated cardiomyopathy (DCM) in vivo in a DCM mouse model established by cardiomyocyte-specific deletion of Lmna.

[0074] The present disclosure provides a large number of LINC complex inhibitory polypeptides suitable for use in applications related to existing and future gene therapy technologies. In particular, LINC complex inhibitory polypeptides smaller in size than the protein construct containing a dominant negative SUN domain described in WO 2019 / 143300A1 are more suitable for use in vector systems with medium packaging limits, such as scAAV vectors with a packaging limit of ~2.3 kb.

[0075] Structure and function of the LINC complex

[0076] The nucleoskeleton and cytoskeleton linker (LINC) complex is a polypeptide complex comprising a protein containing a SUN domain and a protein containing a KASH domain. The structure of the LINC complex is reviewed in, for example, Sosa et al., Curr Opin Struct Biol. (2013) 23(2): 285-91 and Hieda, Cells (2017) 6(1): 3 and Hieda, Cells (2017) 6(1): 3, both of which are incorporated herein by reference in their entirety.

[0077] The LINC complex connects the inner nuclear membrane (INM) and the outer nuclear membrane (ONM) of the nuclear envelope. SUN domain-containing proteins span the INM and associate with lamins and chromatin-binding proteins on the nucleoplasmic side of the INM and with KASH domain-containing proteins on the perinuclear side of the INM. KASH domain-containing proteins span the ONM and associate with cytoskeletal structural components such as actin filaments, microtubule motors, and intermediate filaments on the cytoplasmic side of the ONM, as well as with SUN domain-containing proteins on the perinuclear side of the ONM. SUN domain proteins function as transluminal tethers for KASH domain proteins in the ONM.

[0078] Here, "protein containing SUN domain" refers to any polypeptide containing SUN domain. S ad1 and UN C-84) domain proteins are important INM components and include a conserved carboxyl-terminal SUN domain that is localized in the perinuclear space. The SUN domain contains approximately 175 residues and is located at the end of the helical stem region. The nucleoplasmic domain of the SUN protein interacts with structural components of the nucleus skeleton.

[0079] The SUN domain may comprise or consist of the amino acid sequence shown in SEQ ID NO:5, 14, 27, 28, 29 or 30, or an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence shown in SEQ ID NO:5, 14, 27, 28, 29 or 30.

[0080] In some embodiments, the SUN domain-containing protein is selected from the group consisting of SUN1, SUN2, SUN3, SUN5, SPAG4, and SUCO.

[0081] In some embodiments, the SUN domain-containing protein is SUN1 or SUN2.

[0082] In some embodiments, the SUN domain-containing protein is capable of forming a LINC complex. In some embodiments, the SUN domain-containing protein is capable of interacting with a KASH domain and / or a KASH domain-containing protein.

[0083] Human SUN1 is a polypeptide with the ID UniProtKB O94901, and its amino acid sequence is shown in SEQ ID NO: 1. Human SUN2 is a polypeptide with the ID UniProtKB Q9UH99, and its amino acid sequence is shown in SEQ ID NO: 13. Human SUN3 is a polypeptide with the ID UniProtKB Q8TAQ9, and its amino acid sequence is shown in SEQ ID NO: 23. Human SUN5 is a polypeptide with the ID UniProtKBA9Z1W8, and its amino acid sequence is shown in SEQ ID NO: 24. Human SPAG4 is a polypeptide with the ID UniProtKB Q9NPE6, and its amino acid sequence is shown in SEQ ID NO: 25. Human SUCO is a polypeptide with the ID UniProtKB Q9UBS9, and its amino acid sequence is shown in SEQ ID NO: 26.

[0084] In the present specification, "SUN1", "SUN2", "SUN3", "SUN5", "SPAG4" and "SUCO" refer to SUN1, SUN2, SUN3, SUN5, SPAG4 and SUCO of any species, respectively, including isomers, fragments, variants or homologs thereof.

[0085] As used herein, a "fragment", "variant" or "homologue" of a protein may optionally be characterized as having at least 60%, preferably 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity with the amino acid sequence of a reference protein (e.g., a reference isoform of a reference protein). In some embodiments, a fragment / variant / isomer / homologue may be characterized by the ability to perform a function performed by a reference protein.

[0086] "Fragment" generally refers to a portion of a reference protein. "Variant" generally refers to a protein having an amino acid sequence that contains one or more amino acid substitutions, insertions, deletions or other modifications relative to the amino acid sequence of a reference protein, but maintains a considerable degree of sequence identity (e.g., at least 60%) with the amino acid sequence of the reference protein. "Isoform" generally refers to a reference protein variant expressed by the same species as the reference protein species. "Homolog" generally refers to a variant of a reference protein produced by a different species compared to the species of the reference protein. Homologs include orthologs.

[0087] A "fragment" can be of any length (in terms of number of amino acids), although it can optionally be at least 20% of the length of a reference protein (i.e., the protein from which the fragment is derived), and can be up to one of 50%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of the length of the reference protein.

[0088] An isomer, fragment, variant or homologue may optionally be a functional isomer, fragment, variant or homologue, eg, having a functional property / activity of a reference protein as determined by analysis in an appropriate functionality / activity assay.

[0089] In the present specification, "SUN1" refers to a protein having an amino acid sequence as shown in SEQ ID NO: 1 and a fragment, variant or homolog thereof. In some embodiments, SUN1 comprises or consists of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity with SEQ ID NO: 1.

[0090] In the present specification, "SUN2" refers to a protein having an amino acid sequence as shown in SEQ ID NO: 13 and a fragment, variant or homolog thereof. In some embodiments, SUN2 comprises or consists of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity with SEQ ID NO: 13.

[0091] In the present specification, "SUN3" refers to a protein having an amino acid sequence as shown in SEQ ID NO: 23 and a fragment, variant or homolog thereof. In some embodiments, SUN3 comprises or consists of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity with SEQ ID NO: 23.

[0092] In the present specification, "SUN5" refers to a protein having an amino acid sequence as shown in SEQ ID NO: 24 and a fragment, variant or homolog thereof. In some embodiments, SUN5 comprises or consists of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity with SEQ ID NO: 24.

[0093] In the present specification, "SPAG4" refers to a protein having an amino acid sequence as shown in SEQ ID NO: 25 and a fragment, variant or homologue thereof. In some embodiments, SPAG4 comprises or consists of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity with SEQ ID NO: 25.

[0094] In the present specification, "SUCO" refers to a protein having an amino acid sequence as shown in SEQ ID NO: 26 and a fragment, variant or homolog thereof. In some embodiments, SUCO comprises or consists of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity with SEQ ID NO: 26.

[0095] Here, "protein containing KASH domain" refers to any polypeptide containing KASH domain. KASH (Klarsicht, ANC-1, Syne homology) domain proteins are carboxyl-terminally anchored membrane proteins that target the nuclear membrane. A 50-60 amino acid KASH domain is found at the C-terminus. The KASH domain is hydrophobic and includes a single transmembrane helix that spans the ONM and a region of approximately 30 amino acids that extends into the perinuclear space.

[0096] The KASH domain may comprise or consist of the amino acid sequence shown in SEQ ID NO:37, 38, 39, 40, 41 or 42, or an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence shown in SEQ ID NO:30, 38, 39, 40, 41 or 42.

[0097] In some embodiments, the protein containing a KASH domain is selected from Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4 (also known as SYNE1, SYNE2, SYNE3 and SYNE4, respectively), KASH5 and LRMP. In some embodiments, the protein containing a KASH domain is Nesprin-1, Nesprin-2 or Nesprin-3.

[0098] In some embodiments, the KASH domain-containing protein is capable of forming a LINC complex. In some embodiments, the KASH domain-containing protein is capable of interacting with a SUN domain and / or a protein containing a SUN region.

[0099] Human Nesprin-1 is a polypeptide with the ID UniProtKB Q8NF91, and its amino acid sequence is shown in SEQ ID NO: 31. Human Nesprin-2 is a polypeptide with the ID UniProtKB Q8WXH0, and its amino acid sequence is shown in SEQ ID NO: 32. Human Nesprin-3 is a polypeptide with the ID UniProtKB Q6ZMZ3, and its amino acid sequence is shown in SEQ ID NO: 33. Human Nesprin-4 is a polypeptide with the ID UniProtKB Q8N205, and its amino acid sequence is shown in SEQ ID NO: 34. Human KASH5 is a polypeptide with the ID UniProtKB Q8N6L0, and its amino acid sequence is shown in SEQ ID NO: 35. Human LRMP is a polypeptide with the ID UniProtKB Q12912, and its amino acid sequence is shown in SEQ ID NO: 36.

[0100] In the present specification, "Nesprin-1", "Nesprin-2", "Nesprin-3", "Nesprin-4", "KASH5" and "LRMP" refer to Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4, KASH5 and LRMP of any species, respectively, including isomers, fragments, variants or homologs thereof.

[0101] In the present specification, "Nesprin-1" refers to a protein having an amino acid sequence as shown in SEQ ID NO: 31 and a fragment, variant or homolog thereof. In some embodiments, Nesprin-1 comprises or consists of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity with SEQ ID NO: 31.

[0102] In the present specification, "Nesprin-2" refers to a protein having an amino acid sequence as shown in SEQ ID NO: 32 and a fragment, variant or homolog thereof. In some embodiments, Nesprin-2 comprises or consists of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity with SEQ ID NO: 32.

[0103] In the present specification, "Nesprin-3" refers to a protein having an amino acid sequence as shown in SEQ ID NO: 33 and a fragment, variant or homolog thereof. In some embodiments, Nesprin-3 comprises or consists of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity with SEQ ID NO: 33.

[0104] In the present specification, "Nesprin-4" refers to a protein having an amino acid sequence as shown in SEQ ID NO: 34 and a fragment, variant or homolog thereof. In some embodiments, Nesprin-4 comprises or consists of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity with SEQ ID NO: 34.

[0105] In the present specification, "KASH5" refers to a protein having an amino acid sequence as shown in SEQ ID NO: 35 and a fragment, variant or homolog thereof. In some embodiments, KASH5 comprises or consists of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity with SEQ ID NO: 35.

[0106] In the present specification, "LRMP" refers to a protein having an amino acid sequence as shown in SEQ ID NO: 36 and a fragment, variant or homolog thereof. In some embodiments, the LMRP comprises or consists of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity with SEQ ID NO: 36.

[0107] As used herein, "LINC complex" refers to a polypeptide complex comprising a SUN domain-containing protein and a KASH domain-containing protein.

[0108] The LINC complex is formed by protein-protein interactions between proteins containing SUN domains and proteins containing KASH domains. The LINC complex can include non-covalent and / or covalent interactions between the SUN domains and the KASH domains. Non-covalent interactions include, for example, hydrogen bonds, ionic interactions, van der Waals forces, and hydrophobic bonds. Covalent interactions include, for example, disulfide bonds.

[0109] SUN domain proteins are thought to oligomerize to form trimers through interactions between their stem regions to form a coiled-coil triple helix (Zhou et al., J. Biol. Chem. (2012) 287: 5317-5326). Deletion of the stem region of SUN domain proteins has been shown to disrupt the formation of LINC complexes. The SUN domain presents a β sandwich structure, and the SUN domain portions of the trimer interact extensively through a protruding β fold called the KASH cover; the KASH cover of one SUN domain overlaps the β sandwich portion of the adjacent SUN domain (Sosa et al., Cell (2012) 149: 1035-1047).

[0110] KASH domain proteins can also oligomerize, which may involve protein-protein interactions between transmembrane helices. A single KASH domain interacts with two adjacent SUN domains along the groove formed between the KASH lid of a SUN domain and the upper region of the β sandwich fold of the adjacent SUN domain. In this way, the SUN and KASH domains are thought to interact to form a 3:3 hexameric heterocyclic complex. The 2-3 proline residues immediately before the C-terminus of the KASH domain are thought to be accommodated in a deep pocket within the surface of the SUN domain. This region of KASH is important for the interaction of SUN-KASH; extending the C-terminus by only one amino acid disrupts the formation of the LINC complex. The conserved cysteine ​​residues of the SUN and KASH domains form disulfide bonds, further stabilizing the SUN-KASH complex. Disulfide bonds may be important for force transmission through the LINC complex (Jahed et al., Biophys. J. (2015) 109: 501-509).

[0111] As mentioned above, the LINC complex is thought to be formed through the interaction of the SUN structures of three SUN domain-containing proteins and the KASH structures of three KASH domain-containing proteins. The interactions between SUN and KASH domain proteins are thought to be promiscuous; SUN1 and SUN2 have been shown to interact with Nesprin-1, Nesprin-2, and Nesprin-3.

[0112] The LINC complex according to the present disclosure may include any protein containing a SUN domain and any protein containing a KASH domain. The proteins containing a SUN domain in the LINC complex may be the same or different. The proteins containing a KASH domain in the LINC complex may be the same or different.

[0113] The function of the LINC complex is reviewed in, for example, Hieda, Cells (2017) 6(1):3 (incorporated above by reference) and Stroud, Biophys Rev. (2018) 10(4):1033-1051, which are incorporated herein by reference in their entireties.

[0114] The LINC complex has multiple functions, including providing structural support to the nucleus, shaping and positioning the nucleus, maintaining the connection between the centrosome and the nucleus and the spacing of the nuclear membrane, DNA repair, cell migration, and the movement of chromosomes within the nucleus during meiosis.

[0115] The LINC complex has a stress-sensing function and can convert mechanical stimulation and changes in the extracellular matrix into signals, allowing cells to adapt to the environment by regulating cytoskeleton organization, gene expression, nuclear organization and structure.

[0116] Integrins mediate the transmission of forces from the external microenvironment to the intracellular cytoskeleton, and nuclear-cytoskeletal molecular connections transmit forces to the chromosome organization in the nucleus. The nuclear lamina triggers deformation of the nuclear structure and initiates changes in gene regulation.

[0117] The nuclear envelope is a key structure in this process. On the nucleoplasmic side of the INM, the nuclear lamina (composed of A- and B-type lamina) forms a lattice structure that contributes to the mechanical stress resistance of the nucleus and is essential for the structural integrity of the nuclear membrane. Lamins are involved in processes that are essential for cellular function and viability, including maintenance of nuclear integrity, regulation of the cell cycle, mechanotransduction, cell signaling, and DNA repair.

[0118] Deviations from the normal expression and / or function of nuclear envelope proteins, as well as factors directly or indirectly associated with the nuclear envelope, are associated with a variety of diseases, including muscular dystrophy, cardiomyopathy, lipodystrophy, progeria, cancer, and neurological disease.

[0119] LINC complex inhibitory peptide

[0120] The present disclosure relates to LINC complex inhibitory polypeptides. Here, "LINC complex inhibitory polypeptide" refers to a polypeptide that inhibits the formation and / or function of the LINC complex.

[0121] The LINC complex inhibitory polypeptides disclosed herein can:

[0122] Bind to the constituent proteins of the LINC complex (e.g., proteins containing a KASH domain, such as Nesprin-1, Nesprin-2,

[0123] One or more of Nesprin-3, Nesprin-4, KASH5, and LRMP);

[0124] Inhibit interactions between the constituent proteins of the LINC complex (e.g., interactions between SUN domain-containing proteins and KASH domain-containing proteins);

[0125] inhibits the formation of a LINC complex (i.e., it can inhibit the assembly of a LINC complex; for example, a LINC complex comprising a SUN domain-containing protein and a KASH domain-containing protein);

[0126] Disrupting a LINC complex (e.g., causing or promoting disassembly of a LINC complex, such as by replacement of one or more constituent proteins of the LINC complex; such as a LINC complex comprising a SUN domain-containing protein and a KASH domain-containing protein);

[0127] Disruption of normal subcellular localization of the constituent proteins of the LINC complex (e.g., the LINC complex comprising a SUN domain-containing protein and a KASH domain-containing protein);

[0128] Increase the localization of the constituent proteins of the LINC complex (e.g., the LINC complex comprising a SUN domain-containing protein and a KASH domain-containing protein) to the endoplasmic reticulum;

[0129] reducing the level of a LINC complex (e.g., a LINC complex comprising a SUN domain-containing protein and a KASH domain-containing protein);

[0130] Inhibiting the function / activity of a LINC complex (e.g., a LINC complex comprising a SUN domain-containing protein and a KASH domain-containing protein);

[0131] Increased survival in subjects with laminopathy;

[0132] Increased lifespan in subjects with laminopathy;

[0133] increase or inhibit decreased cardiac function in subjects with laminopathy;

[0134] increasing or inhibiting the reduction in cardiac contractility in subjects with laminopathy;

[0135] increasing or inhibiting the reduction in ejection fraction and / or fractional shortening in subjects with laminopathy;

[0136] Reducing or inhibiting an increase in left ventricular internal diameter in a subject with a laminopathy; and / or

[0137] Increase or inhibit the reduction in left ventricular posterior wall thickness in a subject with a laminopathy.

[0138] It should be understood that the LINC complex inhibitory polypeptides disclosed herein may exhibit more than one of the properties described in the preceding paragraph. A given polypeptide may be evaluated for the properties described in the preceding paragraph using a suitable assay. The assay may be, for example, an in vitro assay, an optional cell-based assay, or a cell-free assay. The assay may be, for example, an in vivo assay, i.e., performed in a non-human animal.

[0139] When the assays are cell-based assays, they may include engineered cells (e.g., by transfection / transduction) to express a putative LINC complex inhibitory polypeptide, thereby determining whether the polypeptide exhibits one or more of the properties. To facilitate detection, the assay may use species labeled with a detectable entity. It will be appreciated that the cells are preferably cells that express the constituent proteins of the LINC complex.

[0140] The constituent proteins of the LINC complex include proteins containing a SUN domain and proteins containing a KASH domain. For the sake of simplicity, in this specification, "constituent proteins of the LINC complex" may be referred to as "LINC complex proteins".

[0141] In a preferred embodiment, the LINC complex comprises a protein containing a SUN domain and a protein containing a KASH domain. In some embodiments, the protein containing a SUN domain may be selected from SUN1, SUN2, SUN3, SUN5, SPAG4 and SUCO (more preferably selected from SUN1 and SUN2). In some embodiments, the protein containing a KASH domain may be selected from Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4, KASH5 and LRMP (more preferably selected from Nesprin-1, Nesprin-2 and Nesprin-3).

[0142] The LINC complex inhibitory polypeptides disclosed herein preferably bind to the LINC complex protein. The binding may be characterized by non-covalent protein-protein interactions between the LINC complex inhibitory polypeptide and the LINC complex protein. The interaction may include electrostatic interactions (e.g., ionic bonds, hydrogen bonds) and / or van der Waals forces.

[0143] The present disclosure relates in particular to LINC complex inhibitory polypeptides that bind to LINC complex proteins that are interaction partners of SUN domain-containing proteins (e.g., SUN domain-containing proteins described herein). In some embodiments, the interaction partner of the SUN domain-containing protein is a KASH domain-containing protein (e.g., a KASH domain-containing protein described herein, e.g., selected from Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4, KASH5, and LRMP). In some embodiments, the interaction partner of the SUN domain-containing protein is a SUN domain-containing protein (e.g., a SUN domain-containing protein selected from SUN1, SUN2, SUN3, SUN5, SPAG4, and SUCO); it is known that SUN domain-containing proteins bind to form multimers (e.g., trimers).

[0144] The LINC complex inhibitory polypeptides disclosed herein can show specific binding to the interaction partner of a protein containing a SUN domain (e.g., a protein containing a KASH domain, such as selected from Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4, KASH5 and LRMP). As used herein, "specific binding" refers to selective binding and can be distinguished from non-specific binding to non-target molecules. The LINC complex inhibitory polypeptide that specifically binds to the interaction partner of a protein containing a SUN domain preferably binds to the related protein with greater affinity than other non-target molecules, and / or for a longer duration.

[0145] The ability of a given polypeptide to specifically bind to a given target molecule can be determined by analysis according to methods known in the art, such as by ELISA, surface plasmon resonance (SPR; see, e.g., Hearty et al., Methods Mol Biol (2012) 907:411-442), biofilm interferometry (see, e.g., Lad et al., (2015) J Biomol Screen 20(4):498-507), flow cytometry, or by radiolabeled antigen binding assay (RIA) enzyme-linked immunosorbent assay.

[0146] In some embodiments, the LINC complex inhibitory polypeptides of the present disclosure bind to the interacting partners of SUN domain-containing proteins (e.g., KASH domain-containing proteins, such as selected from Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4, KASH5, and LRMP) with an affinity in the micromolar range, i.e., KD=9.9×10 -4 Up to 1x10 -6 In some embodiments, the LINC complex inhibitory polypeptide binds to an interacting partner of a SUN domain-containing protein (e.g., a KASH domain-containing protein, such as selected from Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4, KASH5, and LRMP) with an affinity in the nanomolar range, i.e., KD=9.9×10 -7 Up to 1×10 -9 M, the LINC complex inhibitory polypeptide binds to the interacting partner of a SUN domain-containing protein (e.g., a KASH domain-containing protein, such as selected from Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4, KASH5 and LRMP) with subnanomolar affinity, i.e., KD < 1x10 -9M. The LINC complex inhibitory polypeptide binds to the interacting partner of a SUN domain-containing protein (e.g., a KASH domain-containing protein, such as selected from Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4, KASH5 and LRMP) with sub-picomolar affinity, i.e., KD < 1x10 -12 M.

[0147] The LINC complex inhibitory polypeptides disclosed herein can bind to the interacting partner of a protein containing a SUN domain (e.g., a protein containing a KASH domain, e.g., selected from Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4, KASH5, and LRMP) in the same manner as a protein containing a SUN domain (e.g., a protein containing a SUN domain, selected from SUN1, SUN2, SUN3, SUN5, SPAG4, and SUCO). In some embodiments, the LINC complex inhibitory polypeptide can bind to the same region or overlapping region of the interacting partner of a protein containing a SUN domain as the region bound by a protein containing a SUN domain.

[0148] The region of a given target molecule to which a polypeptide binds can be determined by a person skilled in the art using various methods well known in the art, including X-ray co-crystallographic analysis of antibody-antigen complexes, peptide scanning, mutagenesis localization, mass spectrometry hydrogen-deuterium exchange analysis, phage display, competitive ELISA, and "protection" methods based on proteolysis. For example, such methods are described in Gershoni et al. BioDrugs, 2007, 21 (3): 145-156, which is incorporated herein by reference in its entirety.

[0149] In some embodiments, the LINC complex inhibitory polypeptide according to the present disclosure inhibits the interaction between a SUN domain-containing protein (e.g., a SUN domain-containing protein selected from SUN1, SUN2, SUN3, SUN5, SPAG4 and SUCO) and an interacting partner of a SUN domain-containing protein (e.g., a KASH domain-containing protein, such as selected from Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4, KASH5 and LRMP). The inhibition of the interaction between a SUN domain-containing protein and an interacting partner of a SUN domain-containing protein herein includes the inhibition of the binding between a SUN domain-containing protein and an interacting partner of a SUN domain-containing protein (thereby inhibiting the formation of a complex including such a protein), and the destruction of a complex including a SUN domain-containing protein and an interacting partner of a SUN domain-containing protein (e.g., by replacing the constituent proteins in such a complex, and the subsequent decomposition of such a complex).

[0150] In some embodiments, the LINC complex inhibitory polypeptide inhibits the binding of a SUN domain-containing protein (e.g., a SUN domain-containing protein selected from SUN1, SUN2, SUN3, SUN5, SPAG4, and SUCO) to an interacting partner of a SUN domain-containing protein (e.g., a KASH domain-containing protein, e.g., selected from Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4, KASH5, and LRMP). In some embodiments, the LINC complex inhibitory polypeptide is a competitive inhibitor of the binding of a SUN domain-containing protein to an interacting partner of a SUN domain-containing protein. In some embodiments, the LINC complex inhibitory polypeptide blocks the binding of a SUN domain-containing protein to an interacting partner of a SUN domain-containing protein. In some embodiments, the LINC complex inhibitory polypeptide occupies the region of an interacting partner of a SUN domain-containing protein, and the SUN domain-containing protein binds to the interacting partner, thereby inhibiting the interaction between the SUN domain-containing protein and its interacting partner. In some embodiments, the LINC complex inhibitory polypeptide displaces the SUN domain-containing protein from a complex comprising the SUN domain-containing protein and an interacting partner of the SUN domain-containing protein.

[0151] The ability of a given polypeptide to inhibit an interaction between two factors can be determined, for example, by analyzing the relevance of this interaction in the presence of the polypeptide or after incubation of one or both interacting partners with the polypeptide.

[0152] The analysis may include detecting a protein containing a SUN domain / an interaction partner of a protein containing a SUN domain / a complex comprising a protein containing a SUN domain and an interaction partner of a protein containing a SUN domain. Such techniques are well known to those skilled in the art and include, for example, antibody / reporter gene based methods (Western blot, ELISA, immunohisto / cytochemistry, etc.).

[0153] A polypeptide that inhibits a given interaction (e.g., an interaction partner between a protein containing a SUN domain and its interaction partner, e.g., a protein containing a KASH domain) is identified by observing a decrease / reduction in the level of interaction correlation between the interaction partners when one or both interaction partners are incubated with the polypeptide compared to the level observed in the absence of the polypeptide (or in the presence of an appropriate control polypeptide that is known not to inhibit the interaction between the interaction partners). Suitable assays can be performed in vitro, for example using recombinant interaction partners or using cells expressing the interaction partners. The cell may express the interaction partner endogenously, or it may be expressed by a nucleic acid introduced into the cell. For the purposes of such assays, one or both of the interaction partner and / or polypeptide may be labeled or used in conjunction with a detectable entity in order to detect and / or measure the level of interaction.

[0154] The relevance of the interaction between two interacting partners can be, for example, the relevance of a complex formed by the association between the interacting partners, the functional properties of a complex formed by the association between the interacting partners, or the relevance of a downstream activity mediated by a complex formed by the association between the interacting partners.

[0155] A polypeptide that inhibits the interaction between a SUN domain-containing protein (e.g., a SUN domain-containing protein selected from the group consisting of SUN1, SUN2, SUN3, SUN5, SPAG4, and SUCO) and an interacting partner of a SUN domain-containing protein (e.g., a KASH domain-containing protein, e.g., selected from the group consisting of Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4, KASH5, and LRMP), for example, a polypeptide that inhibits the formation of a complex comprising a SUN domain-containing protein and an interacting partner of a protein comprising a SUN domain, and / or a polypeptide that disrupts the formation of a complex comprising a SUN domain-containing protein and an interacting partner of a protein comprising a SUN domain, can be detected by observing one or more of the following incubations with the polypeptide in the presence of the polypeptide or after incubation with one or both of the interacting partners of the polypeptide: Compared to the levels observed in the presence of the polypeptide (or in the presence of an appropriate control polypeptide known not to inhibit interaction between interacting partners): (i) a decrease in the level of the complex comprising the SUN domain-containing protein and the interacting partner of the SUN domain-containing protein, (ii) a decrease in the level of a functional property of the complex comprising the SUN domain-containing protein and the interacting partner for the SUN domain-containing protein, (iii) a decrease in the level associated with a downstream activity mediated by the complex composed of the SUN domain-containing protein and the interacting partner of the SUN domain-containing protein, (v) an increase in the level of free (i.e., uncomplexed) SUN domain-containing protein, and / or (v) an increase in the level of free (i.e., uncomplexed) interacting partner of the SUN domain-containing protein.

[0156] The LINC complex inhibitory polypeptides of the present disclosure can disrupt the normal subcellular localization of a LINC complex protein (eg, a SUN domain-containing protein, or an interacting partner of a SUN domain-containing protein).

[0157] In some embodiments, the LINC complex inhibitory polypeptide reduces the level / ratio of LINC complex proteins localized to the nuclear membrane. In some embodiments, the LINC complex inhibitory polypeptide reduces the level / ratio of the interaction partner of the LINC complex inhibitory polypeptide localized to the nuclear membrane. In some embodiments, the LINC complex inhibitory polypeptide reduces the level / ratio of KASH domain-containing proteins associated with the outer nuclear membrane. In some embodiments, the LINC complex inhibitory polypeptide reduces the level / ratio of SUN domain-containing proteins associated with the inner nuclear membrane.

[0158] In some embodiments, the LINC complex inhibitory polypeptide increases the level / ratio of LINC complex proteins that are not confined to the nuclear membrane. In some embodiments, the LINC complex inhibitory polypeptide increases the level / ratio of proteins containing a KASH domain that are not associated with the outer nuclear membrane (e.g., selected from Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4, KASH5, and LRMP). In some embodiments, the LINC complex inhibitory polypeptide increases the level / ratio of proteins containing a SUN domain that are not associated with the inner nuclear membrane (e.g., selected from SUN1, SUN2, SUN3, SUN5, SPAG4, and SUCO).

[0159] In some embodiments, the LINC complex inhibitory polypeptide increases the level / ratio of LINC complex proteins localized to the endoplasmic reticulum. In some embodiments, the LINC complex inhibitory polypeptide increases the level / ratio of proteins containing a KASH domain localized to the endoplasmic reticulum (e.g., selected from Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4, KASH5, and LRMP). In some embodiments, the LINC complex inhibitory polypeptide increases the level / ratio of proteins containing a SUN domain that are not associated with the inner nuclear membrane (e.g., selected from SUN1, SUN2, SUN3, SUN5, SPAG4, and SUCO).

[0160] The subcellular localization of the constituent proteins of the LINC complex in the cell can be analyzed using techniques known to those skilled in the art. Such techniques include, for example, analysis by immunocytochemistry and reporter gene-based methods. For example, Boni et al., J. Cell Biology (2015) 209 (5): 705-720 and Smoyer et al., J. Cell Biologies (2016) 215 (4): 575-590 describe reporter systems that can image proteins in the ER, INM, and ONM. This method can be used to analyze the levels / ratios of the constituent proteins of the LINC complex in the nuclear envelope, inner nuclear membrane, and outer nuclear membrane.

[0161] LINC complex inhibitory polypeptides that disrupt the normal subcellular localization of LINC complex proteins can be identified using assays that include detecting the presence of associated proteins in a given subcellular location or determining the ratio of associated proteins, such as using antibody / reporter-based methods (Western blots, ELISA, immunomics / cytochemistry, etc.). Subcellular localization can be analyzed, for example, by immunocytochemistry or by Western blots of extracts prepared from different cell components, and organelle markers and / or marker proteins of known subcellular localization can be used.

[0162] The assay may comprise expressing a putative LINC complex inhibitory polypeptide in a cell (e.g., from a nucleic acid encoding the polypeptide introduced (e.g., by transfection / transduction) into the cell), followed by comparing the subcellular localization of the relevant LINC complex protein in such cells with the subcellular localization observed in cells under appropriate control conditions (e.g., untransfected cells, cells transfected / transduced with an empty vector, or cells transfected / transduced with a nucleic acid encoding a polypeptide known not to affect the subcellular localization of the relevant LINC complex protein).

[0163] In some embodiments, the ability of a polypeptide to act as a LINC complex inhibitory polypeptide can be assessed essentially as described in Example 1 herein.

[0164] Nucleic acids for expressing putative LINC complex inhibitory polypeptides can be introduced (e.g., by transfection) into cells, and the cells can then be assessed to determine the subcellular localization of one or more LINC complex proteins (e.g., SUN domain-containing proteins (e.g., selected from SUN1, SUN2, SUN3, SUN5, SPAG4, and SUCO) and / or interacting partners of SUN domain-containing proteins (e.g., KASH domain-containing proteins, e.g., selected from Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4, KASH5, and LRMP). A polypeptide can be identified as a LINC complex inhibitory polypeptide, wherein the subcellular localization of the polypeptide is determined relative to that of cells under appropriate control conditions (e.g., untransfected cells, or cells transfected / transduced with a nucleic acid encoding a polypeptide known not to affect the subcellular localization of a relevant LINC complex protein).

[0165] In some embodiments, cellular expression of a LINC complex-inhibiting polypeptide of the present disclosure: (i) reduces the level of interaction between constituent proteins of a LINC complex (e.g., between a SUN domain-containing protein and a KASH domain-containing protein), (ii) reduces the level of a LINC complex (e.g., a LINC complex comprising a SUN domain-containing protein and a KASH domain-containing protein), (iii) reduces the level of relevance of a function / activity of a LINC complex (e.g., a LINC complex comprising a SUN domain-containing protein and a KASH domain-containing protein), (iv) reduces the level / ratio of LINC complex proteins (e.g., SUN domain-containing proteins or KASH domain-containing proteins) localized to the nuclear membrane, and / or (v) reduces the level of a LINC complex protein localized to the nuclear membrane / The level / ratio of a protein containing a KASH domain (e.g., selected from Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4, KASH5 and LRMP) in the outer nuclear membrane is reduced to less than 1-fold / less than 100%, such as ≤0.99-fold / ≤99%, ≤0.95-fold / ≤95%, ≤0.9-fold / ≤90%, ≤0.85-fold / ≤85%, ≤0.8-fold / ≤80%, ≤0.75-fold / ≤75%, ≤0.7 times / ≤70%, ≤0.65 times / ≤65%, ≤0.6 times / ≤60%, ≤0.55 times / ≥55%, ≤0.5 times / ≤50%, ≤0.45 times / ≤45%, ≤0.4 times / ≤40%, ≤0.35 times / ≤35%, ≤0.3 times / ≤30%, ≤0.25 times / ≤25%, ≤0.2 times / ≤20%, ≤0.15 times / ≤15%, ≤0.1 times / ≤10%, ≤0.05 times / ≤5%, or ≤0.01 times / ≤1%.

[0166] According to the preceding paragraph, a preferred reduction level is a reduction to less than 0.5 times / ≤50%, such as ≤0.4 times / ≤40%, ≤0.3 times / ≤30%, ≤0.2 times / ≤20%, ≤0.15 times / ≤15% or ≤0.1 times / ≤10%.

[0167] In some embodiments, cellular expression of a LINC complex-inhibiting polypeptide of the present disclosure: (i) increases the level / ratio of LINC complex proteins that are not localized to the nuclear membrane (e.g., SUN domain-containing proteins or KASH domain-containing proteins), and / or (ii) increases the level / ratio of LINC complex proteins that are localized to the endoplasmic reticulum (e.g., SUN domain-containing proteins or KASH domain-containing proteins), compared to the level observed in a given assay in the absence of the LINC complex-inhibiting polypeptide or under appropriate control conditions. The level / ratio of a protein (e.g., a KASH protein or a protein containing a KASH structural domain) is increased to greater than 1-fold, such as ≥1.01-fold, ≥1.02-fold, ≥1.03-fold, ≥1.04-fold, ≥1.05-fold, ≥1.1-fold, ≥1.2-fold, ≥1.3-fold, ≥1.4-fold, ≥1.5-fold, ≥1.6-fold, ≥1.7-fold, ≥1.8-fold, ≥1.9-fold, ≥2-fold, ≥3-fold, ≥4-fold, ≥5-fold, ≥6-fold, ≥7-fold, ≥8-fold, ≥9-fold, ≥10-fold, ≥50-fold or ≥100-fold.

[0168] The polypeptides can be evaluated for certain functional properties in appropriate in vivo models. For example, the in vivo therapeutic / preventive effects of the polypeptides can be evaluated in non-human animal models of the diseases / disorders described herein. In such an assay, the polypeptide can be delivered in the form of a nucleic acid encoding the protein, for example using a viral vector with appropriate tropism for cells / tissues where LINC complex inhibition will confer a therapeutic / preventive benefit. For example, in the experimental examples of the present disclosure, putative LINC complex inhibitory polypeptides were evaluated in a dilated cardiomyopathy mouse model established by induced cardiomyocyte-specific deletion of Lmna - see Example 5. The putative LINC complex inhibitory polypeptides were delivered as gene therapy in the form of an AAV9 vector that expresses the polypeptide under the control of a cardiomyocyte-specific promoter.

[0169] The life span and survival of a subject can be assessed by monitoring survival over time in such a model. Cardiac function and myocardial contractility can be assessed by measuring their correlation and can be assessed by echocardiographic / ultrasound measurements of ejection fraction, fractional shortening, left ventricular posterior wall thickness and / or left ventricular internal diameter.

[0170] It will be appreciated that it is preferred to assess one or more of the aforementioned properties of a subject at a specific time point, such as after a period of time sufficient to observe the effects of administering the polypeptide in a relevant model. For example, a subject may be assessed 7 days or more after administration of a viral vector encoding a putative LINC complex inhibitory polypeptide.

[0171] In some embodiments, administration of a LINC complex inhibitory polypeptide of the present disclosure to a subject with a laminopathy (e.g., a cardiomyopathy associated with a LMNA mutation; e.g., via a viral vector encoding a LINC complex inhibitory polypeptide) increases the survival rate or lifespan of the subject, and / or improves cardiac function, myocardial contractility, ejection fraction, contraction, or systolic function in the subject, compared to no administration or administration of an appropriate control polypeptide (e.g., a polypeptide known not to inhibit the LINC complex, e.g., delivered using the same viral vector). The short score and / or left ventricular posterior wall thickness increases to a level greater than 1-fold, such as ≥1.01-fold, ≥1.02-fold, >1.03-fold, ≥1.04-fold, ≥1.05-fold, <1.1-fold, ≥1.2-fold, ≥1.3-fold, ≥1.4-fold, ≥1.5-fold, ≥1.6-fold, ≥1.7-fold, ≥1.8-fold, ≥1.9-fold, ≥2-fold, ≥3-fold, ≥4-fold, ≥5-fold, ≥6-fold, ≥7-fold, ≥8-fold, ≥9-fold, ≥10-fold, ≥50-fold, or ≥100-fold.

[0172] In some embodiments, administration of a LINC complex inhibitory polypeptide of the present disclosure to a subject with a laminopathy (e.g., a cardiomyopathy associated with a LMNA mutation; e.g., via a viral vector encoding a LINC complex inhibitory polypeptide) can reduce the left ventricular internal diameter of the subject to less than 1-fold / less than 100%, e.g., ≤0.99-fold / ≤99%, ≤0.95-fold / ≤95%, ≤0.9-fold / ≤90%, ≤0.85-fold, compared to no administration or administration of an appropriate control polypeptide (e.g., a polypeptide known not to inhibit the LINC complex, e.g., delivered using the same viral vector). / ≤85%, ≤0.8 times / ≤80%, ≤0.75 times / ≤75%, ≤0.7 times / ≤70%, ≤0.65 times / ≥65%, ≤0.6 times / ≤60%, ≤0.55 times / ≤55%, ≤0.5 times / ≤50%, ≤0.45 times / ≤45%, ≤0.4 times / ≤40%, ≤0.35 times / ≤35%, ≤0.3 times / ≤30%, ≤0.25 times / ≤25%, ≤0.2 times / ≤20%, ≤0.15 times / ≤15%, ≤0.1 times / ≤10%, ≤0.05 times / ≤5% or ≤0.01 times / ≤1%.

[0173] In some embodiments, the LINC complex-inhibiting polypeptides of the present disclosure may have one or more new or improved functional properties compared to the LINC complex-inhibiting polypeptide consisting of the amino acid sequence of SEQ ID NO:99.

[0174] In some embodiments, the cellular expression of a LINC complex-inhibiting polypeptide of the present disclosure, compared to cellular expression of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 99 (e.g., in the same type of cell), has the following effects: (i) reducing the level of interaction between the constituent proteins of the LINC complex (e.g., between a SUN domain-containing protein and a KASH domain-containing protein), (ii) reducing the level of a LINC complex (e.g., a LINC complex comprising a SUN domain-containing protein and a KASH domain-containing protein), (iii) reducing the level of relevance of a function / activity of a LINC complex (e.g., a LINC complex comprising a SUN domain-containing protein and a KASH domain-containing protein), (iv) reducing the level / ratio of LINC complex proteins (e.g., SUN domain-containing proteins or KASH domain-containing proteins) localized to the nuclear membrane, and / or (v) reducing the level / ratio of KASH domain-containing proteins (e.g., SUN domain-containing proteins or KASH domain-containing proteins) localized to the nuclear membrane / outer nuclear membrane. For example, the content of selected from Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4, KASH5 and LRMP is less than 1 times / less than 100%, for example ≤0.99 times / ≤99%, ≤0.95 times / ≤95%, ≤0.9 times / ≤90%, ≤0.85 times / ≤85%, ≤0.8 times / ≤80%, ≤0.75 times / ≤75%, ≤0.7 times / ≤70%, ≤0.6 5 times / ≤65%, ≤0.6 times / ≤60%, ≤0.55 times / ≥55%, ≤0.5 times / ≤50%, ≤0.45 times / ≤45%, ≤0.4 times / ≤40%, ≤0.35 times / ≤35%, ≤0.3 times / ≤30%, ≤0.25 times / ≤25%, ≤0.2 times / ≤20%, ≤0.15 times / ≤15%, ≤0.1 times / ≤10%, ≤0.05 times / ≤5%, or ≤0.01 times / ≤1%.

[0175] In some embodiments, the LINC complex of the present disclosure inhibits cellular expression of a polypeptide corresponding to SEQ ID Compared to the level observed in the cell expression of the polypeptide consisting of the amino acid sequence of NO:99 (e.g., by the same type of cells), it has: (i) increasing the level / ratio of LINC complex proteins that are not restricted to the nuclear membrane (e.g., proteins containing a SUN domain or proteins containing a KASH domain), and / or (ii) increasing the level / ratio of LINC complex proteins that are restricted to the endoplasmic reticulum (e.g., proteins containing a SUN domain or proteins containing a KASH domain) to greater than 1 time, for example, ≥1.01 times, ≥1.02 times, ≥1.03 times, ≥1.04 times, ≥1.05 times, ≥1.1 times, ≥1.2 times, ≥1.3 times, ≥1.4 times, ≥1.5 times, ≥1.6 times, ≥1.7 times, ≥1.8 times, ≥1.9 times, ≥2 times, ≥3 times, ≥4 times, ≥5 times, ≥6 times, ≥7 times, ≥8 times, ≥9 times, ≥10 times, ≥50 times or ≥100 times.

[0176] In some embodiments, administration of a LINC complex inhibitory polypeptide of the present disclosure to a subject suffering from a laminopathy (e.g., a cardiomyopathy associated with a LMNA mutation; e.g., via a viral vector encoding the LINC complex inhibitory polypeptide) is combined with administration of a protein represented by SEQ ID NO:99 amino acid sequence composition polypeptide (for example, using the same viral vector delivery) compared to the level observed after the subject's survival rate or life expectancy is increased, and / or the cardiac function, myocardial contractility, ejection fraction, shortening fraction and / or left ventricular posterior wall thickness in the subject is increased to greater than 1 times, for example ≥1.01 times, ≥1.02 times, ≥1.03 times, ≥1.04 times, ≥1.05 times, ≥1.1 times, ≥1.2 times, ≥1.3 times, ≥1.4 times, ≥1.5 times, ≥1.6 times, ≥1.7 times, ≥1.8 times, ≥1.9 times, ≥2 times, ≥3 times, ≥4 times, ≥5 times, ≥6 times, ≥7 times, ≥8 times, ≥9 times, ≥10 times, ≥50 times or ≥100 times.

[0177] In some embodiments, administration of a LINC complex inhibitory polypeptide of the present disclosure to a subject with a laminopathy (e.g., a cardiomyopathy associated with a LMNA mutation; e.g., via a viral vector encoding a LINC complex inhibitory polypeptide) can reduce the subject's left ventricular internal diameter to less than 1-fold / less than 100%, e.g., ≤0.99-fold / ≤99%, ≤0.95-fold / ≤95%, ≤0.9-fold / ≤90%, ≤0.85-fold / ≤85%, ≤0.8-fold / ≤80%, ≤0.75-fold / ≤75%, ≤0.7-fold / ≤70%, ≤0.65-fold, as compared to the level observed after administration of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 99 (e.g., delivered using the same viral vector). / ≥65%, ≤0.6 times / ≤60%, ≤0.55 times / ≤55%, ≤0.5 times / ≤50%, ≤0.45 times / ≤45%, ≤0.4 times / ≤40%, ≤0.35 times / ≤35%, ≤0.3 times / ≤30%, ≤0.25 times / ≤25%, ≤0.2 times / ≤20%, ≤0.15 times / ≤15%, ≤0.1 times / ≤10%, ≤0.05 times / ≤5%, or ≤0.01 times / ≤1%.

[0178] The LINC complex inhibitory polypeptides of the present disclosure may be based on proteins containing a SUN domain, for example, selected from SUN1, SUN2, SUN3, SUN5, SPAG4 and SUCO. In some embodiments, the LINC complex inhibitory polypeptides of the present disclosure comprise an inhibitory region based on proteins containing a SUN domain, for example, selected from SUN1, SUN2, SUN3, SUN5, SPAG4 and SUCO.

[0179] As used herein, a peptide / polypeptide / amino acid sequence "based on" a reference protein comprises or consists of an amino acid sequence having high sequence identity (e.g., at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity) with all or part of the amino acids of the reference protein.

[0180] The "inhibitory region" of a LINC complex inhibitory polypeptide refers to a region of the polypeptide through which inhibition of the LINC complex is achieved. The inhibitory region of the present disclosure generally has a high sequence identity with a portion of the amino acid sequence of a protein containing a SUN domain. The inhibitory region of a LINC complex inhibitory polypeptide of the present disclosure may be a region through which the LINC complex inhibitory polypeptide binds to an interacting partner of a protein containing a SUN domain (e.g., a protein containing a KASH domain, such as one or more of Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4, KASH5, and LRMP). In aspects and embodiments of the present disclosure, the inhibitory region of a LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the α3 helix of the CC2 region of a protein containing a SUN domain and a SUN region.

[0181] The LINC complex inhibitory polypeptide of the present disclosure may comprise or consist essentially of an amino acid sequence having a high degree of sequence identity (e.g., at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity) to the amino acid sequence of all or part of a protein containing a SUN domain, such as selected from SUN1, SUN2, SUN3, SUN5, SPAG4 and SUCO. The LINC complex inhibitory polypeptide of the present disclosure may comprise an inhibitory region comprising or consisting of an amino acid sequence having a high degree of sequence identity (e.g., at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity) to the amino acid sequence of all or part of a SUN domain-containing protein, e.g., selected from SUN1, SUN2, SUN3, SUN5, SPAG4 and SUCO.

[0182] The LINC complex inhibitory polypeptides preferably (i) retain the ability of the SUN domain-containing protein on which they are based to bind to a KASH domain-containing protein (e.g., one or more of Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4, KASH5, and LRMP), but (ii) lack or exhibit reduced levels of one or more other properties of the SUN domain-containing protein on which they are based. In a preferred embodiment, the LINC complex inhibitory polypeptide lacks or exhibits reduced ability to bind to lamins and / or chromatin-bound proteins, and / or lacks or exhibits reduced ability to bind to (e.g., localize to) the inner nuclear membrane, relative to the SUN domain-containing protein on which it is based.

[0183] For example, the LINC complex inhibitory polypeptide / its inhibitory region according to the present disclosure may comprise an amino acid sequence required for binding to a KASH domain-containing protein (e.g., one or more of Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4, KASH5 and LRMP), and may lack an amino acid sequence required for one or more other properties of the SUN domain-containing protein on which it is based (e.g., an amino acid sequence required for binding to lamins and / or chromatin-binding proteins, and / or an amino acid sequence required for binding to the inner nuclear membrane).

[0184] It should be understood that in some embodiments, the LINC complex inhibitory polypeptides of the present disclosure consist essentially of a protein-binding fragment containing a KASH domain of a protein containing a SUN domain. Similarly, in some embodiments, the inhibitory region of the LINC complex inhibitory polypeptides according to the present disclosure consists of a protein-binding fragment containing a KASH domain of a protein containing a SUN domain.

[0185] The LINC complex inhibitory polypeptide may be referred to as a "decoy," "dominant negative," or "mimetic" version of the SUN domain-containing protein on which it is based. That is, in aspects and embodiments of the present disclosure, the LINC complex inhibitory polypeptide may be a polypeptide containing a dominant negative SUN domain.

[0186] The LINC complex inhibitory polypeptides disclosed herein preferably show competitive inhibition of the interaction between a protein containing a SUN domain (e.g., selected from SUN1, SUN2, SUN3, SUN5, SPAG4, and SUCO) and a protein containing a KASH domain (e.g., selected from Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4, KASH5, and LRMP). The decoy / dominant negative / mimic LINC complex inhibitory polypeptide preferably binds to a protein containing a KASH domain (e.g., selected from Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4, KASH5, and LRMP), occupies the site required for interaction with proteins containing endogenous SUN domains, thereby making these species unavailable for binding thereto.

[0187] The LINC complex inhibitory polypeptide can inhibit the formation of LINC complexes and / or destroy existing LINC complexes by inhibiting the assembly of endogenous interaction partners and / or by displacement of endogenous interaction partners. Decoy / dominant negative / mimic LINC complex inhibitory polypeptides form non-functional LINC complexes, or LINC complexes with reduced functional levels compared to LINC complexes formed by wild-type, endogenous SUN domain-containing proteins and KASH domain-containing proteins.

[0188] As mentioned above, dominant negative versions of proteins containing the SUN domain have been described previously. For example, Crisp et al., Journal of Cell Biology. (2006) 172(1): 41-53 described a dominant negative version of the mouse Sun1 protein, and WO2019 / 143300 A1 described a humanized version thereof.

[0189] In aspects and embodiments of the present disclosure, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the α3 helix and the SUN domain of the CC2 region of a protein containing a SUN domain. It should be understood that the amino acid sequence of one or more regions of the LINC complex inhibitory polypeptide described herein corresponding to a protein containing a SUN domain may be included in the inhibitory region of the LINC complex inhibitory polypeptide.

[0190] As used herein, an amino acid sequence that "corresponds" to a particular region of a reference polypeptide or amino acid sequence has at least 60%, e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of the polypeptide / amino acid sequence. An amino acid sequence that "corresponds" to a particular region of a reference polypeptide or amino acid sequence can be identified by sequence alignment of the subject sequence with the reference sequence, e.g., using sequence alignment software such as ClustalOmega ( J. 2005, Bioinformations 21951-960). For example, the amino acid sequence of positions 522 to 717 of human SUN2 corresponds to the amino acid sequence of positions 616 to 812 of human SUN1.

[0191] In some embodiments, the LINC complex inhibitory polypeptide according to the present disclosure consists essentially of a human amino acid sequence. In some embodiments, the inhibitory region of the LINC complex inhibitory polypeptide according to the present disclosure consists essentially of a human amino acid sequence. As used herein, "human amino acid sequence" refers to an amino acid sequence encoded by a nucleic acid of the human genome. That is, in some embodiments, the LINC complex inhibitory polypeptide or the inhibitory region of the LINC complex inhibitor polypeptide consists essentially of an amino acid sequence having 100% amino acid sequence identity with an amino acid sequence encoded by the genome of a human subject. It should be understood that in some embodiments, the amino acid sequence encoded by the genome of a human subject is an amino acid sequence of a protein containing a human SUN domain (e.g., selected from SUN1, SUN2, SUN3, SUN5, SPAG4 and SUCO; e.g., SUN1 or SUN2). These embodiments of the LINC complex inhibitory polypeptide are particularly contemplated when intended to be administered to a human subject, e.g., in the case of a therapeutic / preventive intervention according to the present disclosure.

[0192] In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the α3 helix of the CC2 region of a protein containing a SUN domain. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the α3 helix of the CC2 region of human SUN1. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the α3 helix of the CC2 region of human SUN2. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 12. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO:22.

[0193] In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the SUN domain of a protein containing a SUN domain. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the SUN domain of human SUN1. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the SUN domain of human SUN2. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 8. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO:18.

[0194] In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the α3 helix and the SUN domain of the CC2 region of a protein containing a SUN domain. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the α3 helix and the SUN domain of the CC2 region of human SUN1. In some embodiments, the LINC complex inhibitory polypeptide comprises an inhibitory region comprising an amino acid sequence corresponding to the α3 helix and the SUN domain of the CC2 region of human SUN2. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 44. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO:46.

[0195] In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the α2 helix of the CC2 region of a protein containing a SUN domain. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the α2 helix of the CC2 region of human SUN1. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the α2 helix of the CC2 region of human SUN2. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 11. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO:21.

[0196] In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the α1 helix of the CC2 region of a protein containing a SUN domain. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the α1 helix of the CC2 region of human SUN1. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the α1 helix of the CC2 region of human SUN2. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 10. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO:20.

[0197] In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the CC1 region of a protein containing a SUN domain. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the CC1 region of human SUN1. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the CC1 region of human SUN2. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 9. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 19.

[0198] In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the CC1 region and CC2 region of a protein containing a SUN domain. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the CC1 region and CC2 region of human SUN1. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the CC1 region and CC2 region of human SUN2. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 88. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO:91.

[0199] In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the CC2 region of a protein containing a SUN domain. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the CC2 region of human SUN1. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the CC2 region of human SUN2. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 89. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 92.

[0200] Amino acid sequences with 98%, 99% or 100% sequence identity.

[0201] In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the α2 and α3 helices of the CC2 region of a protein containing a SUN domain. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the α2 and α3 helices of the CC2 region of human SUN1. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to the α2 and α3 helices of the CC2 region of human SUN2. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 90. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO:93.

[0202] In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to a portion of the SMART coiled coil 2 region, CC1 region, and CC2 region of a protein containing a SUN domain. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to positions 483 to 632 of human SUN1 (numbered according to SEQ ID NO: 1). In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to positions 388 to 538 of human SUN2 (numbered according to SEQ ID NO: 13). In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 97. In some embodiments, the LINC complex inhibitory polypeptide comprises an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO:98.

[0203] In some embodiments, the LINC complex inhibitory polypeptide does not consist essentially of the amino acid sequence of a dominant negative version of a protein containing a SUN domain disclosed in the prior art. In some embodiments, the LINC complex inhibitory polypeptide does not consist essentially of the amino acid sequence of a truncated variant of a protein containing a SUN domain disclosed in the prior art. In some embodiments, the LINC complex inhibitory polypeptide does not include an inhibitory region consisting of the amino acid sequence of a dominant negative version of a protein containing a SUN domain disclosed in the prior art. In some embodiments, the LINC complex inhibitory polypeptide does not include an inhibitory region consisting of the amino acid sequence of a truncated variant of a protein containing a SUN domain disclosed in the prior art.

[0204] As used herein, a polypeptide or amino acid sequence that "consists essentially of" a reference amino acid sequence (i) consists of the reference amino acid sequence, or (ii) includes the reference amino acid sequence, wherein the reference amino acid sequence comprises at least 80% (e.g., one of ≥85%, ≥86%, ≥87%, ≥88%, ≥89%, ≥90%, ≥91%, ≥92%, ≥93%, ≥94%, ≥95%, ≥96%, ≥97%, ≥98%, ≥99%) of the polypeptide / amino acid sequence. It is understood that a polypeptide or amino acid sequence that "consists essentially of" a reference amino acid sequence may include the reference amino acid sequence and the addition of amino acids at one or both of the N-terminus and the C-terminus of the reference amino acid sequence, provided that the added amino acids constitute ≤20% of the polypeptide / amino acid sequence.

[0205] For example, a polypeptide consisting of the amino acid sequence of SEQ ID NO:74 consists essentially of the amino acid sequence of SEQ ID NO:44. SEQ ID NO:74 comprises the amino acid sequence of SEQ ID NO:44 (i.e., from position 1 to 197 of SEQ ID NO:84), and the amino acid sequence of SEQ ID NO:44 constitutes ˜98% (i.e., 197 / 201 residues) of the polypeptide. SEQ ID NO:74 comprises the KDEL retention motif (SEQ ID NO-77) C-terminal to the amino acid sequence of SEQ ID NO:44.

[0206] In some embodiments, the amino acid sequence consisting essentially of the reference amino acid sequence consists of the reference amino acid sequence. That is, in some embodiments, the amino acid sequence consisting essentially of the reference amino acid sequence is identical to the reference amino acid sequence. In some embodiments, the amino acid sequence consisting essentially of the reference amino acid sequence includes the same amino acid sequence as the reference amino acid sequence, and also includes one or more additional amino acids (e.g., 1-5, 1-10, or 1-20 amino acids) at one or both ends of the reference sequence.

[0207] In some embodiments, the LINC complex inhibitory polypeptide is substantially Not by The amino acid sequence of SEQ ID NO: 43 or 45. In some embodiments, the LINC complex inhibitory polypeptide Not included An inhibition region consisting of the amino acid sequence of any one of SEQ ID NO: 43 or 45.

[0208] In some embodiments, the LINC complex inhibitory polypeptide is substantially Not by The amino acid sequence of SEQ ID NO: 44 or 46. In some embodiments, the LINC complex inhibitory polypeptide Not includedAn inhibition region consisting of the amino acid sequence of any one of SEQ ID NO: 44 or 46.

[0209] In some embodiments, the LINC complex inhibitory polypeptide is substantially Not by The amino acid sequence of SEQ ID NO: 43, 44, 45 or 46. In some embodiments, the LINC complex inhibitory polypeptide Not included An inhibition region consisting of the amino acid sequence of any one of SEQ ID NO: 43, 44, 45 or 46.

[0210] In some embodiments, the LINC complex inhibitory polypeptide is substantially Not by The amino acid sequence of any one of SEQ ID NO:43, 44, 45, 46, 47 or 48.

[0211] In some embodiments, the LINC complex inhibitory polypeptide is substantially Not by The amino acid sequence of any one of SEQ ID NO:43, 44, 45, 46, 47, 48, 74 or 75.

[0212] In some embodiments, the LINC complex inhibitory polypeptide is substantially Not by The amino acid sequence of any one of SEQ ID NO: 43, 44, 45, 46, 47, 48, 58, 49, 50, 51, 52, 53, 54, 55, 56, 57, 74 or 75. In some embodiments, the LINC complex inhibitory polypeptide Not included An inhibition zone consisting of the amino acid sequence of any one of SEQ ID NO: 43, 44, 45, 46, 47, 48, 58, 49, 50, 51, 52, 53, 54, 55, 56, 57, 74 or 75.

[0213] In some embodiments, the LINC complex inhibitory polypeptide is substantially Not by The amino acid sequence of any one of SEQ ID NO: 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 74 or 75. In some embodiments, the LINC complex inhibitory polypeptide Not included An inhibition zone consisting of the amino acid sequence of any one of SEQ ID NO: 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 74 or 75.

[0214] The present disclosure specifically contemplates LINC complex inhibitory polypeptides consisting essentially of the amino acid sequence of any one of SEQ ID NO: 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 94 or 95, alone or together with one or more other specific sequences. The present disclosure also specifically contemplates disclaiming LINC complex inhibitory polypeptides comprising an inhibitory region consisting of an amino acid sequence of any one of SEQ ID NOs: 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 94, or 95, alone or together with one or more other specified sequences.

[0215] However, in conjunction with certain aspects and embodiments of the present disclosure, the LINC complex inhibitory polypeptide may comprise or consist essentially of the amino acid sequence of any one of SEQ ID NO:43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 94 or 95. Similarly, in conjunction with certain aspects and embodiments of the present disclosure, the LINC complex inhibitory polypeptide may comprise an inhibitory region consisting of an amino acid sequence of any one of SEQ ID NO: 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 94 or 95.

[0216] In some embodiments, the LINC complex inhibitory polypeptide or its inhibitory region comprises or consists essentially of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 63. In some embodiments, the LINC complex inhibitory polypeptide or its inhibitory region comprises or consists essentially of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 64. In some embodiments, the LINC complex inhibitory polypeptide or its inhibitory region comprises or consists essentially of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 65. In some embodiments, the LINC complex inhibitory polypeptide or its inhibitory region comprises or consists essentially of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 66. In some embodiments, the LINC complex inhibitory polypeptide or its inhibitory region comprises or consists essentially of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 67. In some embodiments, the LINC complex inhibitory polypeptide or its inhibitory region comprises or consists essentially of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 68. In some embodiments, the LINC complex inhibitory polypeptide or its inhibitory region comprises or consists essentially of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: NO:69.In some embodiments, the LINC complex inhibitory polypeptide or its inhibitory region comprises or consists essentially of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 70. In some embodiments, the LINC complex inhibitory polypeptide or its inhibitory region comprises or consists essentially of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 71. In some embodiments, the LINC complex inhibitory polypeptide or its inhibitory region comprises or consists essentially of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 72. In some embodiments, the LINC complex inhibitory polypeptide or its inhibitory region comprises or consists essentially of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 73. In some embodiments, the LINC complex inhibitory polypeptide or its inhibitory region comprises or consists essentially of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 74. In some embodiments, the LINC complex inhibitory polypeptide or its inhibitory region comprises or consists essentially of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 94. In some embodiments, the LINC complex inhibitory polypeptide or its inhibitory region comprises or consists essentially of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO:95.

[0217] In some embodiments, the LINC complex inhibitory polypeptide or its inhibitory region comprises or consists essentially of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 101. In some embodiments, the LINC complex inhibitory polypeptide or its inhibitory region comprises or consists essentially of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 102. In some embodiments, the LINC complex inhibitory polypeptide or its inhibitory region comprises or consists essentially of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 103.

[0218] In some embodiments, the LINC complex inhibitory polypeptide or its inhibitory region comprises or consists essentially of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 104. In some embodiments, the LINC complex inhibitory polypeptide or its inhibitory region comprises or consists essentially of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 105. In some embodiments, the LINC complex inhibitory polypeptide or its inhibitory region comprises or consists essentially of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 106. In some embodiments, the LINC complex inhibitory polypeptide or its inhibitory region comprises or consists essentially of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 107. In some embodiments, the LINC complex inhibitory polypeptide or its inhibitory region comprises or consists essentially of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 108. In some embodiments, the LINC complex inhibitory polypeptide or its inhibitory region comprises or consists essentially of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 109.

[0219] In some embodiments, a LINC complex inhibitory polypeptide or an inhibitory region thereof of the present disclosure comprises or consists essentially of an amino acid sequence corresponding to one of the following: 360-812 of SEQ ID NO: 1; 361-812 of SEQ ID NO: 1; 362-812 of SEQ ID NO: 1; 363-812 of SEQ ID NO: 1; 364-812 of SEQ ID NO: 1; 365-812 of SEQ ID NO: 1; 366-812 of SEQ ID NO: 1; 367-812 of SEQ ID NO: 1; 368-812 of SEQ ID NO: 1; 369-812 of SEQ ID NO: 1; 370-812 of SEQ ID NO: 1; 371-812 of SEQ ID NO: 1; 372-812 of SEQ ID NO: 1; 373-812 of SEQ ID NO: 1; SEQ ID 374-812 of SEQ ID NO:1; 375-812 of SEQ ID NO:1; 376-812 of SEQ ID NO:1; 377-812 of SEQ ID NO:1; 378-812 of SEQ ID NO:1; 379-812 of SEQ ID NO:1; 380-812 of SEQ ID NO:1; 381-812 of SEQ ID NO:1; 382-812 of SEQ ID NO:1; 383-812 of SEQ ID NO:1; 384-812 of SEQ ID NO:1; 385-812 of SEQ ID NO:1; 386-812 of SEQ ID NO:1; 387-812 of SEQ ID NO:1; 388-812 of SEQ ID NO:1; 389-812 of SEQ ID NO:1; SEQ ID 390-812 of SEQ ID NO:1; 391-812 of SEQ ID NO:1; 392-812 of SEQ ID NO:1; 393-812 of SEQ ID NO:1; 394-812 of SEQ ID NO:1; 395-812 of SEQ ID NO:1; 396-812 of SEQ ID NO:1; 397-812 of SEQ ID NO:1; 398-812 of SEQ ID NO:1; 399-812 of SEQ ID NO:1; 400-812 of SEQ ID NO:1; 401-812 of SEQ ID NO:1; 402-812 of SEQ ID NO:1; 403-812 of SEQ ID NO:1; 404-812 of SEQ ID NO:1;405-812 of SEQ ID NO:1; 406-812 of SEQ ID NO:1; 407-812 of SEQ ID NO:1; 408-812 of SEQ ID NO:1; 409-812 of SEQ ID NO:1; 410-812 of SEQ ID NO:1; 411-812 of SEQ ID NO:1; 412-812 of SEQ ID NO:1; 413-812 of SEQ ID NO:1; 414-812 of SEQ ID NO:1; 415-812 of SEQ ID NO:1; 416-812 of SEQ ID NO:1; 417-812 of SEQ ID NO:1; 418-812 of SEQ ID NO:1; 419-812 of SEQ ID NO:1; 420-812 of SEQ ID NO:1; SEQ ID 421-812 of SEQ ID NO:1; 422-812 of SEQ ID NO:1; 423-812 of SEQ ID NO:1; 424-812 of SEQ ID NO:1; 425-812 of SEQ ID NO:1; 426-812 of SEQ ID NO:1; 427-812 of SEQ ID NO:1; 428-812 of SEQ ID NO:1; 429-812 of SEQ ID NO:1; 430-812 of SEQ ID NO:1; 431-812 of SEQ ID NO:1; 432-812 of SEQ ID NO:1; 433-812 of SEQ ID NO:1; 434-812 of SEQ ID NO:1; 435-812 of SEQ ID NO:1; 436-812 of SEQ ID NO:1; SEQ ID NO:1, positions 437-812; SEQ ID NO:1, positions 438-812; SEQ ID NO:1, positions 439-812; SEQ ID NO:1, positions 440-812; SEQ ID NO:1, positions 441-812; SEQ ID NO:1, positions 442-812; SEQ ID NO:1, positions 443-812; SEQ ID NO:1, positions 444-812; SEQ ID NO:1, positions 445-812; SEQ ID NO:1, positions 446-812; SEQ ID NO:1, positions 447-812; SEQ ID NO:1, positions 448-812; SEQ ID NO:1, positions 449-812; SEQ ID NO:1, positions 450-812; SEQ ID NO:1, positions 451-812;452-812 of SEQ ID NO:1; 453-812 of SEQ ID NO:1; 454-812 of SEQ ID NO:1; 455-812 of SEQ ID NO:1; 456-812 of SEQ ID NO:1; 457-812 of SEQ ID NO:1; 458-812 of SEQ ID NO:1; 459-812 of SEQ ID NO:1; 460-812 of SEQ ID NO:1; 461-812 of SEQ ID NO:1; 462-812 of SEQ ID NO:1; 463-812 of SEQ ID NO:1; 464-812 of SEQ ID NO:1; 465-812 of SEQ ID NO:1; 466-812 of SEQ ID NO:1; 467-812 of SEQ ID NO:1; SEQ ID 468-812 of SEQ ID NO:1; 469-812 of SEQ ID NO:1; 470-812 of SEQ ID NO:1; 471-812 of SEQ ID NO:1; 472-812 of SEQ ID NO:1; 473-812 of SEQ ID NO:1; 474-812 of SEQ ID NO:1; 475-812 of SEQ ID NO:1; 476-812 of SEQ ID NO:1; 477-812 of SEQ ID NO:1; 478-812 of SEQ ID NO:1; 479-812 of SEQ ID NO:1; 480-812 of SEQ ID NO:1; 481-812 of SEQ ID NO:1; 482-812 of SEQ ID NO:1; 483-812 of SEQ ID NO:1; SEQ ID 484-812 of SEQ ID NO:1; 485-812 of SEQ ID NO:1; 486-812 of SEQ ID NO:1; 487-812 of SEQ ID NO:1; 488-812 of SEQ ID NO:1; 489-812 of SEQ ID NO:1; 490-812 of SEQ ID NO:1; 491-812 of SEQ ID NO:1; 492-812 of SEQ ID NO:1; 493-812 of SEQ ID NO:1; 494-812 of SEQ ID NO:1; 495-812 of SEQ ID NO:1; 496-812 of SEQ ID NO:1; 497-812 of SEQ ID NO:1; 498-812 of SEQ ID NO:1;499-812 of SEQ ID NO:1; 500-812 of SEQ ID NO:1; 501-812 of SEQ ID NO:1; 502-812 of SEQ ID NO:1; 503-812 of SEQ ID NO:1; 504-812 of SEQ ID NO:1; 505-812 of SEQ ID NO:1; 506-812 of SEQ ID NO:1; 507-812 of SEQ ID NO:1; 508-812 of SEQ ID NO:1; 509-812 of SEQ ID NO:1; 510-812 of SEQ ID NO:1; 511-812 of SEQ ID NO:1; 512-812 of SEQ ID NO:1; 513-812 of SEQ ID NO:1; 514-812 of SEQ ID NO:1; SEQ 515-812 of SEQ ID NO:1; 516-812 of SEQ ID NO:1; 517-812 of SEQ ID NO:1; 518-812 of SEQ ID NO:1; 519-812 of SEQ ID NO:1; 520-812 of SEQ ID NO:1; 521-812 of SEQ ID NO:1; 522-812 of SEQ ID NO:1; 523-812 of SEQ ID NO:1; 524-812 of SEQ ID NO:1; 525-812 of SEQ ID NO:1; 526-812 of SEQ ID NO:1; 527-812 of SEQ ID NO:1; 528-812 of SEQ ID NO:1; 529-812 of SEQ ID NO:1; 530-812 of SEQ ID NO:1; SEQ ID NO:1; 531-812; 532-812; 533-812; 534-812; 535-812; 536-812; 537-812; 538-812; 539-812; 540-812; 541-812; 542-812; 543-812; 544-812; 545-812;546-812 of SEQ ID NO:1; 547-812 of SEQ ID NO:1; 548-812 of SEQ ID NO:1; 549-812 of SEQ ID NO:1; 550-812 of SEQ ID NO:1; 551-812 of SEQ ID NO:1; 552-812 of SEQ ID NO:1; 553-812 of SEQ ID NO:1; 554-812 of SEQ ID NO:1; 555-812 of SEQ ID NO:1; 556-812 of SEQ ID NO:1; 557-812 of SEQ ID NO:1; 558-812 of SEQ ID NO:1; 559-812 of SEQ ID NO:1; 560-812 of SEQ ID NO:1; 561-812 of SEQ ID NO:1; SEQ ID NO:1; 562-812 of SEQ ID NO:1; 563-812 of SEQ ID NO:1; 564-812 of SEQ ID NO:1; 565-812 of SEQ ID NO:1; 566-812 of SEQ ID NO:1; 567-812 of SEQ ID NO:1; 568-812 of SEQ ID NO:1; 569-812 of SEQ ID NO:1; 570-812 of SEQ ID NO:1; 571-812 of SEQ ID NO:1; 572-812 of SEQ ID NO:1; 573-812 of SEQ ID NO:1; 574-812 of SEQ ID NO:1; 575-812 of SEQ ID NO:1; 576-812 of SEQ ID NO:1; 577-812 of SEQ ID NO:1; SEQ ID 578-812 of SEQ ID NO:1; 579-812 of SEQ ID NO:1; 580-812 of SEQ ID NO:1; 581-812 of SEQ ID NO:1; 582-812 of SEQ ID NO:1; 583-812 of SEQ ID NO:1; 584-812 of SEQ ID NO:1; 585-812 of SEQ ID NO:1; 586-812 of SEQ ID NO:1; 587-812 of SEQ ID NO:1; 588-812 of SEQ ID NO:1; 589-812 of SEQ ID NO:1; 590-812 of SEQ ID NO:1; 591-812 of SEQ ID NO:1; 592-812 of SEQ ID NO:1;593-812 of SEQ ID NO:1; 594-812 of SEQ ID NO:1; 595-812 of SEQ ID NO:1; 596-812 of SEQ ID NO:1; 597-812 of SEQ ID NO:1; 598-812 of SEQ ID NO:1; 599-812 of SEQ ID NO:1; 600-812 of SEQ ID NO:1; 601-812 of SEQ ID NO:1; 602-812 of SEQ ID NO:1; 603-812 of SEQ ID NO:1; 604-812 of SEQ ID NO:1; 605-812 of SEQ ID NO:1; 606-812 of SEQ ID NO:1; 607-812 of SEQ ID NO:1; 608-812 of SEQ ID NO:1; SEQ ID 609-812 of SEQ ID NO:1; 610-812 of SEQ ID NO:1; 611-812 of SEQ ID NO:1; 612-812 of SEQ ID NO:1; 613-812 of SEQ ID NO:1; 614-812 of SEQ ID NO:1; 615-812 of SEQ ID NO:1; and 616-812 of SEQ ID NO:1. ;

[0220] In some embodiments, a LINC complex inhibitory polypeptide or an inhibitory region thereof of the present disclosure comprises or consists essentially of an amino acid sequence corresponding to one of the following: 258-717 of SEQ ID NO: 13; 259-717 of SEQ ID NO: 13; 260-717 of SEQ ID NO: 13; 261-717 of SEQ ID NO: 13; 262-717 of SEQ ID NO: 13; 263-717 of SEQ ID NO: 13; 264-717 of SEQ ID NO: 13; 265-717 of SEQ ID NO: 13; 266-717 of SEQ ID NO: 13; 267-717 of SEQ ID NO: 13; 268-717 of SEQ ID NO: 13; 269-717 of SEQ ID NO: 13; 270-717 of SEQ ID NO: 13; SEQ ID NO:13; 271-717 of SEQ ID NO:13; 272-717 of SEQ ID NO:13; 273-717 of SEQ ID NO:13; 274-717 of SEQ ID NO:13; 275-717 of SEQ ID NO:13; 276-717 of SEQ ID NO:13; 277-717 of SEQ ID NO:13; 278-717 of SEQ ID NO:13; 279-717 of SEQ ID NO:13; 280-717 of SEQ ID NO:13; 281-717 of SEQ ID NO:13; 282-717 of SEQ ID NO:13; 283-717 of SEQ ID NO:13; 284-717 of SEQ ID NO:13; 285-717 of SEQ ID NO:13; SEQ ID NO:13, positions 286-717; SEQ ID NO:13, positions 287-717; SEQ ID NO:13, positions 288-717; SEQ ID NO:13, positions 289-717; SEQ ID NO:13, positions 290-717; SEQ ID NO:13, positions 291-717; SEQ ID NO:13, positions 292-717; SEQ ID NO:13, positions 293-717; SEQ ID NO:13, positions 294-717; SEQ ID NO:13, positions 295-717; SEQ ID NO:13, positions 296-717; SEQ ID NO:13, positions 297-717; SEQ ID NO:13, positions 298-717; SEQ ID NO:13, positions 299-717;300-717 of SEQ ID NO:13; 301-717 of SEQ ID NO:13; 302-717 of SEQ ID NO:13; 303-717 of SEQ ID NO:13; 304-717 of SEQ ID NO:13; 305-717 of SEQ ID NO:13; 306-717 of SEQ ID NO:13; 307-717 of SEQ ID NO:13; 308-717 of SEQ ID NO:13; 309-717 of SEQ ID NO:13; 310-717 of SEQ ID NO:13; 311-717 of SEQ ID NO:13; 312-717 of SEQ ID NO:13; 313-717 of SEQ ID NO:13; 314-717 of SEQ ID NO:13; SEQ ID NO:13 315-717; SEQ ID NO:13 316-717; SEQ ID NO:13 317-717; SEQ ID NO:13 318-717; SEQ ID NO:13 319-717; SEQ ID NO:13 320-717; SEQ ID NO:13 321-717; SEQ ID NO:13 322-717; SEQ ID NO:13 323-717; SEQ ID NO:13 324-717; SEQ ID NO:13 325-717; SEQ ID NO:13 326-717; SEQ ID NO:13 327-717; SEQ ID NO:13 328-717; SEQ ID NO:13 329-717; SEQ ID NO:13 NO:13 330-717; SEQ ID NO:13 331-717; SEQ ID NO:13 332-717; SEQ ID NO:13 333-717; SEQ ID NO:13 334-717; SEQ ID NO:13 335-717; SEQ ID NO:13 336-717; SEQ ID NO:13 337-717; SEQ ID NO:13 338-717; SEQ ID NO:13 339-717; SEQ ID NO:13 340-717; SEQ ID NO:13 341-717; SEQ ID NO:13 342-717; SEQ ID NO:13 343-717; SEQ ID NO:13 344-717;345-717 of SEQ ID NO:13; 346-717 of SEQ ID NO:13; 347-717 of SEQ ID NO:13; 348-717 of SEQ ID NO:13; 349-717 of SEQ ID NO:13; 350-717 of SEQ ID NO:13; 351-717 of SEQ ID NO:13; 352-717 of SEQ ID NO:13; 353-717 of SEQ ID NO:13; 354-717 of SEQ ID NO:13; 355-717 of SEQ ID NO:13; 356-717 of SEQ ID NO:13; 357-717 of SEQ ID NO:13; 358-717 of SEQ ID NO:13; 359-717 of SEQ ID NO:13; SEQ ID NO:13 360-717; SEQ ID NO:13 361-717; SEQ ID NO:13 362-717; SEQ ID NO:13 363-717; SEQ ID NO:13 364-717; SEQ ID NO:13 365-717; SEQ ID NO:13 366-717; SEQ ID NO:13 367-717; SEQ ID NO:13 368-717; SEQ ID NO:13 369-717; SEQ ID NO:13 370-717; SEQ ID NO:13 371-717; SEQ ID NO:13 372-717; SEQ ID NO:13 373-717; SEQ ID NO:13 374-717; SEQ ID NO:13 375-717; SEQ ID NO:13 376-717; SEQ ID NO:13 377-717; SEQ ID NO:13 378-717; SEQ ID NO:13 379-717; SEQ ID NO:13 380-717; SEQ ID NO:13 381-717; SEQ ID NO:13 382-717; SEQ ID NO:13 383-717; SEQ ID NO:13 384-717; SEQ ID NO:13 385-717; SEQ ID NO:13 386-717; SEQ ID NO:13 387-717; SEQ ID NO:13 388-717; SEQ ID NO:13 389-717;390-717 of SEQ ID NO:13; 391-717 of SEQ ID NO:13; 392-717 of SEQ ID NO:13; 393-717 of SEQ ID NO:13; 394-717 of SEQ ID NO:13; 395-717 of SEQ ID NO:13; 396-717 of SEQ ID NO:13; 397-717 of SEQ ID NO:13; 398-717 of SEQ ID NO:13; 399-717 of SEQ ID NO:13; 400-717 of SEQ ID NO:13; 401-717 of SEQ ID NO:13; 402-717 of SEQ ID NO:13; 403-717 of SEQ ID NO:13; 404-717 of SEQ ID NO:13; SEQ ID NO:13; 405-717; 406-717; 407-717; 408-717; 409-717; 410-717; 411-717; 412-717; 413-717; 414-717; 415-717; 416-717; 417-717; 418-717; 419-717; SEQ ID NO:13; NO:13 420-717; SEQ ID NO:13 421-717; SEQ ID NO:13 422-717; SEQ ID NO:13 423-717; SEQ ID NO:13 424-717; SEQ ID NO:13 425-717; SEQ ID NO:13 426-717; SEQ ID NO:13 427-717; SEQ ID NO:13 428-717; SEQ ID NO:13 429-717; SEQ ID NO:13 430-717; SEQ ID NO:13 431-717; SEQ ID NO:13 432-717; SEQ ID NO:13 433-717; SEQ ID NO:13 434-717;435-717 of SEQ ID NO:13; 436-717 of SEQ ID NO:13; 437-717 of SEQ ID NO:13; 438-717 of SEQ ID NO:13; 439-717 of SEQ ID NO:13; 440-717 of SEQ ID NO:13; 441-717 of SEQ ID NO:13; 442-717 of SEQ ID NO:13; 443-717 of SEQ ID NO:13; 444-717 of SEQ ID NO:13; 445-717 of SEQ ID NO:13; 446-717 of SEQ ID NO:13; 447-717 of SEQ ID NO:13; 448-717 of SEQ ID NO:13; 449-717 of SEQ ID NO:13; SEQ ID NO:13 450-717; SEQ ID NO:13 451-717; SEQ ID NO:13 452-717; SEQ ID NO:13 453-717; SEQ ID NO:13 454-717; SEQ ID NO:13 455-717; SEQ ID NO:13 456-717; SEQ ID NO:13 457-717; SEQ ID NO:13 458-717; SEQ ID NO:13 459-717; SEQ ID NO:13 460-717; SEQ ID NO:13 461-717; SEQ ID NO:13 462-717; SEQ ID NO:13 463-717; SEQ ID NO:13 464-717; SEQ ID NO:13, positions 465-717; SEQ ID NO:13, positions 466-717; SEQ ID NO:13, positions 467-717; SEQ ID NO:13, positions 468-717; SEQ ID NO:13, positions 469-717; SEQ ID NO:13, positions 470-717; SEQ ID NO:13, positions 471-717; SEQ ID NO:13, positions 472-717; SEQ ID NO:13, positions 473-717; SEQ ID NO:13, positions 474-717; SEQ ID NO:13, positions 475-717; SEQ ID NO:13, positions 476-717; SEQ ID NO:13, positions 477-717; SEQ ID NO:13, positions 478-717; SEQ ID NO:13, positions 479-717;480-717 of SEQ ID NO:13; 481-717 of SEQ ID NO:13; 482-717 of SEQ ID NO:13; 483-717 of SEQ ID NO:13; 484-717 of SEQ ID NO:13; 485-717 of SEQ ID NO:13; 486-717 of SEQ ID NO:13; 487-717 of SEQ ID NO:13; 488-717 of SEQ ID NO:13; 489-717 of SEQ ID NO:13; 490-717 of SEQ ID NO:13; 491-717 of SEQ ID NO:13; 492-717 of SEQ ID NO:13; 493-717 of SEQ ID NO:13; 494-717 of SEQ ID NO:13; SEQ ID NO:13; 495-717; 496-717; 497-717; 498-717; 499-717; 500-717; 501-717; 502-717; 503-717; 504-717; 505-717; 506-717; 507-717; 508-717; 509-717; SEQ ID NO:13; NO:13; 510-717; 511-717; 512-717; 513-717; 514-717; 515-717; 516-717; 517-717; 518-717; 519-717; 520-717; 521-717; and 522-717.

[0221] In some embodiments, the LINC complex inhibitory polypeptide or its inhibitory region of the present disclosure Not included or basically No Include An amino acid sequence corresponding to one of the following: 360-812 of SEQ ID NO: 1; 361-812 of SEQ ID NO: 1; 362-812 of SEQ ID NO: 1; 363-812 of SEQ ID NO: 1; 364-812 of SEQ ID NO: 1; 365-812 of SEQ ID NO: 1; 366-812 of SEQ ID NO: 1; 367-812 of SEQ ID NO: 1; 368-812 of SEQ ID NO: 1; 369-812 of SEQ ID NO: 1; 370-812 of SEQ ID NO: 1; 371-812 of SEQ ID NO: 1; 372-812 of SEQ ID NO: 1; 373-812 of SEQ ID NO: 1; 374-812 of SEQ ID NO: 1; NO: 375-812; SEQ ID NO: 376-812;

[0222] 377-812 of SEQ ID NO: 1; 378-812 of SEQ ID NO: 1; 379-812 of SEQ ID NO: 1; 380-812 of SEQ ID NO: 1; 381-812 of SEQ ID NO: 1; 382-812 of SEQ ID NO: 1; 383-812 of SEQ ID NO: 1;

[0223] 384-812 of SEQ ID NO: 1; 385-812 of SEQ ID NO: 1; 386-812 of SEQ ID NO: 1; 387-812 of SEQ ID NO: 1; 388-812 of SEQ ID NO: 1; 389-812 of SEQ ID NO: 1; 390-812 of SEQ ID NO: 1;

[0224] 391-812 of SEQ ID NO:1; 392-812 of SEQ ID NO:1; 393-812 of SEQ ID NO:1; 394-812 of SEQ ID NO:1; 395-812 of SEQ ID NO:1; 396-812 of SEQ ID NO:1; 397-812 of SEQ ID NO:1; 398-812 of SEQ ID NO:1; 399-812 of SEQ ID NO:1; 400-812 of SEQ ID NO:1; 401-812 of SEQ ID NO:1; 402-812 of SEQ ID NO:1; 403-812 of SEQ ID NO:1; 404-812 of SEQ ID NO:1; 405-812 of SEQ ID NO:1; 406-812 of SEQ ID NO:1; SEQ ID 407-812 of SEQ ID NO: 1; 408-812 of SEQ ID NO: 1; 409-812 of SEQ ID NO: 1; 410-812 of SEQ ID NO: 1; 411-812 of SEQ ID NO: 1;

[0225] 412-812 of SEQ ID NO:1; 413-812 of SEQ ID NO:1; 414-812 of SEQ ID NO:1; 415-812 of SEQ ID NO:1; 416-812 of SEQ ID NO:1; 417-812 of SEQ ID NO:1; 418-812 of SEQ ID NO:1; 419-812 of SEQ ID NO:1; 420-812 of SEQ ID NO:1; 421-812 of SEQ ID NO:1; 422-812 of SEQ ID NO:1; 423-812 of SEQ ID NO:1; 424-812 of SEQ ID NO:1; 425-812 of SEQ ID NO:1; 426-812 of SEQ ID NO:1; 427-812 of SEQ ID NO:1; SEQ ID NO:1 428-812; SEQ ID NO:1 429-812; SEQ ID NO:1 430-812; SEQ ID NO:1 431-812; SEQ ID NO:1 432-812; SEQ ID NO:1 433-812; SEQ ID NO:1 434-812; SEQ ID NO:1 435-812; SEQ ID NO:1 436-812; SEQ ID NO:1 437-812; SEQ ID NO:1 438-812; SEQ ID NO:1 439-812; SEQ ID NO:1 440-812; SEQ ID NO:1 441-812; SEQ ID NO:1 442-812; SEQ ID NO:1 443-812; SEQ ID NO:1 444-812 of SEQ ID NO:1; 445-812 of SEQ ID NO:1; 446-812 of SEQ ID NO:1; 447-812 of SEQ ID NO:1; 448-812 of SEQ ID NO:1; 449-812 of SEQ ID NO:1; 450-812 of SEQ ID NO:1; 451-812 of SEQ ID NO:1; 452-812 of SEQ ID NO:1; 453-812 of SEQ ID NO:1; 454-812 of SEQ ID NO:1; 455-812 of SEQ ID NO:1; 456-812 of SEQ ID NO:1;

[0226] 457-812 of SEQ ID NO:1; 458-812 of SEQ ID NO:1; 459-812 of SEQ ID NO:1; 460-812 of SEQ ID NO:1; 461-812 of SEQ ID NO:1; 462-812 of SEQ ID NO:1; 463-812 of SEQ ID NO:1; 464-812 of SEQ ID NO:1; 465-812 of SEQ ID NO:1; 466-812 of SEQ ID NO:1; 467-812 of SEQ ID NO:1; 468-812 of SEQ ID NO:1; 469-812 of SEQ ID NO:1; 470-812 of SEQ ID NO:1; 471-812 of SEQ ID NO:1; 472-812 of SEQ ID NO:1; SEQ ID 473-812 of SEQ ID NO:1; 474-812 of SEQ ID NO:1; 475-812 of SEQ ID NO:1; 476-812 of SEQ ID NO:1; 477-812 of SEQ ID NO:1; 478-812 of SEQ ID NO:1; 479-812 of SEQ ID NO:1; 480-812 of SEQ ID NO:1; 481-812 of SEQ ID NO:1; 482-812 of SEQ ID NO:1; 483-812 of SEQ ID NO:1; 484-812 of SEQ ID NO:1; 485-812 of SEQ ID NO:1; 486-812 of SEQ ID NO:1; 487-812 of SEQ ID NO:1; 488-812 of SEQ ID NO:1; SEQ 489-812 of SEQ ID NO:1; 490-812 of SEQ ID NO:1; 491-812 of SEQ ID NO:1; 492-812 of SEQ ID NO:1; 493-812 of SEQ ID NO:1; 494-812 of SEQ ID NO:1; 495-812 of SEQ ID NO:1; 496-812 of SEQ ID NO:1; 497-812 of SEQ ID NO:1; 498-812 of SEQ ID NO:1; 499-812 of SEQ ID NO:1; 500-812 of SEQ ID NO:1; 501-812 of SEQ ID NO:1; 502-812 of SEQ ID NO:1; 503-812 of SEQ ID NO:1;504-812 of SEQ ID NO:1; 505-812 of SEQ ID NO:1; 506-812 of SEQ ID NO:1; 507-812 of SEQ ID NO:1; 508-812 of SEQ ID NO:1; 509-812 of SEQ ID NO:1; 510-812 of SEQ ID NO:1; 511-812 of SEQ ID NO:1; 512-812 of SEQ ID NO:1; 513-812 of SEQ ID NO:1; 514-812 of SEQ ID NO:1; 515-812 of SEQ ID NO:1; 516-812 of SEQ ID NO:1; 517-812 of SEQ ID NO:1; 518-812 of SEQ ID NO:1; 519-812 of SEQ ID NO:1; SEQ ID NO:1; 520-812 of SEQ ID NO:1; 521-812 of SEQ ID NO:1; 522-812 of SEQ ID NO:1; 523-812 of SEQ ID NO:1; 524-812 of SEQ ID NO:1; 525-812 of SEQ ID NO:1; 526-812 of SEQ ID NO:1; 527-812 of SEQ ID NO:1; 528-812 of SEQ ID NO:1; 529-812 of SEQ ID NO:1; 530-812 of SEQ ID NO:1; 531-812 of SEQ ID NO:1; 532-812 of SEQ ID NO:1; 533-812 of SEQ ID NO:1; 534-812 of SEQ ID NO:1; 535-812 of SEQ ID NO:1; SEQ ID NO:1; 536-812; 537-812; 538-812; 539-812; 540-812; 541-812; 542-812; 543-812; 544-812; 545-812; 546-812; 547-812; 548-812; 549-812; 550-812;551-812 of SEQ ID NO:1; 552-812 of SEQ ID NO:1; 553-812 of SEQ ID NO:1; 554-812 of SEQ ID NO:1; 555-812 of SEQ ID NO:1; 556-812 of SEQ ID NO:1; 557-812 of SEQ ID NO:1; 558-812 of SEQ ID NO:1; 559-812 of SEQ ID NO:1; 560-812 of SEQ ID NO:1; 561-812 of SEQ ID NO:1; 562-812 of SEQ ID NO:1; 563-812 of SEQ ID NO:1; 564-812 of SEQ ID NO:1; 565-812 of SEQ ID NO:1; 566-812 of SEQ ID NO:1; SEQ ID NO:1; 567-812 of SEQ ID NO:1; 568-812 of SEQ ID NO:1; 569-812 of SEQ ID NO:1; 570-812 of SEQ ID NO:1; 571-812 of SEQ ID NO:1; 572-812 of SEQ ID NO:1; 573-812 of SEQ ID NO:1; 574-812 of SEQ ID NO:1; 575-812 of SEQ ID NO:1; 576-812 of SEQ ID NO:1; 577-812 of SEQ ID NO:1; 578-812 of SEQ ID NO:1; 579-812 of SEQ ID NO:1; 580-812 of SEQ ID NO:1; 581-812 of SEQ ID NO:1; 582-812 of SEQ ID NO:1; SEQ ID 583-812 of SEQ ID NO:1; 584-812 of SEQ ID NO:1; 585-812 of SEQ ID NO:1; 586-812 of SEQ ID NO:1; 587-812 of SEQ ID NO:1; 588-812 of SEQ ID NO:1; 589-812 of SEQ ID NO:1; 590-812 of SEQ ID NO:1; 591-812 of SEQ ID NO:1; 592-812 of SEQ ID NO:1; 593-812 of SEQ ID NO:1; 594-812 of SEQ ID NO:1; 595-812 of SEQ ID NO:1; 596-812 of SEQ ID NO:1; 597-812 of SEQ ID NO:1;598-812 of SEQ ID NO:1; 599-812 of SEQ ID NO:1; 600-812 of SEQ ID NO:1; 601-812 of SEQ ID NO:1; 602-812 of SEQ ID NO:1; 603-812 of SEQ ID NO:1; 604-812 of SEQ ID NO:1; 605-812 of SEQ ID NO:1; 606-812 of SEQ ID NO:1; 607-812 of SEQ ID NO:1; 608-812 of SEQ ID NO:1; 609-812 of SEQ ID NO:1; 610-812 of SEQ ID NO:1; 611-812 of SEQ ID NO:1; 612-812 of SEQ ID NO:1; 613-812 of SEQ ID NO:1; SEQ ID NO: 614-812; SEQ ID NO: 615-812; and SEQ ID NO: 616-812. In some embodiments, the LINC complex inhibitory polypeptide or inhibitory region thereof according to the present disclosure; Not included or basically Not includedAn amino acid sequence corresponding to one of the following: 258-717 of SEQ ID NO: 13; 259-717 of SEQ ID NO: 13; 260-717 of SEQ ID NO: 13; 261-717 of SEQ ID NO: 13; 262-717 of SEQ ID NO: 13; 263-717 of SEQ ID NO: 13; 264-717 of SEQ ID NO: 13; 265-717 of SEQ ID NO: 13; 266-717 of SEQ ID NO: 13; 267-717 of SEQ ID NO: 13; 268-717 of SEQ ID NO: 13; 269-717 of SEQ ID NO: 13; 270-717 of SEQ ID NO: 13; 271-717 of SEQ ID NO: 13; SEQ ID NO:13, 272-717; SEQ ID NO:13, 273-717; SEQ ID NO:13, 274-717; SEQ ID NO:13, 275-717; SEQ ID NO:13, 276-717; SEQ ID NO:13, 277-717; SEQ ID NO:13, 278-717; SEQ ID NO:13, 279-717; SEQ ID NO:13, 280-717; SEQ ID NO:13, 281-717; SEQ ID NO:13, 282-717; SEQ ID NO:13, 283-717; SEQ ID NO:13, 284-717; SEQ ID NO:13, 285-717; SEQ ID NO:13, 286-717; SEQ ID NO:13, positions 287-717; SEQ ID NO:13, positions 288-717; SEQ ID NO:13, positions 289-717; SEQ ID NO:13, positions 290-717; SEQ ID NO:13, positions 291-717; SEQ ID NO:13, positions 292-717; SEQ ID NO:13, positions 293-717; SEQ ID NO:13, positions 294-717; SEQ ID NO:13, positions 295-717; SEQ ID NO:13, positions 296-717; SEQ ID NO:13, positions 297-717; SEQ ID NO:13, positions 298-717; SEQ ID NO:13, positions 299-717; SEQ ID NO:13, positions 300-717; SEQ ID NO:13, positions 301-717;302-717 of SEQ ID NO:13; 303-717 of SEQ ID NO:13; 304-717 of SEQ ID NO:13; 305-717 of SEQ ID NO:13; 306-717 of SEQ ID NO:13; 307-717 of SEQ ID NO:13; 308-717 of SEQ ID NO:13; 309-717 of SEQ ID NO:13; 310-717 of SEQ ID NO:13; 311-717 of SEQ ID NO:13; 312-717 of SEQ ID NO:13; 313-717 of SEQ ID NO:13; 314-717 of SEQ ID NO:13; 315-717 of SEQ ID NO:13; 316-717 of SEQ ID NO:13; SEQ ID NO:13 317-717; SEQ ID NO:13 318-717; SEQ ID NO:13 319-717; SEQ ID NO:13 320-717; SEQ ID NO:13 321-717; SEQ ID NO:13 322-717; SEQ ID NO:13 323-717; SEQ ID NO:13 324-717; SEQ ID NO:13 325-717; SEQ ID NO:13 326-717; SEQ ID NO:13 327-717; SEQ ID NO:13 328-717; SEQ ID NO:13 329-717; SEQ ID NO:13 330-717; SEQ ID NO:13 331-717; SEQ ID NO:13 NO:13 332-717; SEQ ID NO:13 333-717; SEQ ID NO:13 334-717; SEQ ID NO:13 335-717; SEQ ID NO:13 336-717; SEQ ID NO:13 337-717; SEQ ID NO:13 338-717; SEQ ID NO:13 339-717; SEQ ID NO:13 340-717; SEQ ID NO:13 341-717; SEQ ID NO:13 342-717; SEQ ID NO:13 343-717; SEQ ID NO:13 344-717; SEQ ID NO:13 345-717; SEQ ID NO:13 346-717;347-717 of SEQ ID NO:13; 348-717 of SEQ ID NO:13; 349-717 of SEQ ID NO:13; 350-717 of SEQ ID NO:13; 351-717 of SEQ ID NO:13; 352-717 of SEQ ID NO:13; 353-717 of SEQ ID NO:13; 354-717 of SEQ ID NO:13; 355-717 of SEQ ID NO:13; 356-717 of SEQ ID NO:13; 357-717 of SEQ ID NO:13; 358-717 of SEQ ID NO:13; 359-717 of SEQ ID NO:13; 360-717 of SEQ ID NO:13; 361-717 of SEQ ID NO:13; SEQ ID NO:13 362-717; SEQ ID NO:13 363-717; SEQ ID NO:13 364-717; SEQ ID NO:13 365-717; SEQ ID NO:13 366-717; SEQ ID NO:13 367-717; SEQ ID NO:13 368-717; SEQ ID NO:13 369-717; SEQ ID NO:13 370-717; SEQ ID NO:13 371-717; SEQ ID NO:13 372-717; SEQ ID NO:13 373-717; SEQ ID NO:13 374-717; SEQ ID NO:13 375-717; SEQ ID NO:13 376-717; SEQ ID NO:13 377-717; SEQ ID NO:13 378-717; SEQ ID NO:13 379-717; SEQ ID NO:13 380-717; SEQ ID NO:13 381-717; SEQ ID NO:13 382-717; SEQ ID NO:13 383-717; SEQ ID NO:13 384-717; SEQ ID NO:13 385-717; SEQ ID NO:13 386-717; SEQ ID NO:13 387-717; SEQ ID NO:13 388-717; SEQ ID NO:13 389-717; SEQ ID NO:13 390-717; SEQ ID NO:13 391-717;392-717 of SEQ ID NO:13; 393-717 of SEQ ID NO:13; 394-717 of SEQ ID NO:13; 395-717 of SEQ ID NO:13; 396-717 of SEQ ID NO:13; 397-717 of SEQ ID NO:13; 398-717 of SEQ ID NO:13; 399-717 of SEQ ID NO:13; 400-717 of SEQ ID NO:13; 401-717 of SEQ ID NO:13; 402-717 of SEQ ID NO:13; 403-717 of SEQ ID NO:13; 404-717 of SEQ ID NO:13; 405-717 of SEQ ID NO:13; 406-717 of SEQ ID NO:13; SEQ ID NO:13; 407-717; 408-717; 409-717; 410-717; 411-717; 412-717; 413-717; 414-717; 415-717; 416-717; 417-717; 418-717; 419-717; 420-717; 421-717; SEQ ID NO:13; NO:13 422-717; SEQ ID NO:13 423-717; SEQ ID NO:13 424-717; SEQ ID NO:13 425-717; SEQ ID NO:13 426-717; SEQ ID NO:13 427-717; SEQ ID NO:13 428-717; SEQ ID NO:13 429-717; SEQ ID NO:13 430-717; SEQ ID NO:13 431-717; SEQ ID NO:13 432-717; SEQ ID NO:13 433-717; SEQ ID NO:13 434-717; SEQ ID NO:13 435-717; SEQ ID NO:13 436-717;437-717 of SEQ ID NO:13; 438-717 of SEQ ID NO:13; 439-717 of SEQ ID NO:13; 440-717 of SEQ ID NO:13; 441-717 of SEQ ID NO:13; 442-717 of SEQ ID NO:13; 443-717 of SEQ ID NO:13; 444-717 of SEQ ID NO:13; 445-717 of SEQ ID NO:13; 446-717 of SEQ ID NO:13; 447-717 of SEQ ID NO:13; 448-717 of SEQ ID NO:13; 449-717 of SEQ ID NO:13; 450-717 of SEQ ID NO:13; 451-717 of SEQ ID NO:13; SEQ ID NO:13 452-717; SEQ ID NO:13 453-717; SEQ ID NO:13 454-717; SEQ ID NO:13 455-717; SEQ ID NO:13 456-717; SEQ ID NO:13 457-717; SEQ ID NO:13 458-717; SEQ ID NO:13 459-717; SEQ ID NO:13 460-717; SEQ ID NO:13 461-717; SEQ ID NO:13 462-717; SEQ ID NO:13 463-717; SEQ ID NO:13 464-717; SEQ ID NO:13 465-717; SEQ ID NO:13 466-717; SEQ ID NO:13 467-717; SEQ ID NO:13 468-717; SEQ ID NO:13 469-717; SEQ ID NO:13 470-717; SEQ ID NO:13 471-717; SEQ ID NO:13 472-717; SEQ ID NO:13 473-717; SEQ ID NO:13 474-717; SEQ ID NO:13 475-717; SEQ ID NO:13 476-717; SEQ ID NO:13 477-717; SEQ ID NO:13 478-717; SEQ ID NO:13 479-717; SEQ ID NO:13 480-717; SEQ ID NO:13 481-717;482-717 of SEQ ID NO:13; 483-717 of SEQ ID NO:13; 484-717 of SEQ ID NO:13; 485-717 of SEQ ID NO:13; 486-717 of SEQ ID NO:13; 487-717 of SEQ ID NO:13; 488-717 of SEQ ID NO:13; 489-717 of SEQ ID NO:13; 490-717 of SEQ ID NO:13; 491-717 of SEQ ID NO:13; 492-717 of SEQ ID NO:13; 493-717 of SEQ ID NO:13; 494-717 of SEQ ID NO:13; 495-717 of SEQ ID NO:13; 496-717 of SEQ ID NO:13; SEQ ID NO:13, positions 497-717; SEQ ID NO:13, positions 498-717; SEQ ID NO:13, positions 499-717; SEQ ID NO:13, positions 500-717; SEQ ID NO:13, positions 501-717; SEQ ID NO:13, positions 502-717; SEQ ID NO:13, positions 503-717; SEQ ID NO:13, positions 504-717; SEQ ID NO:13, positions 505-717; SEQ ID NO:13, positions 506-717; SEQ ID NO:13, positions 507-717; SEQ ID NO:13, positions 508-717; SEQ ID NO:13, positions 509-717; SEQ ID NO:13, positions 510-717; SEQ ID NO:13, positions 511-717; SEQ ID NO:13 NO:13; 512-717 of SEQ ID NO:13; 513-717 of SEQ ID NO:13; 514-717 of SEQ ID NO:13; 515-717 of SEQ ID NO:13; 516-717 of SEQ ID NO:13; 517-717 of SEQ ID NO:13; 518-717 of SEQ ID NO:13; 519-717 of SEQ ID NO:13; 520-717 of SEQ ID NO:13; 521-717 of SEQ ID NO:13; and 522-717 of SEQ ID NO:13. ;

[0227] The LINC complex inhibitory polypeptide of the present disclosure may contain one or more additional amino acids or amino acid sequences. That is, the LINC complex inhibitory polypeptide may contain one or more amino acids or amino acid sequences in addition to the inhibitory region of the polypeptide (i.e., the region containing the amino acid sequence corresponding to the α3 helix of the CC2 region and the SUN domain of the protein containing the SUN domain).

[0228] For example, a LINC complex inhibitory polypeptide may comprise an amino acid sequence that facilitates expression, folding, trafficking, processing, purification, or detection.

[0229] According to various aspects and embodiments of the present disclosure, the LINC complex inhibitory polypeptide may include a sequence that prevents the polypeptide from being secreted from a cell expressing the polypeptide. In some embodiments, the polypeptide comprises an endoplasmic reticulum (ER) retention motif. According to the present disclosure, such a sequence may be provided to the C-terminus of the inhibition zone of the LINC complex inhibitory polypeptide. In some embodiments, a sequence (e.g., an ER retention motif) for preventing the polypeptide from being secreted from a cell expressing the polypeptide is provided at the C-terminus of the amino acid sequence of the polypeptide. In some embodiments, a sequence (e.g., an ER retention motif) for preventing the polypeptide from being secreted from a cell expressing the polypeptide is not followed by any other amino acids at the C-terminus of the polypeptide.

[0230] Endoplasmic reticulum retention sequences are known in the art. In some embodiments, the ER retention motif is a KDEL sequence. In some embodiments, the ER retention motif is a KDEL motif or a variant thereof that is effective for retaining a protein comprising the C-terminus of the motif in the endoplasmic reticulum. The KDEL variant may comprise or consist of an amino acid sequence that conforms to the original sequence motif: [K / R / H / Q / S / A]-[D / E / N / Q]-EL (e.g., in Hulo et al., 2006, Nucleic Acids Research 34: D227-D230), or Raykhel et al., 2007 (J. Cell Biol. 179(6): 1193-1204), which proposes an expanded original sequence motif definition. Raykhel et al. demonstrated ER retention using variants that included F at position 4 (i.e., K position), WY as a replacement for KRHQSA, a wide range of residues at position 3 (i.e., D position) beyond DENQ, F or M at position 1 (i.e., L position), and D at position 2 (i.e., E position).

[0231] For example, a variant of the KDEL motif may be, for example, one of CDEL, KCEL or HVEL, as proposed by Raykhel et al. Thus, in some aspects disclosed herein, the endoplasmic reticulum (ER) retention motif is KDEL or a variant thereof that exhibits ER retention activity.

[0232] In some embodiments, the ER retention motif comprises or consists of the amino acid sequence of SEQ ID NO:77 or a variant comprising one or more (eg, 1 or 2) substitutions to the amino acid sequence of SEQ ID NO:77.

[0233] In some embodiments, the LINC complex inhibitory polypeptide may include a signal peptide. According to the present disclosure, the signal peptide may be provided to the N-terminus of the inhibitory region of the LINC complex inhibitory polypeptide. In some embodiments, the signal peptide is provided at the N-terminus of the amino acid sequence of the polypeptide.

[0234] In some embodiments, the signal peptide does not have any other amino acids before the N-terminus of the polypeptide. The signal peptide is usually composed of a sequence of 5-30 hydrophobic amino acids that form a single alpha helix. Secreted proteins and proteins expressed on the cell surface usually include signal peptides. The signal peptide can be present at the N-terminus of the peptide / polypeptide and can be present in newly synthesized peptides / polypeptides. The signal peptide is usually removed by cleavage and is therefore not included in the mature peptide / polypeptide.

[0235] Signal peptides for many proteins are known and recorded in databases such as GenBank, UniProt, Swiss Prot, TrEMBL, Protein Information Resource, Protein Data Bank, Ensembl, and InterPro, and / or can be identified / predicted, for example, using amino acid sequence analysis tools such as SignalP (Petersen et al., 2011 Nature Methods 8:785-786) or Signal-BLAST (Frank and Sippl, 2008 Bioinformations 24:2172-2176). In some embodiments, the N-terminal signal sequence is derived from a secretory protein or a type I transmembrane protein. In some embodiments, the secretory protein or type I transmembrane protein is selected from: human serum albumin, proinsulin, transferrin receptor, EGF receptor, promelanocortin, carboxypeptidase, complement protein, fibrinogen, cytokine, chemokine, fibrinogen, pancreatic digestive enzyme (e.g., protease, amylase or lipase) or endoplasmic reticulum lumen protein (e.g., protein disulfide isomerase or GRP94). In some embodiments, the N-terminal signal peptide is derived from human serum albumin.

[0236] In some embodiments, the signal peptide includes a signal peptidase cleavage site. The signal peptidase cleavage site is used to remove the signal peptide from the mature polypeptide. In some embodiments, the LINC complex inhibitory polypeptide of the present disclosure comprises a signal peptidase cleavage site derived from a secretory protein or a type I transmembrane protein (e.g., a secretory protein or a type I transmembrane protein described above).

[0237] In some embodiments, the signal peptide comprises or consists of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 76. In some embodiments, the signal peptide comprises or consists of an amino acid sequence having at least 60%, such as at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 100.

[0238] In some embodiments, the LINC complex inhibitory polypeptide may comprise a detectable portion, such as a fluorescent label, a phosphorescent label, a luminescent label, an immunodetectable label (e.g., an epitope label), a radioactive label, a chemical label, a nucleic acid label, or an enzyme label. The LINC complex inhibitory polypeptide may be covalently or non-covalently labeled with a detectable portion.

[0239] In some embodiments, the detectable moiety is located at the N-terminus of the polypeptide (before or after treatment of the polypeptide by a signal peptidase to remove any signal peptide). In some embodiments, the detectable moiety is located at the C-terminus of the polypeptide, for example, downstream (after) a sequence for preventing secretion of the polypeptide from a cell expressing the polypeptide (e.g., downstream of an ER retention motif).

[0240] In some embodiments, the detectable portion is or comprises an epitope tag. In some embodiments, the epitope tag is selected from hemagglutinin alpha (HA), ALFA, histidine (His; e.g., 6XHis), c-Myc, glutathione S-transferase (GST), green fluorescent protein (GFP), maltose binding protein (MBP), FLAG, E, biotin, protein A, protein G, streptavidin, T7, thioredoxin, V5, or vesicular stomatitis virus glycoprotein (VSV-g) tags. In some embodiments, the detectable portion is or comprises a portion having a detectable activity, e.g., an enzyme activity on a given substrate. Examples of such portions include, e.g., horseradish peroxidase (HRP) and luciferase portions.

[0241] In some embodiments, the detectable moiety is or includes a HA tag.In some embodiments, the detectable moiety is or includes an ALFA tag.

[0242] In some embodiments, the detectable portion comprises or consists of the amino acid sequence of SEQ ID NO: 78, or a variant comprising one or more (e.g., 1, 2, 3, or 4) substitutions to the amino acid sequence of SEQ ID NO: 88. In some embodiments, the detectable portion comprises or consists of the amino acid sequence of SEQ ID NO: 79, or a variant comprising one or more (e.g., 1, 2, 3, or 4) substitutions to the amino acid sequence of SEQ ID NO: 99.

[0243] In some embodiments, the LINC complex inhibitory polypeptide of the present disclosure has one of the following structures:

[0244] N-terminus - [Signal peptide] - [Detectable entity] - [Inhibitory region comprising an amino acid sequence corresponding to the α3 helix of the CC2 region and the SUN region of a SUN domain-containing protein] - [Sequence that prevents secretion of the polypeptide from a cell expressing the polypeptide] - C-terminus

[0245] N-terminus - [detectable entity] - [signal peptide] - [inhibitory region comprising an amino acid sequence corresponding to the α3 helix of the CC2 region and the SUN region of a protein containing a SUN domain] - [sequence that prevents secretion of the polypeptide from a cell expressing the polypeptide] - C-terminus

[0246] N-terminus - [detectable entity] - [inhibitory region comprising an amino acid sequence corresponding to the α3 helix of the CC2 region and the SUN region of a protein containing a SUN domain] - [sequence that prevents secretion of the polypeptide from a cell expressing the polypeptide] - C-terminus

[0247] N-terminal - [an inhibitory region comprising an amino acid sequence corresponding to the α3 helix of the CC2 region and the SUN domain of a protein containing a SUN domain] - [a sequence that prevents secretion of the polypeptide from a cell expressing the polypeptide] - C-terminal

[0248] In some embodiments, the LINC complex inhibitory polypeptide of the present disclosure comprises one or more linker sequences between amino acid sequences. In some embodiments, the linker sequence has a length of 1-2, 1-3, 1-4, 1-5 or 1-10 amino acids. In some embodiments, the linker sequence can be provided at one or both ends of one or more regions selected from the following group: an inhibitory region comprising an amino acid sequence corresponding to the α3 helix of the CC2 region and the SUN domain-containing protein SUN domain; a signal peptide; a sequence that prevents the polypeptide from being secreted from a cell expressing the polypeptide; and / or a detectable entity of a LINC complex inhibitory polypeptide.

[0249] The linker sequence is known to those skilled in the art and is described, for example, in Adv Drug Deliv Rev (2013) 65 (10) by Chen et al.: 1357-1369, the entire contents of which are incorporated herein by reference. In some embodiments, the linker sequence may be a flexible linker sequence. The flexible linker sequence allows for relative movement of the amino acid sequence connected by the linker sequence. Flexible linkers are known to those skilled in the art and are described in Chen et al., Adv Drug Deliv Rev (2013) 65 (10) : 1357-1369. Flexible linker sequences typically contain a high proportion of glycine and / or serine residues. In some embodiments, the linker sequence contains at least one glycine residue and / or at least one serine residue. In some embodiments, the linker sequence consists of glycine and serine residues.

[0250] In preferred embodiments, the size of the LINC complex inhibitory polypeptide (ie, in terms of the number of amino acids that make up the LINC complex inhibitory polypeptide) allows for delivery of the LINC complex inhibitory polypeptide as a gene therapy, ie, in the form of a nucleic acid encoding the polypeptide.

[0251] In some embodiments, the size of the LINC complex inhibitory polypeptide is such that the size of the polynucleotide encoding the polypeptide (i.e., based on the number of nucleotides constituting the polynucleotide) is within the packaging limit of the vector used to deliver the polynucleotide. In some embodiments, the size of the LINC complex inhibitory polypeptide is such that the size of the polynucleotide encoding the polypeptide is within the packaging limit of the vector described herein. In some embodiments, the size of the LINC complex inhibitory polypeptide is such that the size of the polynucleotide encoding the polypeptide is within the packaging limit of an adeno-associated virus (AAV) vector (e.g., an AAV vector described herein). In some embodiments, the size of the LINC complex inhibitory polypeptide is such that the size of the polynucleotide encoding the polypeptide is within the packaging limit of an scAAV vector.

[0252] In some embodiments, the LINC complex inhibitory polypeptide consists of an amino acid sequence comprising less than 510 amino acids. In some embodiments, the LINC complex inhibitory polypeptide consists of an amino acid sequence comprising less than 457 amino acids.

[0253] In some embodiments, the LINC complex inhibitory polypeptide consists of an amino acid sequence comprising less than 600 amino acids, e.g., ≤550,

[0254] ≤500、≤450、≤400、≤350、≤340、≤330、≤320、≤310、≤300、≤290、≤280、≤270、≤260、≤250、

[0255] One of ≤240, ≤230, ≤220 or ≤210 amino acids.

[0256] The LINC complex inhibitory polypeptide disclosed herein can be prepared according to polypeptide production methods known to those skilled in the art.

[0257] Polypeptides can be prepared by chemical synthesis, such as liquid phase or solid phase synthesis. For example, peptides / polypeptides can be synthesized using methods such as Chandrudu et al., Molecules (2013), 18: 4373-4388, the entire contents of which are incorporated herein by reference. Alternatively, antigen binding molecules and polypeptides can be produced by recombinant expression. Molecular biology techniques suitable for polypeptide recombinant production are well known in the art, such as Green and Sambrook, Molecular Cloning: "Laboratory Manual" (4th Edition), Cold Spring Harbor Press, 2012, and Nat Methods. (2008); 5 (2): 135-146, the entire contents of these two documents are incorporated herein by reference. Methods for recombinant production of antigen binding molecules are also described in Frenzel et al. Front Immunol. (2013); 4.217 and Kunert and Reinhart, Appl Microbiol Biotechnol. (2016) 100: 3451-3461, the entire contents of both documents are incorporated herein by reference.

[0258] Nucleic acids and vectors encoding LINC complex inhibitory polypeptides

[0259] The present disclosure provides nucleic acids encoding LINC complex inhibitory polypeptides of the present disclosure. In some embodiments, the nucleic acid comprises or consists of DNA and / or RNA. In some embodiments, the nucleic acid is or comprises a polynucleotide. The nucleic acid may comprise or consist of a polynucleotide having a nucleotide sequence encoding a polypeptide of the present disclosure.

[0260] The LINC complex-inhibiting polypeptide of the present disclosure can be produced in a cell by translation of RNA encoding the polypeptide. The LINC complex-inhibiting polypeptide of the present disclosure can be produced in a cell by transcription of a nucleic acid encoding the polypeptide and subsequent translation of RNA.

[0261] In preferred embodiments, the nucleic acid is of a size that allows it to be delivered as a gene therapy, ie, in a suitable vector.

[0262] In some embodiments, the nucleic acid of the present disclosure consists of a nucleotide sequence whose size is within the packaging limit of a vector for delivering a polynucleotide. In some embodiments, the nucleic acid consists of a nucleotide sequence whose size is within the packaging limit of a vector described herein. In some embodiments, the nucleic acid consists of a nucleotide sequence whose size is within the packaging limit of an adeno-associated virus (AAV) vector (e.g., an AAV vector described herein). In some embodiments, the nucleic acid consists of a nucleotide sequence whose size is within the packaging limit of a scAAV vector.

[0263] The nucleic acid of the present disclosure may include a nucleotide sequence encoding a polypeptide, and may additionally include one or more non-coding nucleotide sequences. The non-coding nucleotide sequence may be, for example, a 5' cap, a 5' UTR, a 3' UTR and / or a Poly A tail sequence.

[0264] In some embodiments, the nucleotide sequence of the nucleic acid consists of less than 6000 nucleotides, such as ≤5000, ≤4500, ≤4000,

[0265] One of ≤3500, ≤3000, ≤2500, ≤2400 or ≤2300 nucleotides.

[0266] In some embodiments, the nucleotide sequence encoding the protein of the nucleic acid of the present disclosure consists of less than 1530 nucleotides. In some embodiments, the nucleotide sequence encoding the protein of the nucleic acid of the present disclosure consists of less than 1371 nucleotides.

[0267] In some embodiments, the protein encoding nucleotide sequence of the nucleic acid consists of less than 1800 nucleotides, e.g., ≤1650, ≤1500,

[0268] one of ≤1350, ≤1200, ≤1050, ≤1020, ≤990, ≤960, ≤930, ≤900, ≤870, ≤840, ≤810, ≤780, ≤750, ≤720, ≤690, ≤660 or ≤630 nucleotides.

[0269] In some embodiments, the nucleic acid is a vector or is contained in a vector. Therefore, the present disclosure also provides a vector comprising a nucleic acid encoding a LINC complex inhibitory polypeptide of the present disclosure.

[0270] The nucleic acids and vectors disclosed herein can be provided in purified or isolated form, i.e., from other nucleic acids or naturally occurring biological materials. "Vector" as used herein refers to a nucleic acid used as a carrier for transferring exogenous nucleic acids into cells. A vector can be a vector for expressing nucleic acids in cells (i.e., the vector can be an expression vector). Such a vector can include a promoter sequence operably linked to a nucleotide sequence encoding a sequence to be expressed. The vector can also include a stop codon and an expression enhancer. Any suitable vector, promoter, enhancer, and stop codon known in the art can be used to express peptides or polypeptides from the vectors disclosed herein.

[0271] The term "operably linked" can include situations where a selected nucleic acid sequence and a regulatory nucleic acid sequence (e.g., a promoter and / or enhancer) are covalently linked so that expression of the nucleic acid sequence is under the influence or control of the regulatory sequence (thereby forming an expression cassette). Thus, if the regulatory sequence is capable of affecting transcription of the nucleic acid sequence, the regulatory sequence is operably linked to the selected nucleic acid sequence. The resulting transcript can then be translated into a polypeptide, such as a LINC complex inhibitory polypeptide.

[0272] Suitable vectors include plasmids, binary vectors, DNA vectors, mRNA vectors, viral vectors (e.g., gamma-retroviral vectors (e.g., mouse leukemia virus (MLV) derived vectors), lentiviral vectors, adenoviral vectors, acinar-associated viral vectors, vaccinia viral vectors, and herpes viral vectors), transposon-based vectors, and artificial chromosomes (e.g., yeast artificial chromosomes), as described, for example, in Maus et al., Annu Rev Immunol (2014) 32: 189-225 or Morgan and Boyerinas, Biomedicies 2016 4, 9, all of which are incorporated herein by reference. In a preferred embodiment, the vector is an adeno-associated viral vector or a lentiviral vector.

[0273] In some embodiments, the vector is selected based on the tropism of the cell type / tissue / organ to which the nucleic acid is desired to be delivered. In some embodiments, the vector is selected based on the tropism of the cell type / tissue / organ in which the LINC complex inhibitory polypeptide is desired to be expressed. For example, it may be desirable to deliver the nucleic acid / express the LINC complex inhibitory polypeptide in a cell type / tissue / organ affected by a disease to be treated / prevented according to the present disclosure (e.g., a cell type, tissue / organ in which disease symptoms are manifested).

[0274] In some embodiments, it is desirable to deliver a nucleic acid encoding a LINC complex inhibitory polypeptide to muscle cells / tissues (e.g., cardiac and / or skeletal muscle cells / tissues), and in such embodiments a vector having tropism for such cells / tissues may be used. In some embodiments, the vector may be cardiac. In some embodiments, the vector may be myotropic.

[0275] In a preferred embodiment, the vector is an adeno-associated virus vector. Adeno-associated virus vectors and their applications in vector gene therapy are reviewed in, for example, Wang et al., Nat. Rev. D Rug Discov. (2019) 18: 358-378 and Li and Samulski, Nat. Rev. Genet. (2020) 12: 255-272, the entire contents of which are incorporated herein by reference. In some embodiments, the vector may be an adeno-associated virus vector described in Wang et al., Nat. Rev. D Rug Discov. (2019) 18: 358-378. In some embodiments, the vector may be an adeno-associated virus vector described in Li and Samulski, Nat. Rev. Genet. (2020) 12: 255-272.

[0276] In some embodiments, the vector is a self-complementary adeno-associated virus (scAAV) vector. Self-complementary adeno-associated virus vectors are described, for example, in McCarty, Mol Ther. (2008) 16 (10): 1648-56, the entire contents of which are incorporated herein by reference. Traditional AAV has a single-stranded DNA genome and relies on the DNA replication machinery of the transduced cells to synthesize the complementary strand, thereby delaying transgene expression. In contrast, scAAV contains complementary sequences that spontaneously anneal upon infection, eliminating the need for DNA synthesis in the transduced host cells. Compared to classic single-stranded AAV vectors, scAAV vectors have been shown to accelerate the onset of transgene expression and increase transgene expression levels.

[0277] In some embodiments, the vector can be an adeno-associated virus vector of one of the following serotypes: AAV1, AAV2, AAV2i8, AAV5, AAV6, AAV8, AAV9, AAV9.45, AAV10, or AAVrh74. In some embodiments, the vector is an AAV9 vector.

[0278] In some embodiments, the vector may be an adeno-associated virus vector. In some embodiments, the vector may be an adeno-associated virus vector of one of the following serotypes: AAV1, AAV8, AAV9, AAV9.45.

[0279] In some embodiments, the vector can be a skeletal muscle-tropic adeno-associated virus vector. In some embodiments, the vector can be an adeno-associated virus vector of one of the following serotypes: AAV1, AAV6, AAV7, AAV8, AAV9, AAV9.45.

[0280] In some embodiments, the vector includes modifications to increase binding and / or transduction to a cell type of interest (ie, compared to the level of binding / transduction of an unmodified vector). In some embodiments, the modification is to a capsid protein.

[0281] In some embodiments, the carrier comprises a capsid protein comprising a cell targeting peptide. In some embodiments, the cell targeting peptide is as described in Büning and Srivastava, Molecular Therapy: Methods and Clinical Development (2019) 12: 248-265, which is incorporated herein by reference in its entirety, such as the cell targeting peptides shown in its Table 1, 2, 3 or 4.

[0282] In some embodiments, the carrier comprises a capsid protein, and the capsid protein comprises a replacement of one or more tyrosine residues, such as one or more surface-exposed tyrosine residues. In some embodiments, one or more tyrosine residues of the capsid protein are replaced by phenylalanine. In some embodiments, the carrier comprises a capsid protein, wherein one or more tyrosine residues are replaced by another amino acid, such as Iida et al., Biomed Res Int. (2013) 2013: described in 974819, the entire contents of which are incorporated herein by reference.

[0283] In some embodiments, the vector may be an adeno-associated viral vector as described in Büning and Srivastava, supra. In some embodiments, the vector may be an adeno-associated viral vector as described in Iida et al., supra.

[0284] In some embodiments, the nucleic acid / vector comprises one or more sequences for controlling the expression of the nucleic acid. Thus, in some embodiments, the nucleic acid / vector comprises a control element for inducing the expression of the nucleic acid.

[0285] Sequences for controlling nucleic acid expression can provide expression of the nucleic acid in cells or tissues of a particular type. For example, expression can be carried out under the control of a cell type or tissue specific promoter.

[0286] The promoter of cell type or tissue-specific expression of nucleic acid according to the present invention can be selected according to the disease to be treated / prevented. For example, the promoter can drive the expression in the cell type / tissue / organ (for example, the cell type, tissue / organ showing disease symptoms) affected by the disease.

[0287] In some embodiments, the promoter can provide expression in muscle cells / tissues (e.g., heart and / or skeletal muscle cells / tissues). In some embodiments, the promoter can be a cardiac or myocardial specific promoter (e.g., cTNT, α-MHC, or MLC2v promoter). In some embodiments, the promoter can be a skeletal muscle / striated muscle cell specific promoter (e.g., MCK, MHCK7, or desmin promoter). In some embodiments, the promoter is cTNT.

[0288] In some embodiments, the promoter may be a vascular endothelial cell-specific promoter (e.g., Tie2 promoter). In some embodiments, the promoter may be a vascular smooth muscle cell-specific promoter (e.g., SM22a promoter). In some embodiments, the promoter may be a monocyte / macrophage-specific promoter (e.g., LysM promoter).

[0289] Sequences for controlling nucleic acid expression can provide expression of nucleic acid in response to, for example, a given agent / signal. For example, expression can be carried out under the control of an inducible promoter. The agent can provide induced expression of nucleic acid in vivo by administering the agent to a subject to which a modified cell according to the present disclosure has been administered, or can provide inducible expression of nucleic acid in vitro / in vitro by administering the agent to cells in vitro or in vitro culture.

[0290] In some embodiments, a nucleic acid or vector according to the present disclosure may employ a conditional expression system to control expression of a nucleic acid encoding a LINC complex inhibitory polypeptide by a cell comprising the nucleic acid / vector. "Conditional expression" may also be referred to herein as "inducible expression" and refers to expression that depends on certain conditions, such as the presence of a specific agent. Conditional expression systems are well known in the art and are described, for example, in Ryding et al. Journal of Endocrinology (2001) 171, 1-14, the entire contents of which are incorporated herein by reference.

[0291] Cells encoding / containing / expressing LINC complex inhibitory polypeptide

[0292] The present disclosure also provides cells comprising or expressing the LINC complex inhibitory polypeptide of the present disclosure. Cells comprising or expressing the nucleic acid or vector of the present disclosure are also provided.

[0293] The cell may be a eukaryotic cell, such as a mammalian cell. The mammal may be a primate (rhesus monkey, cynomolgus monkey, non-human primate or human) or a non-human mammal (e.g., rabbit, guinea pig, rat, mouse or other rodent (including rodents), cat, dog, pig, sheep, goat, cattle (including cows, such as cows, or any animal of the order Bos), horse (including equine), donkey and non-human primate). In a preferred embodiment, the cell may be a human cell.

[0294] The present disclosure also provides a method for producing a cell comprising a nucleic acid or vector of the present disclosure or a cell comprising / expressing a LINC complex inhibitory polypeptide of the present disclosure, the method comprising introducing a nucleic acid or vector of the present disclosure into a cell. In some embodiments, introducing a nucleic acid / vector of the present disclosure into a cell comprises transformation, transfection, electroporation or transduction (e.g., adeno-associated virus transduction). In some embodiments, the nucleic acid / vector is introduced into a cell in vivo, for example, after administering a vector of the present disclosure (e.g., a viral vector, e.g., an adeno-associated virus vector) to a subject. In some embodiments, the nucleic acid / vector is introduced into a cell in an ex vivo culture or in vitro culture.

[0295] In some embodiments, the method further comprises culturing the cell under conditions suitable for expression of the nucleic acid or vector by the cell.

[0296] The present disclosure also provides cells obtained or obtainable by a method according to the present disclosure.

[0297] Composition

[0298] The present disclosure also provides compositions comprising the LINC complex inhibitory polypeptides, nucleic acids, vectors and cells described herein. In particular, the present disclosure provides pharmaceutical compositions and drugs comprising the LINC complex inhibitory polypeptides, nucleic acids, vectors and cells of the present disclosure.

[0299] The composition may comprise the relevant preparation (ie, LINC complex inhibitory polypeptide / nucleic acid / vector / cell) in a formulation suitable for clinical use. The present disclosure particularly relates to a pharmaceutical composition / medicament comprising a nucleic acid of the present disclosure and a vector.

[0300] The compositions of the present disclosure may comprise one or more pharmaceutically acceptable carriers (e.g., liposomes, micelles, microspheres, nanoparticles), diluents / excipients (e.g., starch, cellulose, cellulose derivatives, polyols, glucose, maltodextrin, magnesium stearate), adjuvants, fillers, buffers, preservatives (e.g., vitamin A, vitamin E, starch, cellulose, gelatin, polyethylene glycol (PEG), polyvinyl pyrrolidone (PVP), xylitol, sorbitol, mannitol), stabilizers, solubilizers, surfactants (e.g., wetting agents), masking agents, or colorants (e.g., titanium oxide).

[0301] The term "pharmaceutically acceptable" as used herein relates to compounds, ingredients, materials, compositions, dosage forms, etc., which are suitable for use in contact with the tissues of the subject (e.g., a human subject) within the scope of sound medical judgment without undue toxicity, irritation, allergic response, or other problems or complications, and commensurate with a reasonable benefit / risk ratio. Each carrier, diluent, excipient, adjuvant, filler, buffer, preservative, antioxidant, lubricant, binder, stabilizer, solubilizer, surfactant, masking agent, colorant, flavoring agent, or sweetener of the compositions of the present disclosure must also be "acceptable" in the sense of being compatible with the other ingredients of the formulation. Suitable carriers, diluents, excipients, adjuvants, fillers, buffers, preservatives, antioxidants, lubricants, binders, stabilizers, solubilizers, surfactants, masking agents, colorants, flavoring agents, or sweeteners can be found in standard pharmaceutical texts, for example, Remington's The Science and Practice of Pharmacy.

[0302] (Ed. A. Adejare), 23rd edition (2020), Academic Press.

[0303] The pharmaceutical compositions / medicines disclosed herein can be formulated for administration to a subject, for example, by a route of administration suitable for the properties of the therapeutic agent and the disease to be treated / prevented. In some embodiments, the pharmaceutical compositions / medicines can be formulated for parenteral, systemic, topical, intracavitary, intravascular, intravenous, intraarterial, intramuscular, intrathecal, intraocular, intraconjunctival, intratumoral, subcutaneous, intradermal, oral or transdermal administration. In some embodiments, the pharmaceutical compositions / medicines can be formulated for administration by injection or infusion, or by ingestion.

[0304] Drugs and pharmaceutical compositions can be formulated for administration to a blood vessel or a target tissue / organ (eg, a tissue / organ affected by a disease (eg, a tissue / organ showing symptoms of a disease / disorder)).

[0305] The pharmaceutical composition / drug may comprise a LINC complex inhibitory polypeptide / nucleic acid / vector / cell in a sterile or isotonic medium. The pharmaceutical composition / drug may be provided in a fluid form, including a gel form. The fluid formulation may be formulated for administration by injection or infusion (e.g., via a cannula) into a blood vessel or a selected area of ​​the human or animal body. The pharmaceutical composition / drug may be provided in a solid form, such as in a lyophilized form.

[0306] The present disclosure also provides a method for producing the pharmaceutical composition / drug of the present disclosure. Such a method may include mixing the LINC complex inhibitory polypeptide / nucleic acid / vector / cell described herein with a pharmaceutically acceptable carrier, diluent, excipient, adjuvant, filler, buffer, preservative, antioxidant, lubricant, adhesive, stabilizer, solubilizer, surfactant, masking agent, colorant, flavoring agent or sweetener. This method generally includes the step of combining the LINC complex inhibitory polypeptide / nucleic acid / vector / cell with a carrier constituting one or more auxiliary components. Typically, the composition is prepared by uniformly and tightly combining the active compound with a carrier (e.g., a liquid carrier, a finely divided solid carrier, etc.), and then molding the product if necessary.

[0307] LINC complex inhibitory polypeptides, nucleic acids, vectors, cells and compositions according to the present disclosure can be modified and / or formulated to facilitate delivery to cells / tissues of interest (e.g., cardiac and / or skeletal muscle cells / tissues) and / or uptake by target tissues.

[0308] For example, as described in Li et al. Int. J. Mol. Sci. (2015) 16: 19518-19536 and Fu et al., Bioconjug Chem. (2014) 25(9): 1602-1608, the entire contents of which are incorporated herein by reference.

[0309] In some embodiments, the articles of the present disclosure may be encapsulated in nanoparticles or liposomes. In some embodiments, the articles of the present disclosure may be associated (covalently or non-covalently) with cell penetrating peptides (e.g., protein transduction domains, trojan peptides, arginine-rich peptides, carrier cell peptides), cationic polymers, cationic lipids, or viral vectors.

[0310] Nanoparticles can be organic, such as micelles, liposomes, proteins, solid lipid particles, solid polymer particles, dendrimers and polymer therapeutic agents. Nanoparticles can be inorganic, such as nanotubes or metal particles, optionally with the addition of organic molecules. In some embodiments, nanoparticles are described in Chen et al., Mol Ther Methods Clin Dev. (2016) 3: 16023, the entire contents of which are incorporated herein by reference. In some embodiments, nanoparticles are PLGA, polypeptides, poly (β-amino esters), DOPE, polycations containing β-cyclodextrin, linear PEI, PAMAM dendrimers, branched PEI, chitosan or polypolyphosphate nanoparticles.

[0311] In some embodiments, the LINC complex inhibitory polypeptides, nucleic acids, and vectors disclosed herein include modifications to bind one or more moieties that facilitate delivery to and / or uptake by a target cell type or tissue (e.g., cardiac and / or skeletal muscle cells / tissues). In some embodiments, the LINC complex inhibitory polypeptides, nucleic acids, and vectors disclosed herein are linked (e.g., chemically conjugated) to one or more moieties that facilitate delivery to and / or uptake by a target cell type or tissue.

[0312] The moiety that promotes delivery to the cell type or tissue of the target and / or uptake by the tissue of the target is described in, for example, Benizri et al., Bioconjug Chem. (2019) 30(2): 366-383, the entire contents of which are incorporated herein by reference. The moiety includes, for example, N-acetylgalactosamine (GalNAc), α-tocopherol, cell penetrating peptides, nucleic acid aptamers, antibodies and antigen-binding fragments / derivatives thereof, cholesterol, squalene, polyethylene glycol (PEG), fatty acids (e.g., palmitic acid), and nucleolar lipid moieties.

[0313] The articles of manufacture of the present disclosure can be formulated in a sustained-release delivery system to release a LINC complex inhibitory polypeptide, nucleic acid, vector, cell or composition at a predetermined rate. The sustained-release delivery system can maintain a constant drug / treatment / prevention concentration over a specific period of time. In some embodiments, the articles of manufacture of the present disclosure are formulated into liposomes, gels, implants, devices or drug-polymer conjugates, such as hydrogels.

[0314] Method for Identifying LINC Complex Inhibitory Peptides

[0315] The present disclosure also provides methods of identifying LINC complex inhibitory polypeptides.

[0316] The method generally comprises introducing a nucleic acid encoding a candidate LINC complex inhibitory polypeptide comprising an amino acid sequence corresponding to a SUN region of a SUN domain-containing protein or corresponding to a KASH region of a KASH domain-containing protein, and analyzing the subcellular localization of a SUN domain-containing protein interaction partner (in the case where the candidate LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to a SUN domain in a SUN domain-containing protein), or analyzing the subcellular localization of a KASH domain-containing protein interaction partner (in the case where the candidate LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to a KASH-domain of a KASH domain-containing protein) to determine whether the candidate LINC complex inhibitory polypeptide alters / disrupts the normal subcellular localization of the relevant interaction partner.

[0317] More specifically, the present disclosure provides a method for identifying a LINC complex inhibitory polypeptide, comprising:

[0318] introducing a nucleic acid encoding a candidate LINC complex inhibitory polypeptide, wherein the candidate LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to a SUN domain of a SUN domain-containing protein (e.g., SUN1, SUN2, SUN3, SUN5, SPAG4, or SUCO); and

[0319] The cells are then analyzed to determine the subcellular localization of interacting partners of the SUN domain-containing protein (e.g., a KASH domain-containing protein, such as Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4, KASH5, or LRMP);

[0320] Among them, a candidate LINC complex inhibitory polypeptide is identified as a LINC complex inhibitory polypeptide for which a change in the subcellular localization of an interacting partner of a SUN domain-containing protein is detected.

[0321] Also provided is a method for identifying a LINC complex inhibitory polypeptide, comprising:

[0322] Introducing a nucleic acid encoding a candidate LINC complex inhibitory polypeptide, wherein the candidate LINC complex inhibitory polypeptide comprises a protein containing a KASH domain (e.g., Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4, KASH5 or

[0323] The amino acid sequence corresponding to the KASH structure of LRMP); and

[0324] The cells are then analyzed to determine the subcellular localization of interacting partners of the KASH domain-containing protein (e.g., a SUN domain-containing protein, such as SUN1, SUN2, SUN3, SUN5, SPAG4, or SUCO);

[0325] The candidate LINC complex inhibitory polypeptide is identified as a LINC complex inhibitory polypeptide for which a change in the subcellular localization of an interacting partner of a KASH domain-containing protein is detected.

[0326] It should be understood that the changes in the subcellular localization of the relevant interaction partner as described in the previous two paragraphs refer to the changes in the subcellular localization relative to the interaction partner in control cells into which the nucleic acid encoding the candidate LINC complex inhibitory polypeptide has not been introduced, or in cells into which the nucleic acid encoding the control polypeptide known not to affect the subcellular localization of the relevant interaction partner has been introduced.

[0327] The method is preferably performed using cells cultured in vitro.

[0328] In some embodiments, introducing a nucleic acid into a cell can include transformation, transfection, electroporation, or transduction (eg, adeno-associated viral transduction).

[0329] In some embodiments, a nucleic acid encoding a candidate LINC complex inhibitory polypeptide may be provided in a vector, such as a vector according to the embodiments described herein.

[0330] The nucleic acid encoding the candidate LINC complex-inhibiting polypeptide preferably includes regulatory elements that provide for expression of the candidate LINC complex-inhibiting polypeptide in the cell into which the nucleic acid has been introduced. After the nucleic acid has been introduced into the cell, the cell is preferably maintained under conditions suitable for expression of the candidate LINC complex-inhibiting polypeptide from the nucleic acid in the cell.

[0331] It will also be appreciated that after introduction of the nucleic acid into the cells, sufficient time is preferably allowed for changes in the subcellular localization of the relevant interaction partner prior to analysis of the cells in order to assess the subcellular location of the relevant interaction partner.

[0332] The subcellular localization of a given polypeptide (e.g., a protein containing a SUN domain or a given interaction partner of a protein containing a KASH domain) can be analyzed by methods well known to those skilled in the art. Such methods include antibody / reporter gene-based methods (Western blots, ELISA, immunohistochemistry / cytochemistry, etc.). For example, subcellular localization can be analyzed, for example, by immunocytochemistry or by Western blots of extracts prepared from different cell fractions. Such analysis can use organelle markers and / or labeled proteins of known subcellular localization.

[0333] The method may use an interacting partner of a SUN domain-containing protein or a KASH domain-containing protein conjugated to a fluorescent marker, and may include analyzing the subcellular localization of the species by fluorescence microscopy. This method may employ antibody-based detection of an interacting partner of a SUN domain-containing protein or a KASH domain-containing protein, and may include analyzing the subcellular localization of such species by immunofluorescence microscopy.

[0334] In some embodiments, a candidate LINC complex inhibitory polypeptide is identified as a LINC complex inhibitor polypeptide in which a reduced proportion of a relevant interaction partner localized to the nuclear envelope is detected (relative to the proportion localized to the nuclear envelope in a control cell into which a nucleic acid encoding the candidate LINC complex inhibitory polypeptide has not been introduced, or a control cell into which a nucleic acid encoding a control polypeptide known not to affect the subcellular localization of a relevant interaction partner has been introduced).

[0335] In some embodiments, a candidate LINC complex inhibitory polypeptide is identified as a LINC complex inhibitor polypeptide in which an increased proportion of the relevant interaction partner that is not localized to the nuclear membrane, or an increased proportion of the relevant interaction partner that is localized to the endoplasmic reticulum is detected (relative to the proportion of localization to the nuclear envelope in control cells into which a nucleic acid encoding the candidate LINC complex inhibitory polypeptide has not been introduced, or control cells into which a nucleic acid encoding a control polypeptide known not to affect the subcellular localization of the relevant interaction partner has been introduced).

[0336] In some embodiments, methods for identifying a LINC complex-inhibitory polypeptide may include analysis of a candidate LINC complex-inhibitory polypeptide substantially as described in Example 1 herein.

[0337] In some embodiments, the method for identifying a LINC complex inhibitory polypeptide comprises:

[0338] introducing into the cell a nucleic acid encoding a candidate LINC complex inhibitory polypeptide comprising an amino acid sequence corresponding to a SUN domain of a SUN domain-containing protein; and

[0339] The cells were then analyzed to determine the subcellular localization of Nesprin-2;

[0340] The candidate LINC complex inhibitory polypeptide is identified as a LINC complex inhibitory polypeptide that detects an increased ratio of Nesprin-2 localized in the endoplasmic reticulum.

[0341] The present disclosure also provides LINC complex inhibitory polypeptides identified according to the methods of the present disclosure.

[0342] Therapeutic and preventive applications

[0343] The LINC complex inhibitory polypeptides, nucleic acids, vectors, cells and compositions described herein can be used in therapeutic and prophylactic methods.

[0344] The present disclosure provides LINC complex inhibitory polypeptides, nucleic acids, vectors, cells and compositions described herein for use in drug treatment or prevention methods. Also provided are uses of LINC complex inhibitory polypeptides, nucleic acids, vectors, cells and compositions described herein in the preparation of drugs for treating or preventing diseases / disorders. Also provided are methods for treating or preventing diseases / disorders, comprising administering to a subject a therapeutically effective amount or a preventively effective amount of LINC complex inhibitory polypeptides, nucleic acids, vectors, cells and compositions described herein.

[0345] The terms "disorder," "disease," and "symptom" are used interchangeably to refer to a pathological problem with a body part, organ, or system that may be characterized by a recognizable group of signs or symptoms.

[0346] The therapeutic or preventive interventions disclosed herein can be effective in slowing the development or progression of a disease / disorder, alleviating symptoms of a disease / disorder, or reducing the pathology of a disease / symptom. The intervention can be effective in preventing the progression of a disease / disorder, such as preventing the disease / disorder from worsening or slowing the rate at which a disease / disorder develops. In some embodiments, the intervention can result in an improvement in a disease / condition, such as a reduction in symptoms of a disease / condition or a reduction in some other correlation of disease / condition severity / activity. In some embodiments, the intervention can prevent a disease / disorder from developing to a later stage (e.g., a more severe stage or a chronic stage).

[0347] As used herein, the terms "develop," "developing," and "development," eg, of a disease, refer to the onset of a disease as well as the progression, worsening, or exacerbation of a disease state / related disorder.

[0348] Various aspects of the present disclosure relate to the treatment / prevention of diseases in which LINC complex dysfunction is pathologically implicated. Such diseases include, for example, nuclear envelope diseases (e.g., laminopathy). The therapeutic and prophylactic uses of the formulations and methods of the present disclosure extend to the treatment and / or prevention of any disease that would benefit from LINC complex inhibition.

[0349] Aspects of the present disclosure relate to the treatment of diseases associated with mutations in a given gene or genes. Here, a disease "associated" with a given gene mutation is a disease caused or aggravated by such a mutation, or such a mutation is a risk factor for disease development or progression. In some embodiments, compared to cells containing two copies of a non-mutated (wild-type) reference allele of a gene (i.e., homozygous), a mutation causes one or more of the following in a mutant allele cell containing one or more copies of a gene: a reduction in the level of a gene product (e.g., RNA and / or protein (or its specific isomer)) of a wild-type allele gene; an increase in the level of a gene product of a non-wild-type allele; an increase in the level of a gene product of a wild-type allele.

[0350] Aspects of the present disclosure relate to the treatment / prevention of the nuclear envelope. Nuclear envelope diseases are diseases / pathological conditions associated with mutations in genes encoding nuclear envelope proteins (i.e., proteins contained in the ONM, perinuclear space, or INM or directly / indirectly associated therewith). The nuclear envelope is reviewed, for example, by Chi et al., Journal of Biomedical Science (2009) 16:96, which is incorporated herein by reference in its entirety. Nuclear envelope diseases include diseases / pathological conditions associated with mutations in LMNA, LMNB1, LMNB2, EMD, LAP2, LBR, ZMPSTE24, SYNE-1, and NUP62.

[0351] Thus, in some embodiments, the disease / disorder to be treated / prevented in accordance with the present disclosure is characterized by one or more of LMNA, LMNB1, LMNB2, EMD, LAP2, LBR, ZMPSTE24, SYNE-1, and NUP62 mutations.

[0352] In particular, aspects of the present disclosure relate to the treatment / prevention of laminopathies.

[0353] Laminopathy is reviewed in Burke and Stewart, Nat Rev Mol Cell Biol. (2013) 14(1): 13-24, and Hah and Kim, Cells (2019) 8(3): 231, the entire contents of which are incorporated herein by reference. Laminopathy is often associated with tissue-specific defects in nuclear load-bearing, which reduces the cell's tolerance to physical forces. In the experimental examples herein, the inventors demonstrate that LINC complex inhibition improves the symptoms of a range of laminopathy.

[0354] As used herein, a "laminopathy" is a disease / pathological condition associated with mutations in genes encoding lamin proteins.

[0355] Genes encoding lamins include LMNA, which encodes lamins A and C, and LMNB1, LMNB2, which encode lamins B1 and B2. Thus, aspects of the present disclosure relate to the treatment / prevention of diseases associated with mutations in LMNA, LMNB1 and / or LMNB2.

[0356] In some embodiments, the mutation is known or predicted to reduce the level of a lamin subtype encoded by a wild-type allele of a gene encoding a lamin (e.g., LMNA, LMNB1, or LMNB2). In some embodiments, the mutation is a missense mutation. In some embodiments, the mutation is known or predicted to result in the production of a truncated version of a lamin encoded by a wild-type allele of a gene encoding a lamin. In some embodiments, the mutation is known or predicted to result in the production of misfolded and / or degraded lamins.

[0357] In some embodiments, the mutation is known or predicted to increase the level of a lamin isoform encoded by a wild-type allele of a gene encoding a lamin protein (eg, LMNA, LMNB1, or LMNB2).

[0358] In some embodiments, the mutation is known or predicted to increase the level of a disease-associated lamin variant (e.g., progerin). In some embodiments, the mutation is known or predicted to increase the level of a lamin encoded by a disease-associated allele of a gene encoding a lamin.

[0359] In some embodiments, the laminopathy is a skeletal muscle laminopathy. In some embodiments, the laminopathy is a myopathy. In some embodiments, the laminopathy is a myopathy associated with a LMNA mutation.

[0360] In some embodiments, the disease to be treated / prevented in accordance with the present disclosure is characterized by one or more of a myopathy, a cardiomyopathy, a dilated cardiomyopathy, a muscular dystrophy, a cardiac dystrophy, a skeletal muscular dystrophy, a progeria, a neuropathy, a lipodystrophy, a skeletal dysplasia, a lipodystrophy, a leukodystrophy, or a skin disease.

[0361] In some embodiments, the disease to be treated / prevented in accordance with the present disclosure is characterized by one or more of muscular dystrophy, cardiac dystrophy, or skeletal muscular dystrophy.

[0362] In some embodiments, the laminopathy is associated with a mutation in LMNA, LMNB1, and / or LMNB2. In some embodiments, the laminopathy is selected from: Hutchinson-Gilford progeria syndrome; Emery-Dreifuss muscular dystrophy; Emery-Dreifuss muscular dystrophy type 2, autosomal dominant; Lipodystrophy, partial, acquired; Epilepsy, progressive myoclonus, 9; Charcot-Marie-Tooth disease, axonal, type 2e; Muscular dystrophy; Lipodystrophy, familial partial, type 2; Cardiomyopathy, dilated, 1 hour; Pelger-Huet anomaly; Raynaud's syndrome; Muscle disease; Leukodystrophy; Dilated cardiomyopathy; Congenital muscular dystrophy; Mandibular limb dysplasia with lipodystrophy type a; Cardiomyopathy, dilated, 1a; Restrictive skin disease, lethal; Familial Familial partial lipodystrophy; epilepsy; lipoatrophy with diabetes, white matter papules, hepatic steatosis, and hypertrophic cardiomyopathy; leukodystrophy, demyelinating, adult-onset, autosomal dominant; acquired generalized lipodystrophy; muscular dystrophy type 3, autosomal recessive; disease Charcot-Marie-Tooth disease; Charcot-Marie-Tooth disease, axonal, type 2b1; cardiomyopathy, dilated, 1b; atrial standstill 1; limb-girdle muscular dystrophy; cardiomyopathy, dilated, with hypergonadotropin; Slovenian heart-hand syndrome; monogenic diabetes mellitus; arrhythmic right ventricular cardiomyopathy; cardiomyopathy, dilated, 1e; aging; mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome; adrenoleukodystrophy poor; atypical Werner syndrome; endometriosis; spinocerebellar ataxia 31; progressive muscular atrophy; neurogenic enteropathy; autosomal dominant leukodystrophy with autonomic neuropathy; Werner syndrome; myopathy; LMNA-related dilated cardiomyopathy; congenital muscular dystrophy 1b; hypertrophic cardiomyopathy; noncompacted left ventricle; diabetes mellitus, non-insulin-dependent; arrhythmic right ventricular dysplasia, familial, 9 cases; heart disease; atrial fibrillation; cardiac conduction defect; myoclonus; progressive myoclonic epilepsy; myoclonic epilepsy; peripheral nervous system diseases; dental diseases; atrioventricular block; fibromyalgia; autosomal dominant limb-girdle muscular dystrophy; LMNA-related premature carpel syndrome; amyotrophic lateral sclerosis; neural tube defect; cervical cancer; neural tube defect, folate sensitive; brain degeneration; acanthosis nigricans; 3-hydroxyacyl-CoA dehydrogenase deficiency; congenital fibrous type disorder; acroosteolysis; Wolff-Parkinson-White syndrome; sick sinus syndrome; calcinosis; undifferentiated pleomorphic sarcoma; ventricular tachycardia, catecholaminergic polymorphism, 1, with or without atrial dysfunction and / or dilated cardiomyopathy; lipodystrophy, familial part, type 1; axonal neuropathy; paroxysmal ventricular fibrillation; Brugada syndrome; rigid spinal muscular dystrophy; limb-girdle muscular dystrophy type 1b; insulin-resistant acanthosis nigricans;Generalized lipodystrophy-associated progeroid syndrome; osteoporosis; rigid spinal muscular dystrophy; neuropathy; catecholaminergic polymorphic ventricular tachycardia; cataract; Bethlehem myopathy; congenital generalized lipodystrophy; restrictive cardiomyopathy; muscular dystrophy, congenital meroglobin deficiency, 1a; proximal spinal muscular atrophy; muscular dystrophy type B-5 cases of glucose metabolism abnormalities; congenital generalized lipodystrophy, type 1; Emery-Dreifuss muscular dystrophy; cardiomyopathy, dilated, 1d; myopathy, proximal myopathy, and ophthalmoplegia; muscle tissue diseases; ovarian cystadenoma; embryopathy; Fanconi anemia, complement group a; body mass index; quantitative trait locus 11; myelodysplastic syndrome; skin Skin disorders; Anorexia nervosa; Spinal muscular atrophy; Inclusion body myositis; Aniridia 1; Myositis; Hairy hepato-gut syndrome 1; Neuromuscular disorders; Nutritional deficiency disorders; Thoracic outlet syndrome; Muscle disorders; Muscular atrophy; Hallermann-Streiff syndrome; Rere-Related disorders; Miller-Dick anencephaly syndrome; Lipodystrophy, congenital generalized, type 4; Lipodystrophy, familial part, type 3; Wiedemann-Rautenstrauch syndrome; Lipodystrophy, congenital generalized, type 2; Ataxia-neuropathy spectrum; Alopecia, neurologic defects, and endocrine disorders syndrome; Lipodystrophy, familial part, type 4; Second degree atrioventricular block; Acute necrotizing encephalopathy; median neuropathy; intrinsic cardiomyopathy; familial isolated arrhythmic ventricular dysplasia, right dominant; female genital organ prolapse; familial isolated arrhythmic ventricular dysplasia; familial isolated arrhythmic ventricular dysplasia, left dominant; complete generalized lipodystrophy; blood type - Ahonen; autosomal semidominant severe lipodystrophy laminopathy; ulnar neuropathy; pelvic muscular atrophy; Alzheimer's disease; ischemic stroke; ataxia-telangiectasia; rheumatic spondyloarthropathy 1; human immunodeficiency virus type 1; neuroblastoma; vascular diseases; nervous system diseases; respiratory failure; Turner syndrome; carpal tunnel syndrome; Barrett's esophagus; sleep apnea; cerebrovascular disease disease; proteasome-associated autoinflammatory syndrome; Joubert syndrome; viral infectious diseases; Alzheimer's disease; personality disorders; hereditary sensory and autonomic neuropathy, type III; Roche oculocerebrorenal syndrome; diabetes mellitus; fatty liver; Leigh syndrome; muscular dystrophy, Duchenne type; hydrocephalus; dermatomyositis; megacolon disease 1; long Qt syndrome; such as Angelman syndrome; central nervous system diseases; congenital disorders of glycosylation; pulmonary edema, achalasia, and mental retardation syndrome; polycystic ovary syndrome; hypoglycemia; muscle hypertrophy; Kearns-Sayre syndrome; cone-rod dystrophy; Aicardi-Goutieres syndrome; Andersen's arrhythmic periodic paralysis; muscular dystrophy, Becker type;Legg-Calve-Perthes disease; androgen insensitivity syndrome; proper stretching; Axenfeld-Rieger syndrome; muscular dystrophy-glycodystrophy, type C, 5 cases; glomerulonephritis; seizures; chikungunya fever; Western syndrome; Ulrich congenital muscular dystrophy; focal segmental glomerulosclerosis; Walker-Warburg syndrome; renal dysplasia / dysgenesis 1; popliteal pterygium syndrome; microcephaly; juvenile dermatomyositis; distal arthrogryposis; myocarditis; twisted artery syndrome; scoliosis; membranous nephropathy; microvascular complications of diabetes mellitus type 3; epidermolysis bullosa; short syndrome; hyperfright; nonalcoholic fatty liver disease; muscular dystrophy-glycometabolism ataxia, type a, 4; congenital hydrocephalus; cerebellar and peripheral ataxia with hearing loss and diabetic arrhythmias; muscular dystrophy-diabetes, type a, 1; ptosis; laryngitis; Ablepharon-Macrostomia syndrome; supravalvular aortic stenosis; congenital myopathy; metabolic encephalomyopathy crisis, recurrent, with rhabdomyolysis, arrhythmias, and neurodegeneration; lissencephaly 1; polycystic liver disease type 1 with or without renal cysts; idiopathic inflammatory myopathy; simple epidermolysis bullosa; focal segmental glomerulosclerosis; gonadal dysgenesis; choroidal and retinal atrophy with rotation; syringomyelia; ichthyosis vulgaris; joint contractures, distal, type 1a; acute insulin response; brachydactyly; cerebellar dysgenesis ; Cranio-metaphyseal dysplasia, autosomal dominant; Alport syndrome 1, X-linked; Lissencephaly; Muscular dystrophy-dysglucose metabolism disorder, type B, 6; Diarrhea, 5 cases, with villous enteropathy, congenital; Epidermolysis bullosa connective tissue; Aicardii-goutieres syndrome; Sanji muscular dystrophy; Retinitis; Marden-Walker syndrome; Retinitis; Glucan body myopathy with or without immunodeficiency, type 1; Epidermolysis bullosa, junctional, Herlitz type; Macroglossia; Parkinson's disease 15, autosomal recessive early onset; Myopathy, myogenic, 3; Microvascular complications of diabetes mellitus type 7; Myo-oculoencephalopathy; Melkersson-R Osenthal syndrome; X-linked myopathy with hyperautophagic choroiditis; muscular dystrophy, limb girdle, autosomal recessive 8; Crouzon syndrome with acanthosis nigricans muscular dystrophy, limb girdle, autosomal recessive 6; polymicrogyria; dystrophic disorders; microvascular complications of diabetes mellitus type 6; microvascular complications of diabetes mellitus type 4; hypotonia; pontocerebellar dysgenesis; congenital fibrosarcoma; intrauterine growth retardation, metaphyseal dysplasia, congenital adrenal dysgenesis, and genital anomalies muscular dystrophy, limb girdle, autosomal recessive 7; myopathy, congenital, fiber type disproportion; agenesis incomplete, Ig type; refractory anemia; extraocular muscle fibrosis, congenital, 1; ataxia and polyneuropathy, adult onset;Al-Raqad syndrome; senile cataract; muscular dystrophy-glucose metabolism disorder, type C, 1; neuronal migration disorder; Ayme-Gripp syndrome; agammaglobulin deficiency; autosomal recessive limb-girdle muscular dystrophy type 2a; encephalitis; muscular dystrophy, congenital, macrocephalic; autosomal recessive limb-girdle muscular dystrophy; Alkuraya-Kucinskas syndrome; muscular dystrophy-glucose metabolism disorder, type C, 4; congenital muscular dystrophy type 1a; Behr syndrome; Dandy-Walker complex; muscular dystrophy type C- 2 cases of glycomalnutrition; Emery-Dreyfus muscular dystrophy; muscular dystrophy, limb girdle, autosomal recessive 3; autosomal recessive limb girdle muscular dystrophy; cerebrovascular disease type 1 with or without ocular abnormalities; familial isolated dilated cardiomyopathy; epithelial recurrent erosive dystrophy; muscular dystrophy; avian mycobacterium complex infection; autosomal recessive limb girdle muscular dystrophy type 2l; visual epilepsy; Valsalva sinus aneurysm; autosomal recessive limb girdle muscular dystrophy type 2b; serum creatine phosphokinase; spastic paraplegia, ataxia, and mental retardation; multinucleated neurons, amniotic fluid , renal dysplasia, cerebellar hypoplasia, anhydrencephaly; dilated eustachian tube; autosomal disorders; Ck syndrome; neuronitis; startle disease 1; attenuated myopathy; bilateral temporo-occipital polymicrogyria; isolated hyperglycemia; Charcot-Marie-Tooth disease, axonal, type 2b2; cardiomyopathy with hyaline masses and linear rods; congenital muscular dystrophy without intellectual disability; blood group, system I; Saleh myopathy; hallux adductus syndrome; dural sinus malformation; blood group, East Brock system; blood group, Colton system; arthrosis Ehlers-Danlos syndrome; lama2-related muscular dystrophy; muscular dystrophy, congenital Sex, with infantile cataracts and hypogonadism; intrauterine infection; muscular dystrophy, congenital, partition protein positive; congenital muscular dystrophy with cerebellar involvement; Fukuyama muscular dystrophy; chronic lymphoproliferative disease; congenital muscular dystrophy with intellectual disability; incomplete development of embryogenesis; androgen insensitivity syndrome, mild; congenital muscular dystrophy, causing joint contractures; congenital muscular glucose metabolism disorder with brain and eye abnormalities type VI collagen-related myopathy; dominant Emory-Dreyfus muscular dystrophy; congenital muscular dystrophy caused by glucose metabolism disorder; proximal myopathy with focal mitochondrial deletion in pediatric scoliosis. ;

[0363] In some embodiments, the laminopathy is a laminopathy associated with LMNA mutations. In some embodiments, the laminopathy is selected from Hutchinson-Gilford progeria syndrome; dilated cardiomyopathy; muscular dystrophy, congenital, Lmna-associated; Emery Dreifuss muscular dystrophy type 2, autosomal dominant; muscular dystrophy; mandibular dysplasia with lipodystrophy type a; dilated cardiomyopathy, 1a; Charcot-Marie-Tooth disease; limb girdle muscular dystrophy; dilated cardiomyopathy with hypogonadism; Emery Dreifuss muscular dystrophy type 3, autosomal recessive; lipodystrophy, familial partial, type 2; Emery Dreifuss muscular dystrophy; Charcot-Marie-Tooth disease, axonal, type 2b1; heart-hand syndrome, Slovenian type; familial partial lipodystrophy of the elderly; restrictive skin disease, fatal; arrhythmogenic right ventricular cardiomyopathy; dental disease; heart disease; Werner syndrome; hypertrophic cardiomyopathy; left ventricular nonfilling; atrioventricular block; calcifications; acroosteolysis; autosomal dominant acrocardia; diabetes mellitus, non-insulin-dependent; osteoporosis; atrial fibrillation; atrial standstill 1; acanthosis nigricans; cardiac conduction defects; catecholaminergic polymorphic ventricular tachycardia; mandibular dysplasia, deafness, anterior features, and lipodystrophy syndrome; sick sinus syndrome; Pelger Huet anomaly; Charcot-Marie-Tooth disease, axonal type, type 2e; congenital generalized lipodystrophy; restrictive cardiomyopathy; congenital dysproportion of fiber type; lipodystrophy, congenital generalized, type 1; myofibrillar myopathy; lipodystrophy, familial partial, type 1; axonal neuropathy; atypical Werner syndrome; ovarian cystadenoma; Fanconi anemia, complement group a; body mass index quantitative trait locus 11; skin diseases; myotonic muscular dystrophy 1 case; neuromuscular diseases; craniofacial dysmorphism syndrome; Bethlem myopathy 1; acquired generalized lipodystrophy; dilated cardiomyopathy, 1e; lipodystrophy, congenital generalized, type 4; undifferentiated pleomorphic sarcoma; lipodystrophy, familial partial, type 3; muscular dystrophy, congenital carnosine deficiency, 1a; proximal spinal muscular atrophy; dystrophic polysaccharide disorder, type B, 5; congenital muscular dystrophy, 1b; Reynolds syndrome; Wiedemann-Rautenstrauch syndrome; Emery Dreifuss muscular dystrophy 1, X-linked; lipodystrophy, congenital generalized, type 2; monogenic diabetes mellitus; dilated cardiomyopathy, 1d; myopia, proximal and ophthalmoplegia; muscle tissue diseases; lipodystrophy, familial partial, type 4; dilated cardiomyopathy, 1h; second-degree atrioventricular block; median neuropathy; intrinsic cardiomyopathy; female genital organ prolapse; complete generalized lipodystrophy; myotonic spinal muscular dystrophy; emergency; ulnar nerve injury; limb muscular dystrophy type 1b; Lmna-related dilated cardiomyopathy;Pelvic muscle wasting; Generalized lipodystrophy-associated progesterone syndrome; Muscle diseases; Dilated cardiomyopathy, 1b; Autosomal genetic disorders; Familial isolated arrhythmogenic ventricular dysplasia, right dominant; Familial isolated arrhythmogenic ventricular dysplasia, biventricular type; Familial isolated arrhythmogenic ventricular dysplasia, left dominant; Lmna-related premature carpel syndrome; Autosomal semidominant severe lipodystrophy layer lesion. ;

[0364] In some embodiments, the diseases treated / prevented by the present disclosure are selected from the diseases associated with the cDNA or protein variants shown in Table 1 (starting on the next page).

[0365] In some embodiments, the diseases treated / prevented by the present disclosure are selected from the diseases shown in Table 1.

[0366] In some embodiments, the diseases to be treated / prevented by the present disclosure are selected from the diseases indicated in normal font in Table 1.

[0367] In some embodiments, the diseases to be treated / prevented by the present disclosure are selected from the diseases indicated in bold in Table 1.

[0368]

[0369]

[0370]

[0371]

[0372]

[0373]

[0374]

[0375]

[0376]

[0377]

[0378]

[0379]

[0380]

[0381]

[0382]

[0383]

[0384]

[0385]

[0386]

[0387]

[0388]

[0389]

[0390]

[0391]

[0392]

[0393]

[0394]

[0395]

[0396]

[0397]

[0398]

[0399] A further aspect of the present disclosure relates to the treatment / prevention of diseases characterized by dyslipidemia, such as conditions characterized by hyperlipidemia. LINC complex inhibition has recently been shown to be a suitable therapeutic / preventive intervention for dyslipidemia, in particular hyperlipidemia such as hypercholesterolemia - see, for example, WO 2021 / 01898A1, e.g., Example 18.

[0400] A further aspect of the present disclosure relates to the treatment / prevention of diseases associated with LDL receptor deficiency (ie, reduced levels of LDL receptor protein and / or function).

[0401] In some embodiments, the disease / disorder to be treated / prevented by the present disclosure is dyslipidemia and / or hypercholesterolemia. In some embodiments, the disease / disorder is a disease / disorder characterized by dyslipidemia and / or hypercholesterolemia. In some embodiments, the disease / disorder is a disease / disorder associated with dyslipidemia and / or hypercholesterolemia (e.g., a disease / condition in which dyslipidemia and / or hypercholesterolemia is a risk factor for the onset, development, or progression of the disease / disorder).

[0402] Dyslipidemia refers to excessively high or low blood lipid levels. The present disclosure is particularly directed to the treatment of hyperlipidemia, in which the lipid or lipoprotein levels in the blood are elevated. Hyperlipidemia includes hypertriglyceridemia, hypercholesterolemia, and combined hyperlipidemia (a combination of hypertriglyceridemia and hypercholesterolemia). Hyperlipidemia is associated with atherosclerosis, hypertension, and cardiovascular disease.

[0403] Hyperlipidemia refers to elevated levels of lipids or lipoproteins in the blood. Hyperlipidemia includes hypertriglyceridemia, hypercholesterolemia, and combined hyperlipidemia (a combination of hypertriglyceridemia and hypercholesterolemia). Hyperlipidemia is associated with atherosclerosis, hypertension, and cardiovascular disease.

[0404] Hypercholesterolemia is high levels of cholesterol in the blood. In many cases, hypercholesterolemia is the result of a high-fat diet and an inactive lifestyle combined with genetic risk factors. Hypercholesterolemia can also be the result of a genetic mutation (such as familial hypercholesterolemia), type 2 diabetes, hypothyroidism, kidney disease, or as a side effect of treatment with certain medications (such as corticosteroids).

[0405] Hypercholesterolemia is described, for example, in Bhatnagar et al., BMJ (2008) 337:a993. The UK National Health Service defines hypercholesterolemia as a blood total cholesterol level ≥5 mmol / L or a blood low-density lipoprotein level ≥3 mmol / L. The National Institutes of Health defines hypercholesterolemia as a blood total cholesterol level ≥240 mg / dL. Hypertriglyceridemia is described, for example, in Berglund et al., J. Clin. Endocrinol. Metab. (2012) 97(9):2969-89, defined as a blood triglyceride level ≥150 mg / dL (≥1.7 mmol / L). Hypercholesterolemia is a well-recognized risk factor for the development of cardiovascular disease, particularly that caused by atherosclerosis—see, e.g., Nelson Prim Care. (2013) Mar;40(1):195-211. Hypercholesterolemia has also been reported to lead to steatosis and nonalcoholic liver disease—see, e.g., Arguello et al., Biochim Biophys Acta (2015) 1852(9):1765-78.

[0406] In some embodiments, the disease characterized by hyperlipidemia can be familial hyperlipidemia or acquired (secondary) hyperlipidemia.

[0407] In some embodiments, the familial hyperlipidemia is selected from Buerger-Gruetz syndrome, familial apolipoprotein CII deficiency, type Ic hyperlipoproteinemia, familial hypercholesterolemia, familial combined hyperlipidemia, familial betalipoproteinosis, familial hypertriglyceridemia, and type V hyperlipoproteinemia. In some embodiments, the familial hyperlipidemia is familial hypercholesterolemia.

[0408] LDL receptor deficiency may occur, for example, as a result of an LDLR mutation. Thus, aspects of the present disclosure relate to the treatment / prevention of diseases associated with LDLR mutations. In some embodiments, the mutation is known or predicted to reduce the level of one or more LDL receptor subtypes encoded by the wild-type LDLR allele and / or increase the level of one or more disease-associated LDL receptor variants. In some embodiments, the disease associated with the LDLR mutation is familial hypercholesterolemia.

[0409] In some embodiments, the disease to be treated / prevented by the present disclosure is characterized by one or more of hyperlipidemia, hypercholesterolemia, atherosclerosis, stenosis or hypertension. In some embodiments, the disease to be treated / prevented by the present disclosure is characterized by atherosclerosis.

[0410] In some embodiments, the disease to be treated / prevented is selected from atherosclerosis, cardiovascular disease, stroke, and familial hyperlipidemia.

[0411] According to various aspects of the present disclosure, the methods of treating and / or preventing diseases / disorders of the present disclosure may include one or more of the following:

[0412] Improve the survival rate of diseased subjects;

[0413] Prolonging the lifespan of diseased subjects;

[0414] Increase or inhibit the decline of cardiac function;

[0415] Delay the onset of decreased heart function;

[0416] Increase or inhibit the decrease of myocardial contractility;

[0417] increase or inhibit reduction in ejection fraction and / or fractional shortening;

[0418] Reduce or inhibit the increase in left ventricular internal diameter;

[0419] Increase or inhibit the decrease in left ventricular posterior wall thickness; and / or

[0420] Reduce or inhibit the development of atherosclerosis.

[0421] According to various aspects of the present disclosure, methods are provided for or including (e.g., in the context of treatment / prevention of diseases / disorders described herein) one or more of the following: inhibiting the interaction between a protein containing a SUN domain and a protein containing a KASH domain; inhibiting the formation of a LINC complex comprising a protein containing a SUN domain and a protein containing a KASH domain; disrupting a LINC complex comprising a protein containing a SUN domain and a protein containing a KASH domain; disrupting the normal subcellular localization of a protein containing a SUN domain or a protein containing a KASH domain; increasing the localization of a constituent protein of a LINC complex (e.g., a protein containing a KASH domain) to the endoplasmic reticulum; reducing the level of a LINC complex comprising a protein containing a SUN domain and a protein containing a KASH domain; and / or inhibiting the function / activity of a LINC complex comprising a protein containing a SUN domain and a protein containing a KASH domain. Also provided are agents of the present disclosure for use in such methods, and uses of agents of the present disclosure in the preparation of pharmaceutical compositions or drugs for use in such methods. It should be understood that the method generally comprises administering to a subject a LINC complex-inhibiting polypeptide, nucleic acid, vector, cell, or composition described herein.

[0422] Similarly, after a therapeutic or prophylactic intervention of the present disclosure (e.g., compared to levels before the intervention), one or more of the following may be observed in a subject: inhibition of the interaction between a SUN domain-containing protein and a KASH domain-containing protein; inhibition of the formation of a LINC complex comprising a SUN domain-containing protein and a KASH domain-containing protein; disruption of a LINC complex comprising a SUN domain-containing protein and a KASH domain-containing protein; disruption of the normal subcellular localization of a SUN domain-containing protein or a KASH domain-containing protein; increased localization of a constituent protein of the LINC complex (e.g., a KASH domain-containing protein) to the endoplasmic reticulum; a decrease in the level of a LINC complex comprising a SUN domain-containing protein and a KASH domain-containing protein; and / or inhibition of the function / activity of a LINC complex comprising a SUN domain-containing protein and a KASH domain-containing protein.

[0423] In some embodiments, the therapeutic / preventive interventions of the present disclosure may be described as being "associated with" one or more of the effects described in the preceding paragraphs. Such properties can be readily assessed by one skilled in the art using techniques routinely practiced in the art.

[0424] Administration of the LINC complex inhibitory polypeptides, nucleic acids, vectors, cells and compositions disclosed herein is preferably in a "therapeutically effective" or "prophylactically effective" amount, which is sufficient to show a therapeutic or prophylactic benefit to the subject. The actual dosage, dosage rate and administration time will depend on the nature and severity of the disease / disorder and the specific item being administered. Treatment prescriptions, such as dosage decisions, are the responsibility of general practitioners and other physicians, and typically take into account the disease / disorder to be treated, the condition of the individual subject, the place of delivery, the method of administration, and other factors known to the physician. Examples of the above techniques and protocols can be found in Remington's "The Science and Practice of Pharmacy" (Ed. A. Adejare), 23rd edition (2020), Academic Press.

[0425] In preferred embodiments, administration is a nucleic acid / vector, or a composition comprising a nucleic acid / vector according to the disclosure. In preferred embodiments, administration results in modification of one or more cells to comprise / express a nucleic acid / vector, and / or to comprise / express a LINC complex inhibitory polypeptide of the disclosure.

[0426] Administration of the products of the present disclosure can be, for example, parenteral, systemic, topical, intracavitary, intravascular, intravenous, intraarterial, intramuscular, intrathecal, intraocular, intraconjunctival, intratumoral, subcutaneous, intradermal, oral or transdermal administration. The administration method can be injection, infusion or ingestion.

[0427] In some aspects and embodiments, the preparations of the present disclosure may be administered to a target tissue / organ (e.g., a tissue / organ affected by a disease / disorder (e.g., a tissue / organ showing symptoms of a disease / disorder)). In some aspects and embodiments, the preparations of the present disclosure may be administered into the blood by injection or infusion (e.g., via a cannula) (i.e., intravenous / intra-arterial administration), or may be administered subcutaneously or orally.

[0428] In some aspects and embodiments according to the present disclosure, the substances of the present disclosure can be delivered in a targeted manner, i.e., wherein the concentration of the relevant agent in a subject is increased in a given tissue / organ relative to other parts of the body. In some embodiments, the method comprises intravascular (e.g., intravenous or intraarterial), intramuscular or subcutaneous administration, and wherein the relevant preparation is formulated in a targeted drug delivery system (e.g., as described above)

[0429] The specific mode of administration and / or site of administration can be selected based on where LINC complex inhibition is desired, such as cardiac and / or skeletal muscle cells / tissues.

[0430] In some embodiments, the therapeutic or prophylactic interventions of the present disclosure may further comprise the administration of another agent for the treatment / prevention of the relevant disease / disorder.

[0431] Administration of the LINC complex inhibitory polypeptides, nucleic acids, vectors, cells and compositions described herein can be administered alone or in combination with other treatments, either simultaneously or sequentially, depending on the condition to be treated. Simultaneous administration refers to administration with another therapeutic agent, for example as a pharmaceutical composition containing two drugs (combination preparation), or immediately after each other, and optionally by the same route of administration (e.g., to the same tissue, artery, vein or other blood vessel). Sequential administration refers to administration of one preparation after a given time interval, followed by administration of another preparation alone. It is not required that the two agents be administered by the same route, although this is the case in some embodiments. The time interval can be any time interval.

[0432] Multiple doses of the LINC complex-inhibiting polypeptides, nucleic acids, vectors, cells and compositions of the present disclosure may be provided. One or more doses, or each dose, may be administered simultaneously or sequentially with another therapeutic agent.

[0433] Multiple dosages can be separated by predetermined time intervals, which can be selected as 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or 31 days, or selected as 1 month, 2 months, 3 months, 4 months, 5 months or 6 months. For example, administration can be performed once every 7 days, 14 days, 21 days or 28 days (plus or minus 3 days, 2 days or 1 day).

[0434] In some embodiments, the methods of the present disclosure may include determining whether a subject suffers from a disease as described herein. In some embodiments, the methods include diagnosing a disease as described herein. Determining whether a subject suffers from a disease as described herein may include analyzing one or more symptoms / correlations of a subject's disease.

[0435] In some embodiments, a subject may be suspected of having or having a disease, for example, based on the presence of other symptoms indicative of a disease in the subject or in the subject's cells / tissues / organs. In some embodiments, a subject may be considered at risk of developing the disease, for example because of a genetic predisposition or other risk factor for the disease.

[0436] In some embodiments, the method comprises determining whether the subject has a mutation in a gene described herein. In some embodiments, the method comprises detecting a mutation in a gene described herein.

[0437] The determination of the gene mutation described herein can confirm a diagnosis or suspected diagnosis, or can confirm that the subject is at risk of developing a disease. The determination can diagnose a disease or disease susceptibility for treatment / prevention with the LINC complex inhibitory polypeptide, nucleic acid, vector, cell or composition described herein.

[0438] Genetic factors can be determined by methods known to those of ordinary skill in the art, including PCR-based assays and sequencing assays. By determining the presence of the genetic factor, for example in a sample obtained from a subject, a diagnosis can be confirmed, and / or the subject can be classified as at risk for developing a disease described herein, and / or the subject can be identified as suitable for treatment with a LINC complex inhibitory polypeptide, nucleic acid, vector, cell or composition described herein.

[0439] The sample obtained from the subject can be analyzed in vitro or after processing the sample obtained from the subject. The sample obtained from the subject can be of any kind. The biological sample can be taken from any tissue or body fluid, such as a blood sample, a sample derived from blood, a serum sample, a lymph sample, a semen sample, a saliva sample, a synovial fluid sample. The blood-derived sample can be a selected portion of the patient's blood, such as a selected cell-containing portion or a plasma or serum portion. The sample can include a tissue sample or a biopsy; or cells isolated from a subject.

[0440] In some embodiments, the method includes determining whether the subject includes an allelic mutation of one or more of LMNA, LMNB1, LMNB2, EMD, LAP2, LBR, ZMPSTE24, SYNE-1, and NUP62. In some embodiments, the method includes determining whether the subject includes an allelic mutation of one or more of LMNA, LMNB1, and LMNB2. In some embodiments, the method includes determining whether the subject includes an allelic mutation of LMNA. In some embodiments, the method includes determining whether the subject includes an allelic mutation of LDLR.

[0441] In such embodiments, the detection of mutations can identify the subject as a subject to be administered a LINC complex inhibitory polypeptide, nucleic acid, vector, cell, or composition as described herein. Thus, in some embodiments, the method includes selecting a subject determined to contain one or more mutations in LMNA, LMNB1, LMNB2, EMD, LAP2, LBR, ZMPSTE24, SYNE-1, and NUP62 for administration with a LINC complex inhibitory polypeptide, nucleic acid, vector, cell, or composition as described herein. In some embodiments, the method includes selecting a subject determined to contain one or more mutations in LMNA, LMNB1, and LMNB2 for administration with a LINC complex inhibitory polypeptide, nucleic acid, vector, cell, or composition as described herein. In some embodiments, the method includes selecting a subject determined to contain a LMNA mutation for administration with a LINC complex inhibitory polypeptide, nucleic acid, vector, cell, or composition as described herein. In some embodiments, the method includes selecting a subject determined to contain a LMNA mutation for administration with a LINC complex inhibitory polypeptide, nucleic acid, vector, cell, or composition as described herein. In some embodiments, the method includes selecting a subject determined to contain a LDLR mutation for administration with a LINC complex inhibitory polypeptide, nucleic acid, vector, cell, or composition as described herein.

[0442] In some embodiments, the method comprises testing a sample obtained from a subject suspected of having a disease for the presence of at least one LMNA mutation; wherein the presence of the at least one LMNA mutation indicates that a LINC complex-inhibiting polypeptide, nucleic acid, vector, cell, or composition described herein is to be administered to the subject.

[0443] Subjects

[0444] The subject of various aspects of the present disclosure can be any animal or human. Therapeutic and preventive applications can be for humans or animals (veterinary use). The subject to be treated with the LINC complex inhibitory polypeptide, nucleic acid, vector, cell or composition described herein can be a subject in need thereof. The subject is preferably a mammal, more preferably a human. The subject can be a non-human mammal, but more preferably a human. The subject may be male or female. The subject may be a patient.

[0445] The subject may have been diagnosed with a disease or condition described herein, may be suspected of having such a disease / condition, or may be at risk of developing / infecting such a disease / condition. In embodiments of the present disclosure, a subject may be selected for treatment based on a method of characterizing certain markers of such a disease / condition.

[0446] In some embodiments, the subject comprises a mutation according to any of the embodiments described above. In some embodiments, the subject comprises a mutation that causes a disease / disorder described herein (eg, a laminopathy).

[0447] Reagent test kit

[0448] In some aspects of the present disclosure, a kit is provided. In some embodiments, the kit may have at least one container having a predetermined amount of a LINC complex-inhibiting polypeptide, nucleic acid, vector, cell, or composition described herein.

[0449] In some embodiments, a kit may include materials for producing a LINC complex-inhibiting polypeptide, nucleic acid, vector, cell, or composition described herein.

[0450] The kit may provide a LINC complex inhibitory polypeptide, nucleic acid, vector, cell or composition and instructions for administration to a patient to treat a particular disease / disorder.

[0451] In some embodiments, the kit may further include at least one container with a predetermined amount of another therapeutic agent. In such embodiments, the kit may also include a second drug or pharmaceutical composition so that the two drugs or pharmaceutical compositions can be administered simultaneously or separately so that they provide a combined treatment for a specific disease or condition.

[0452] The kits of the present disclosure may include instructions for use, such as in the form of instructions or leaflets. The instructions may include a protocol for performing any one or more of the methods described herein.

[0453] Sequence identity

[0454] Pairwise and multiple sequence alignments for determining percent identity between two or more amino acid or nucleic acid sequences can be achieved in a variety of ways known to those skilled in the art, for example, using well-known computer software such as ClustalOmega ( J. 2005, Bioinformations 21951-960), T-offee (Notredame et al. 2000, J. Mol. Biol. (2000) 302205-217), Kalign (Lassmann and Sonnhammer 2005, BMC Bioinformatics, 6 (298)) and MAFFT (Katoh and Standley 2013, Molecular Biology and Evolution, 30 (4) 772-780) software. When using such software, it is preferred to use default parameters, such as gap penalty and extension penalty.

[0455] sequence

[0456]

[0457]

[0458]

[0459]

[0460]

[0461]

[0462]

[0463]

[0464]

[0465]

[0466]

[0467]

[0468]

[0469]

[0470]

[0471]

[0472] Numbered paragraphs

[0473] The following numbered paragraphs (paragraphs) provide further description of features and feature combinations contemplated in conjunction with the present invention:

[0474] 1. A nucleic acid encoding a LINC complex inhibitory polypeptide, wherein the LINC complex inhibitory polypeptide comprises: (i) an inhibitory region comprising an amino acid sequence corresponding to the α3 helix of the CC2 region and the SUN domain of a protein containing a SUN domain, and (ii) an endoplasmic reticulum retention motif;

[0475] And wherein the LINC complex inhibitory polypeptide does not comprise the amino acid sequence of any one of SEQ ID NO:43, 45 or 58.

[0476] 2. The nucleic acid according to paragraph 1, wherein the inhibitory region of the LINC complex inhibitory polypeptide does not substantially consist of the amino acid sequence of SEQ ID NO: 44 or 46.

[0477] 3. The nucleic acid according to paragraph 1 or 2, wherein the inhibitory region of the LINC complex inhibitory polypeptide does not substantially consist of any one of the amino acid sequences of SEQ ID NO: 49, 50, 51, 52, 53, 54, 55, 56, 57, 59, 60, 61 or 62.

[0478] 4. The nucleic acid according to any one of paragraphs 1-3, wherein the inhibitory region of the LINC complex inhibitory polypeptide consists essentially of an amino acid sequence having at least 80% amino acid sequence identity with the amino acid sequence of one of SEQ ID NO: 63, 64, 65, 66, 67, 68 or 94.

[0479] 5. The nucleic acid according to any one of paragraphs 1-4, wherein the LINC complex inhibitory polypeptide comprises or consists essentially of an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of one of SEQ ID NO: 69, 70, 71, 72, 73, 74 or 95.

[0480] 6. The nucleic acid of any one of paragraphs 1-5, wherein the LINC complex inhibitory polypeptide comprises a signal peptide.

[0481] 7. The nucleic acid according to any one of paragraphs 1 to 6, wherein the nucleic acid is a vector suitable for delivering a nucleic acid encoding a LINC complex inhibitory polypeptide for gene therapy.

[0482] 8. The nucleic acid of paragraph 7, wherein the vector is an adeno-associated virus (AAV) vector.

[0483] 9. A LINC complex inhibitory polypeptide comprising: (i) an inhibitory region comprising an amino acid sequence corresponding to the α3 helix of the CC2 region and the SUN domain of a protein containing a SUN domain, and (ii) an endoplasmic reticulum retention motif;

[0484] And wherein the LINC complex inhibitory polypeptide does not comprise the amino acid sequence of SEQ ID NO: 43 or 45.

[0485] 10. The LINC complex inhibitory polypeptide according to paragraph 9, wherein the inhibitory region of the LINC complex inhibitory polypeptide does not substantially consist of the amino acid sequence of SEQ ID NO: 44 or 46.

[0486] 11. The LINC complex inhibitory polypeptide of paragraph 9 or 10, wherein the inhibitory region of the LINC complex inhibitory polypeptide is not substantially composed of SEQ ID NO: 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61 or 62.

[0487] 12. The LINC complex inhibitory polypeptide according to any one of paragraphs 9-11, wherein the inhibitory region of the LINC complex inhibitory polypeptide essentially consists of an amino acid sequence having at least 80% amino acid sequence identity with the amino acid sequence of one of SEQ ID NO: 63, 64, 65, 66, 67, 68 or 94.

[0488] 13. The LINC complex inhibitory polypeptide according to any one of paragraphs 9-12, wherein the LINC complex inhibitory polypeptide comprises or consists essentially of an amino acid sequence having at least 80% amino acid sequence identity with the amino acid sequence of one of SEQ ID NO: 69, 70, 71, 72, 73, 74 or 95.

[0489] 14. The LINC complex inhibitory polypeptide according to any one of paragraphs 9 to 13, wherein the LINC complex inhibitory polypeptide comprises a signal peptide.

[0490] 15. A method for identifying a LINC complex inhibitory polypeptide, comprising:

[0491] introducing a nucleic acid encoding a candidate LINC complex inhibitory polypeptide, wherein the candidate LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to a SUN domain of a SUN domain-containing protein; and

[0492] The cells were then analyzed to determine the subcellular localization of the interacting partners of the SUN domain-containing proteins;

[0493] When a change in the subcellular localization of an interacting partner of a SUN domain-containing protein is detected, a candidate LINC complex inhibitory polypeptide is identified as a LINC complex inhibitory polypeptide.

[0494] 16. A method for identifying a LINC complex inhibitory polypeptide, comprising:

[0495] introducing a nucleic acid encoding a candidate LINC complex inhibitory polypeptide, wherein the candidate LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to a KASH domain of a KASH domain-containing protein; and

[0496] The cells were then analyzed to determine the subcellular localization of the interacting partners of the KASH domain-containing proteins;

[0497] When a change in the subcellular localization of an interacting partner of a KASH domain-containing protein is detected, a candidate LINC complex inhibitory polypeptide is identified as a LINC complex inhibitory polypeptide.

[0498] 17. According to the method of paragraph 15 or 16, when an increase in the ratio of the interacting partners of the protein containing the SUN / KASH domain localized in the endoplasmic reticulum is detected, the candidate LINC complex inhibitory polypeptide is determined to be a LINC complex inhibitory polypeptide.

[0499] 18. A LINC complex inhibitory polypeptide identified by the method according to any one of paragraphs 15 to 17.

[0500] 19. A nucleic acid encoding the LINC complex inhibitory polypeptide according to any one of paragraphs 9-14 or 18.

[0501] 20. A vector comprising the nucleic acid of paragraph 19, wherein the vector is suitable for delivering a nucleic acid encoding a LINC complex inhibitory polypeptide for gene therapy.

[0502] 21. The vector of paragraph 20, wherein the vector is an adeno-associated virus (AAV) vector.

[0503] 22. A cell comprising the nucleic acid according to any one of paragraphs 1-8 or 19, the LINC complex inhibitory polypeptide according to any one of paragraphs 9-14 or 18, or the vector according to paragraph 20 or 21.

[0504] 23. A pharmaceutical composition comprising the nucleic acid according to any one of paragraphs 1-8 or 19, the LINC complex inhibitory polypeptide according to any one of paragraphs 9-14 or 18, the vector according to paragraph 20 or 21, or the cell according to paragraph 22.

[0505] 24. Use of a nucleic acid according to any one of paragraphs 1-8 or 19, a LINC complex inhibitory polypeptide according to any one of paragraphs 9-14 or 18, a vector according to paragraph 20 or 21, a cell according to paragraph 22, or a pharmaceutical composition according to paragraph 23 for a method of treatment or prevention.

[0506] 25. Use of a nucleic acid according to any one of paragraphs 1 to 8 or 19, a LINC complex inhibitory polypeptide according to any one of paragraphs 9 to 14 or 18, a vector according to paragraph 20 or 21, a cell according to paragraph 22, or a pharmaceutical composition according to paragraph 23 for a method of treating or preventing a laminopathy.

[0507] 26. Use of a nucleic acid according to any one of paragraphs 1-8 or 19, a LINC complex inhibitory polypeptide according to any one of paragraphs 9-14 or 18, a vector according to paragraph 20 or 21, a cell according to paragraph 22, or a pharmaceutical composition according to paragraph 23 in the preparation of a medicament for treating or preventing a laminopathy.

[0508] 27. A method for treating or preventing a laminopathy, comprising administering to a subject a therapeutically or prophylactically effective amount of a nucleic acid according to any one of paragraphs 1-8 or 19, a LINC complex inhibitory polypeptide according to any one of paragraphs 9-14 or 18, a vector according to paragraph 20 or 21, a cell according to paragraph 22, or a pharmaceutical composition according to paragraph 23.

[0509] 28. Use of a nucleic acid, a LINC complex inhibitory polypeptide, a vector, a cell or a pharmaceutical composition according to paragraph 25, the use according to paragraph 26 or the method according to paragraph 27, wherein the laminopathy is characterized by one or more of myopathy, cardiomyopathy, dilated cardiomyopathy, muscular dystrophy, cardiac myodystrophy, skeletal muscular dystrophy, progeria, neuropathy, lipodystrophy, skeletal dysplasia, lipodystrophy, leukodystrophy or skin disease.

[0510] 29. The use, application or method of a nucleic acid, a LINC complex inhibitory polypeptide, a vector, a cell or a pharmaceutical composition according to any one of paragraphs 25 to 28, wherein the laminopathy is associated with a LMNA mutation.

[0511] 30. The use, application or method of a nucleic acid, LINC complex inhibitory polypeptide, vector, cell or pharmaceutical composition of any one of paragraphs 25 to 29, wherein the laminopathy is selected from: Hutchinson-Gilford progeria syndrome; dilated cardiomyopathy; muscular dystrophy, congenital, Lmna-related; Emery Dreifuss muscular dystrophy type 2, autosomal dominant; muscular dystrophy; mandibular dysplasia with lipodystrophy type a; dilated cardiomyopathy, 1a; Charcot-Marie-Tooth disease; limb girdle muscular dystrophy; dilated cardiomyopathy with hypogonadotropic hypergonadism; Emery Dreifuss muscular dystrophy type 3, autosomal recessive; lipodystrophy, familial partial, type 2; Emery Dreifuss muscular dystrophy; Charcot-Marie-Tooth disease, axonal, type 2b1; heart-hand syndrome, Slovenian type; familial partial lipodystrophy of the elderly; restrictive skin disease, fatal; arrhythmogenic right ventricular cardiomyopathy; dental disease; heart disease; Werner syndrome; hypertrophic cardiomyopathy; left ventricular nonfilling; atrioventricular block; calcifications; acroosteolysis; autosomal dominant acrocardia; diabetes mellitus, non-insulin-dependent; osteoporosis; atrial fibrillation; atrial standstill 1; acanthosis nigricans; cardiac conduction defects; catecholaminergic polymorphic ventricular tachycardia; mandibular dysplasia, deafness, anterior features, and lipodystrophy syndrome; sick sinus syndrome; Pelger Huet anomaly; Charcot-Marie-Tooth disease, axonal type, type 2e; congenital generalized lipodystrophy; restrictive cardiomyopathy; congenital dysproportion of fiber type; lipodystrophy, congenital generalized, type 1; myofibrillar myopathy; lipodystrophy, familial partial, type 1; axonal neuropathy; atypical Werner syndrome; ovarian cystadenoma; Fanconi anemia, complement group a; body mass index quantitative trait locus 11; skin diseases; myotonic muscular dystrophy 1 case; neuromuscular diseases; Hallermann Streiff syndrome; Bethlem myopathy 1; acquired generalized lipodystrophy; dilated cardiomyopathy, 1e; lipodystrophy, congenital generalized, type 4; undifferentiated pleomorphic sarcoma; lipodystrophy, familial partial, type 3; muscular dystrophy, congenital carnosine deficiency, 1a; proximal spinal muscular atrophy; dystrophic polysaccharide disorder of the muscular cord, type B, 5; congenital muscular dystrophy, 1b; Reynolds syndrome; Wiedemann-Rautenstrauch syndrome; Emery Dreifuss muscular dystrophy 1, X-linked; lipodystrophy, congenital generalized, type 2; monogenic diabetes mellitus; dilated cardiomyopathy, 1d; myopia, proximal and ophthalmoplegia; muscle tissue diseases; lipodystrophy, familial partial, type 4; dilated cardiomyopathy, 1h; second-degree atrioventricular block; median neuropathy; intrinsic cardiomyopathy; female genital organ prolapse; complete generalized lipodystrophy; myotonic muscular dystrophy; emergency;Ulnar nerve injury; limb-circle muscular dystrophy type 1b; Lmna-related dilated cardiomyopathy; pelvic muscle wasting; generalized lipodystrophy-related progesterone syndrome; muscle diseases; dilated cardiomyopathy, 1b; autosomal genetic disorders; familial isolated arrhythmogenic ventricular dysplasia, right dominant; familial isolated arrhythmogenic ventricular dysplasia, biventricular type; familial isolated arrhythmogenic ventricular dysplasia, left dominant; Lmna-related progeria syndrome; and autosomal semidominant severe lipodystrophy layer disease. ;

[0512] 31. A method for treating or preventing a disease characterized by hyperlipidemia using a nucleic acid according to any one of paragraphs 1-8 or paragraph 19, a LINC complex inhibitory polypeptide according to any one of paragraphs 9-14 or paragraph 18, a vector according to paragraph 20 or paragraph 21, a cell according to paragraph 22, or a pharmaceutical composition according to paragraph 23.

[0513] 32. Use of a nucleic acid according to any one of paragraphs 1-8 or 19, a LINC complex inhibitory polypeptide according to any one of paragraphs 9-14 or 18, a vector according to paragraph 20 or 21, a cell according to paragraph 22, or a pharmaceutical composition according to paragraph 23 in the preparation of a medicament for treating or preventing a disease characterized by hyperlipidemia.

[0514] 33. A method for treating or preventing a disease characterized by hyperlipidemia, comprising administering to a subject a therapeutically or prophylactically effective amount of a nucleic acid according to any one of paragraphs 1-8 or 19, a LINC complex inhibitory polypeptide according to any one of paragraphs 9-14 or 18, a vector according to paragraph 20 or 21, a cell according to paragraph 22, or a pharmaceutical composition according to paragraph 23.

[0515] 34. The use of a nucleic acid, a LINC complex inhibitory polypeptide, a vector, a cell or a pharmaceutical composition according to paragraph 31, the use according to paragraph 32 or the method according to paragraph 33, wherein the disease characterized by hyperlipidemia is selected from atherosclerosis, cardiovascular disease, stroke and familial hyperlipidemia.

[0516] ***

[0517] The present invention includes any combination of the described aspects and preferred features unless such a combination is expressly impermissible or explicitly avoided.

[0518] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0519] Various aspects and embodiments of the present disclosure will now be described by way of example with reference to the accompanying drawings. Other aspects and embodiments will be apparent to those skilled in the art. All documents mentioned herein are incorporated herein by reference.

[0520] Throughout the specification, including the following claims, unless the context requires otherwise, the word "comprise" and variations such as "comprises" and "comprising", will be understood to mean the inclusion of a stated integer, step, or group of integers or steps but not the exclusion of any other integer, step, group of integers or steps.

[0521] It must be noted that the singular forms "a," "an," and "the" used in the specification and the appended claims include plural references unless the context clearly dictates otherwise. Herein, ranges may be expressed as from "about" one particular value, and / or to "about" another particular value. When such a range is expressed, another embodiment includes from the from particular value and / or to the other particular value. Similarly, when values ​​are expressed as approximations, by use of the antecedent "about," it will be understood that the particular value forms another embodiment.

[0522] Where a nucleic acid sequence is disclosed herein, its reverse complement is also expressly contemplated.

[0523] The methods described herein can be performed in vitro or in vivo. In some embodiments, the methods described herein are performed in vitro. The term "in vitro" is intended to cover experiments with cells in culture, while the term "in vivo" is intended to cover experiments with intact multicellular organisms. BRIEF DESCRIPTION OF THE DRAWINGS

[0524] Embodiments and experiments illustrating the principles of the present invention will now be discussed with reference to the accompanying drawings.

[0525] Figure 1 . Alignment of the amino acid sequences of mouse Sun1, mouse Sun2, human Sun1, and human Sun2. The amino acid sequences starting from 6 amino acids upstream of the lumenal domain were aligned using ClustalOmega software. The residues and domains of interest are indicated.

[0526] Figure 2 Schematic representation of human SUN1 protein and various constructs characterized in Example 1 (ie, constructs (A) to (H)). The domain structure of the lumenal domain of human SUN1 included in the constructs is shown.

[0527] Figure 3Schematic diagram and micrographs showing the results of an analysis of the ability of different putative dominant negative SUN1 constructs to achieve LINC complex disruption as determined by an increase in ER-localized Nesprin-2. Arrows in micrographs indicate cells expressing high levels of the relevant construct. Whether the construct was determined to cause Nesprin-2 localization is indicated.

[0528] Figure 4 Schematic representation of the human SUN1 protein and various constructs characterized in Example 5 (i.e., constructs A, D, D2, E, and G). The domain structure of the lumenal domain of human SUN1 included in the construct is shown. The length of the SUN1 derived sequence + KDEL is shown.

[0529] Figures 5A to 5D Figure . shows the results of the analysis of the efficacy of different putative dominant negative SUN1 constructs in a mouse model of dilated cardiomyopathy. Briefly, Lmna carrying a cardiac-specific Cre FF:mcm Mice were injected with tamoxifen (TMX) to induce Lmna deletion. After 17 days of TMX treatment, mice were given a single dose (1*10 14 vg / kg) of AAV9 encoding DNhSUN1_201aa ('201aa'; Figure 4 Construct G), DNhSUN_1255aa('255aa'; Figure 4 Construct E), DNh SUN1_334aa ('334aa'; attached Figure 4 construct D2) or DNh SUN_1457aa ('457aa'; see Figure 4 As a control condition, wild-type mice (WT) or Lmna mice given TMX from day 17 under the control of the cTNT promoter were FF:mcm Mice (DCM) were given a single dose (1*10 14vg / kg) of AAV9 encoding GFP. Survival rate was monitored, cardiac function was assessed by echocardiography, and left ventricular internal diameter (LVID) and left ventricular posterior wall (LVPW) thickness during diastole and systole were assessed by ultrasound. (5A) shows the survival percentage of mice in different treatment groups over time. For each group, N=6. ***Long-rank (Mantel Cox) P=0.0005, pairwise comparison with DCM control. (5B) shows the short-axis shortening fraction (FS) and ejection fraction (EF) of mice in different treatment groups over time. **Mann-Whitney P<0.0087, compared with DCM control group. Data are expressed as mean ± standard deviation. (5C and 5D) show the left ventricular internal diameter (LVID; 5C) in diastole (d) and systole (s) over time; and left ventricular posterior wall (LVPW) thickness (5D), respectively. Data are expressed as mean ± standard deviation.

[0530] Figures 6A to 6D Figure . shows the results of the analysis of the efficacy of different putative dominant negative SUN1 constructs in a mouse model of dilated cardiomyopathy. Briefly, Lmna carrying a cardiac-specific Cre FF:mcm Mice were injected with tamoxifen (TMX) to induce the loss of Lmna. After 17 days of TMX treatment, mice were given a single dose (1*10 14 vg / kg) encoding DNhSUN1_322aa('322aa'; Figure 4 ) or DNhSUN_1457aa ('457aa'; Figure 4 As a control condition, wild-type mice (WT) or Lmna mice given TMX from day 17 were injected with AAV9 under the control of the cTNT promoter. FF:mcm Mice (DCM) were given a single dose (1*10 14vg / kg) of AAV9 encoding GFP. Survival rate was monitored, cardiac function was assessed by echocardiography, and left ventricular inner diameter (LVID) and left ventricular posterior wall (LVPW) thickness during diastole and systole were assessed by ultrasound. (6A) Shows the survival percentage of mice in different treatment groups over time. 322aa group N=6, 457aa group N=6, DCM group N=5, WT group N=7. ***Long-rank (Mantel Cox) P<0.0007, compared with the DCM control group. Data are expressed as mean ± SD. (6B) Shows the fractional shortening (FS) and ejection fraction (EF) of mice in different treatment groups over time. **Mann-Whitney P<0.0095, compared with the DCM control group. Data are expressed as mean ± SD. (6C and 6D) show left ventricular internal diameter (LVID) in diastole (d) and systole (s), respectively; 6C and left ventricular posterior wall (LVPW) thickness (6D) over time. Data are presented as mean ± SD.

[0531] Example 1: In vitro analysis of the inhibitory effect of different dominant negative SUN1 constructs on the LINC complex

[0532] 1.1 Materials and methods

[0533] 1.1.1 Bioinformatics

[0534] The amino acid sequences of proteins containing SUN domains and their homologs were obtained from NCBI and Uniprot. Sequence alignment was performed using ClustalOmega (https: / / www.ebi.ac.uk / Tools / msa / clustalo). Domain analysis was performed using SMART (http: / / smart.embl-heidelberg.de / ).

[0535] 1.1.2 Molecular biology

[0536] DNA sequences encoding the full-length DNSUN1 coding sequence and its truncated variants were synthesized and cloned into the pTwistEF1-Alpha plasmid. The nucleic acid encoding the DNSUN1 construct consists of a human serum albumin signal sequence at the N-terminus, followed by an HA tag and an ALFA tag, followed by one of the various truncated luminal SUN1 domain sequences, followed by a KDEL sequence at the C-terminus. The amino acid sequences of the dominant negative human SUN1 (DNhSUN1) constructs characterized in the disclosed embodiments are shown in SEQ ID NOs: 80-87 and 96, and their sequence features are as follows Figure 1 , 2 and 4.

[0537]

[0538] 1.1.3 Cell culture and transfection

[0539] HeLa cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 4.5 g / L D-glucose, 4 mM L-glutamine, 1 mM sodium pyruvate, 10% fetal bovine serum and 100 U / ml penicillin; 100 mg / ml streptomycin at 37°C and 5% CO2. For immunofluorescence studies, cells were seeded on coverslips or 8-well slides (ibidi, catalog #80826). For each well in the 8-well slide, 200 ng of plasmid DNA encoding a putative dominant negative SUN1 construct was transfected for 15 minutes by adding a preformed transfection complex containing 0.3 ml Lipofectamine 3000 (Invitroen) and 0.2 ml P3000 reagent (Invitrocen) per 100 ng of plasmid DNA in Opti-MEM medium (Invitrogen).

[0540] 1.1.4 Immunofluorescence microscopy

[0541] The day after transfection, HeLa cells were fixed in cold methanol at -20°C for 10 min, and permeabilized and blocked in blocking buffer containing 3% bovine serum albumin and 0.5% Trixon X-100 in phosphate-buffered saline (PBS) for 30 min.

[0542] Anti-Nesprin-2 mouse monoclonal antibody, anti-ALFA antibody (conjugated with Abberior Star580) -X2 anti-ALFA, NanoTag Biotechnologies N1502-Ab580-L) to detect the relevant DNSUN1 constructs, and a mouse monoclonal anti-lamin B2 antibody was used to stain the nuclear membrane. Cells were incubated in primary antibodies in blocking buffer for 1-2 hours at room temperature. After primary antibody incubation, cells were washed three times with 0.5% Triton X-100 in PBS and then incubated with fluorophore-conjugated mouse antibody isotype-specific secondary antibodies (Thermo Fisher Scientific A-21121, goat anti-mouse IgG1 conjugated with Alexa Fluor 488 and A-21242, goat anti-mouse IgG2b conjugated with AlexeFluor647) and Hoechst to stain DNA for 30 minutes-1 hour at room temperature. Cells were washed again and then mounted in Extended Diamond or 1% DABCO (1,4-diazabicyclo[2.2.2]octane) in 10% PBS / 90% glycerol. Widefield epifluorescence imaging was performed on an Olympus IX-83 with a motorized stage and equipped with a 20x 0.45NA LUCPlan FL N or 40x 0.6NA Ph2 LUCPlan FLN objective. Digital images were captured using CellSens software and processed using Fiji software.

[0543] 1.2 Results

[0544] The inventors evaluated the ability of different truncated variants of SUN1 that included a C-terminal KDEL sequence to determine which regions of SUN1 were required for the protein to function as a dominant negative SUN1 protein, thereby achieving LINC complex inhibition. Specifically, the inventors investigated the role of two coiled-coil regions identified by SMART domain analysis, such as the CC1 and CC2 domains described in Xu et al., 2018, and the involvement of three alpha helices of the CC2 region.

[0545] The lumen regions of human SUN1, human SUN1, mouse SUN1, and mouse SUN2 are arranged as follows Figure 1 shown.

[0546] The different truncated variants studied in this example are Figure 2 shown.

[0547] The ability of DNSUN1 to act as a dominant negative inhibitor of the LINC complex was assessed by transiently expressing different truncated SUN1 constructs in cells and subsequently assessing the subcellular localization of the KASH domain-containing protein Nesprin-2. At low expression levels, DNSUN1 localizes to the nuclear membrane in the perinuclear space. When expressed at high levels, DNSUN1 localizes throughout the lumen of the endoplasmic reticulum, which is the same membrane compartment as the perinuclear space. See Crisp et al., 2006.

[0548] In cells expressing high levels of dominant-negative SUN domain-containing LINC complex inhibitory proteins, the normal nuclear membrane localization of KASH domain-containing proteins is disrupted, and KASH domain-containing proteins are localized to the endoplasmic reticulum due to the large excess of dominant-negative proteins competing with endogenous SUN domain-containing proteins for interaction with KASH domain-containing proteins. This can be easily visualized by using antibodies specific for KASH domain-containing proteins by immunofluorescence microscopy.

[0549] In the present study, plasmids encoding different truncated SUN1 constructs were expressed in HeLa cells by transient transfection, and DNSUN1 and Nesprin-2 (a KASH domain-containing protein highly expressed in HeLa cells) in the cells were subsequently analyzed by immunofluorescence staining.

[0550] The results are as follows Figure 3 As expected, full-length DNSUN1 (i.e., protein having the amino acid sequence of SEQ ID NO:80; DNhSUN1_457aa), which has previously been shown to disrupt the LINC complex in HeLa cells and suppress pathology of LMNA-associated mutations in a mouse model of laminopathy, was found to displace Nesprin-2 from the nuclear envelope. Also as expected, a DNSUN1 construct containing only the SUN domain (i.e., encoding a protein having the amino acid sequence of SEQ ID NO:87; DNhSUN1_181aa), lacking any coiled-coil domain preceding its alpha helix to promote multimerization, failed to displace Nesprin-2.

[0551] Unexpectedly, all other DNhSUN1 constructs tested (DNhSUN1_413aa, DNhSUN1_362aa, DNh-SUN1_322aa, DNh3UN1_255aa, DNhhSUN1_216aa, and DNhSUN1_201aa) were able to displace Nesprin-2 from the nuclear envelope into the endoplasmic reticulum, despite previous studies expecting that some constructs would be unable to interact with proteins containing the KASH domain.

[0552] Nie et al., 2016 and Jahed et al., 2018b disclosed that a truncated variant of Sun2 containing the complete CC2 domain and the SUN domain was inhibited by the CC2 region from forming a trimeric complex required for interaction with the KASH domain of Nesprin-2. Similarly, Sosa et al., 2012 reported that a truncated variant of Sun2 containing the α3 helix of the CC2 domain and the SUN domain could not bind to KASH.

[0553] However, in the current study, a SUN1-based homology construct was found to disrupt the normal localization of Nesprin-2, thereby functioning as an inhibitor of the LINC complex.

[0554] 1.3 Discussion

[0555] In this example, the inventors demonstrated that a series of different lengths of the SUN1 lumenal domain sequence (as shown in SEQ ID NO: 43, 44, 63-67 and 94) can affect the disruption of the LINC complex. Surprisingly, previous structural and biochemical studies of the lumenal domain of the SUN protein could not predict the effect of truncating the SUN1 lumenal domain in the DNSUN1 construct of the present invention.

[0556] The characterized dominant negative SUN1 protein can achieve LINC complex disruption by forming multimers (e.g., trimers) that behave as competitive inhibitors of the binding of endogenous SUN domain-containing proteins to KASH domain-containing proteins. The fact that only low levels of dominant negative SUN1 protein are localized to the nuclear membrane suggests that dominant negative SUN1 protein can also achieve LINC complex disruption by forming hetero-oligomers with endogenous SUN domain-containing proteins, thereby weakening the connection between the cytoskeleton and the nuclear lamina mediated by the intact LINC complex.

[0557] The dominant negative SUN1 construct may form hetero-oligomers with endogenous SUN proteins, even though they cannot homo-trimerize. This may explain why truncated lumenal SUN proteins that are reported to be monomeric and unable to bind KASH in vitro may still be able to disrupt the LINC complex, as shown in this example. Alternatively, the in vitro environment in which the binding and gel filtration experiments were performed may simply be biochemically different from the cellular environment and therefore cannot predict the function of the truncated lumenal SUN proteins in cells.

[0558] Example 2: Further in vitro analysis of the inhibitory effects of different dominant negative SUN constructs on the LINC complex

[0559] In further experiments, the present inventors characterized the function of all possible truncation mutants of the lumenal domains of human SUN1 and human SUN2 as LINC complex inhibitors.

[0560] Briefly, constructs were prepared as described in Example 1.1.2 (i.e., comprising an N-terminal signal peptide, an HA / ALFA tag, and a protein-derived region containing a SUN domain and a C-terminal KDEL motif), except that each possible truncation mutant of the SUN1 lumenal domain from SUN1(361-812) to SUN1(636-812) was prepared (i.e., SUN1(362-812), SUN1(363-812), and SUN1(364-812), etc.).

[0561] Similarly, every possible truncation mutant of the SUN2 lumenal domain from SUN2(258-717) to SUN2(522-717) was prepared (ie, SUN2(259-717), SUN2(260-717), SUN2(261-717), and SUN2(262-717), etc.).

[0562] As described in Example 1.1, the ability of different constructs to disrupt the normal subcellular localization of Nesprin-2 in HeLa cells was assessed.

[0563] All constructs evaluated that included at least the α3 helix and the SUN domain of the CC2 region (i.e., constructs that included at least positions 616-812 of human SUN1 and constructs that included at least positions 522-717 of human SUN2) were determined to displace Nesprin-2 at the nuclear membrane and enter the endoplasmic reticulum and therefore function as LINC complex inhibitors.

[0564] Example 3: In vivo demonstration of the LLNC complex inhibitory polypeptides characterized in Examples 1 and 2 for the treatment of lamins associated with Lmna mutations Effect of disease

[0565] AAV or a lentiviral vector encoding a nucleic acid of the LINC complex inhibitory polypeptide described in Examples 1 and 2, or a nanoparticle comprising the nucleic acid is administered to mice having a mouse model of Lmna mutation-associated cardiomyopathy, muscular dystrophy, and progeria.

[0566] Mouse models of Lmna mutation-associated muscular dystrophy include conditional Lmna knockout mice. Flx / Flx The generation of Lmna mice and MLC-Cre mice is described in Wang et al., Differentiation, (2015) 89(1-2): 11-21 and Mourkioti et al., Genesis. (2008) 46(8): 424-30. Flx / Flx Mice were crossed with MLC-Cre mice to obtain Lmna Flx / + ;MLC-Cre mice, which were then crossed with LmnaFlx / + Mice hybridization to generate Lmna Flx / Flx ; MLC Cre, providing conditional knockout of Lmna in muscle cells.

[0567] Mouse models of Lmna mutation-associated cardiomyopathy and muscular dystrophy include Lmna-H222P mice described in Arimura et al., Hum Mol Genet. (2005) 14(1): 155-69, Lmna-N195K mice described, for example, in Mounkes et al., Hum Mol Genet. (2005) 14(15): 2167-80, and conditional Lmna deletion-associated mouse models of dilated cardiomyopathy, for example, described in Chai et al., Nat Commun (2021) 12(1): 4722 (see Example 5.1 below).

[0568] Mouse models of Lmna mutation-associated progeria, including the Lmna-G609G mouse, are described in Osori et al., Sci-Transl Med. (2011) 3(106): 106ra107.

[0569] Mice with Lmna mutation-associated cardiomyopathy administered with a nucleic acid encoding a LINC complex inhibitory polypeptide described in Example 1 or 2 have improved cardiac function (e.g., increased myocardial contractility, increased ejection fraction, and / or increased fractional shortening) compared to untreated mice or mice treated with a vector alone (e.g., an empty vector).

[0570] Mice with Lmna mutation-associated muscular dystrophy or Lmna variant-associated progeria administered with a nucleic acid encoding a LINC complex inhibitory polypeptide described in Example 1 or 2 have an extended lifespan compared to untreated mice or mice treated with a vector alone (eg, an empty vector).

[0571] Example 4: In vivo testing of the LINC complex inhibitory polypeptides characterized in Examples 1 and 2 for treating hyperlipidemia certificate

[0572] An AAV or lentiviral vector encoding the nucleic acid encoding the LINC complex inhibitory polypeptide described in Examples 1 and 2, or a nanoparticle comprising the nucleic acid, is administered to mice having a mouse model of atherosclerosis and familial hypercholesterolemia.

[0573] Mouse models of atherosclerosis and familial hypercholesterolemia were established by feeding Ldlr knockout mice (C57BL / 6JInv, Jackson Laboratory) a Western diet (WTD; D12079B, Research Diets, NJ) for 15 weeks.

[0574] Compared to untreated mice or mice treated with a vector alone (e.g., an empty vector), Ldlr mice with atherosclerosis and familial hypercholesterolemia administered with a nucleic acid encoding a LINC complex inhibitory polypeptide described in Example 1 or 2 had significantly increased risk of developing atherosclerosis. - / - mice, had smaller, less advanced, and less complex atherosclerotic lesions.

[0575] Example 5: In vivo evaluation of the efficacy of different LINC complex inhibitory peptides

[0576] The present inventors next investigated the ability of different DNhSUN1 LINC complex inhibitory peptides to treat LNMA mutation-associated dilated cardiomyopathy in vivo in a mouse model.

[0577] 5.1 Materials and methods

[0578] Preparation of AAV encoding LINC complex inhibitory peptide

[0579] The coding sequence of the DNhSUN1 construct was PCR amplified from the synthesized gene, restriction digested, and ligated into an AAV transfection plasmid containing the cTnT cardiac promoter, chimeric intron, WPRE (Woodchuck hepatitis virus post-transcriptional regulatory element) and bovine growth hormone polyA tail. An AAV transfection plasmid containing the GFP coding sequence was also prepared for the preparation of AAV vector GFP, which was used as an experimental control. The LINC complex inhibitory polypeptides used in the experiments of this example differ from those of Example 1 in that they contain a minimal human serum albumin signal peptide (SEQ ID NO: 100) and lack HA and ALFA tags:

[0580]

[0581] Adeno-associated virus was produced by transient triple transfection of HEK293T cells with an adenoviral helper plasmid, a rep / cap plasmid encoding AAV2-rep and AAV9-cap, and a transgene-specific plasmid. Four days after transfection, the cell pellet and supernatant were harvested. The supernatant was clarified by filtration and applied to the POROS by gravity flow. TM CaptureSelect TMAAV9 affinity resin (Thermo Fisher Scientific, Waltham, MA, USA). Cells were resuspended in lysis buffer (phosphate-buffered saline, 200 mM NaCl, 0.001% Pluronic F-68), lysed by 4-5 cycles of freeze / thaw, sonicated, and treated with benzoic acid enzymes to shear and digest DNA. Cell debris was pelleted by centrifugation, and the cell lysate was collected and filtered through a 0.45 μm syringe filter. The filtered lysate was then applied to the AAV9 affinity resin by gravity flow. After washing with wash buffer (phosphate-buffered saline, 500 mM NaCl), AAV9 viral particles were eluted using 100 mM glycine (pH 2.5) and collected in a microcentrifuge tube containing 1 / 10 volume of 1 M Tris (pH 8). After 2 rounds of buffer exchange into PBS containing 0.01% Pluronic F-68 and passed through After concentration using an Ultra 100KDA concentrator (Merck KGaA, Darmstadt, Germany), the solution containing AAV virions was filtered through a 0.22 μm 4 mm Millex syringe filter unit (Merck KGaA, Dalmstadt) and stored at 4° C. or −80° C. Plasmid DNA standards (Kohlbrenner and Weber, Methods Mol. Biol. (2017) 1521: 91-107) were used, and gel imaging was performed on a ChemiDoc imaging system (Bio-Rad Laboratories, Hercules, CA, USA), and image quantification was performed using image Lab software (Bio-Rad Laboratories).

[0582] Lmna-deficient dilated cardiomyopathy (DCM) mouse model

[0583] The mouse strains were housed in a ventilated animal barrier facility at 21 ± 1 °C and 55–70% humidity with food and water provided ad libitum and maintained on a 12-h light–dark cycle in compliance with all ethical regulations.

[0584] To generate Lmna-deficient mouse models of dilated cardiomyopathy, Wang et al., Differentiation. (2015) 89(1-2): 11-21, described conditional “knockout” or “suspension” Lmna Flx / FlxMice of the Lmna strain were crossed with mice carrying a tamoxifen-inducible Cre recombinase under the control of the cardiomyocyte-specific α-myosin heavy chain promoter (αMHC-MerCreMer, abbreviated as mcm) purchased from the Jackson Laboratory (JAX stock number 005657; see also Chai et al., Nat Commun (2021) 12(1):4722). FF:mcm Dilated cardiomyopathy was induced in mice by intraperitoneal injection of 40 mg / kg tamoxifen on postnatal day 14 (P14), resulting in specific deletion of Lmna in cardiomyocytes. A solution of tamoxifen (Merck) (16 g / L) was prepared in corn oil (Sigma).

[0585] In vivo delivery of adeno-associated virus

[0586] 17 days after tamoxifen treatment, 1x10 14 Mice were retro-orbitally injected with different AAV9 at a dose of 100 vg / kg. Animals were randomly selected. TMX and AAV9 injections were performed under anesthesia using 1.5% isoflurane mixed with oxygen. AAV9 dilutions were freshly prepared in PBS containing 0.001% Pluronic F-68 before administration.

[0587] Echocardiography

[0588] Cardiac function was assessed by ultrasound recording using Prospect-T1 (Sharp-S). Mice were shaved 1 day before ultrasound examination. Animals were anesthetized with 1.5% isoflurane mixed with oxygen. B-mode and M-mode readings were taken at heart rates between 450bpm and 350bpm. Fractional shortening (FS) and ejection fraction (EF) were calculated from the parasternal long axis using the device's software analysis tool. Cardiac measurements of left ventricular internal diameter (LVID) and left ventricular posterior wall (LVPW) were taken in the diastolic (d) and systolic (s) states of the parasternal short axis.

[0589] 5.2 Results and Discussion

[0590] In the first experiment, P14 Lmna carrying the cardiac-specific Cre recombinase FF:mcm Mice were injected with tamoxifen (TMX) to induce deletion of the Lmna gene. After 17 days of TMX treatment, mice were given a single dose (1x1014 vg / kg) of a gene encoding DNhSUN1_201aa ( Figure 4 Construct G), DNhSUN_1255aa ( Figure 4 Construct E), DNh SUN1_334aa ( Figure 4Construct D2) or DNh SUN_1457aa ( Figure 4 As a control condition, wild-type mice (WT) or Lmna mice given TMX from day 17 were injected with AAV9 under the control of the cTNT promoter. FF:mcm Mice (DCM) were given a single dose (1x10 14 vg / kg) of AAV9 encoding GFP. Survival was monitored, cardiac function was assessed by echocardiography, and left ventricular internal diameter (LVID) and left ventricular posterior wall (LVPW) thickness were assessed by ultrasound during diastole (d) and systole.

[0591] The results are as follows Figures 5A to 5D shown.

[0592] Figure 5A Treatment with all DNhSUN1 variants showed an increase in median lifespan compared to DCM control animals (39 days). The shortest construct, DNhSUN1_201aa (Construct G), had the shortest lifespan extension at 66.5 days. Mice treated with DNhSUN1_334aa (Construct D2) survived an average of 214.5 days, surpassing the full-length DNhSUN_1-457aa (Construct A) which survived 162.5 days. Animals treated with DNhSUN1_255aa (Construct E) showed the longest lifespan extension; only 2 animals died, and 4 mice were still alive after 275 days.

[0593] Figure 5B Treatment with AAV encoding DNhSUN1_201aa, DNhSUN_1.255a, DNhSUN1_334aa, or DNhSUN1T457aa improved cardiac function in Lmna DCM mice. Echocardiographic analysis showed that at 17 days after AAV9 administration (i.e., day 31 after TMX administration), Lmna treated with all AAV9-cTnT-DNhSUN1 truncation variants showed a significant improvement in cardiac function compared with AAV9-cTnT-GFP treated mice (DCM). FF:mcm The shortening fraction (FS) and ejection fraction (EF) were significantly improved.

[0594] Figure 5C and 5DThe results showed that Lmna DCM mice had increased LVID and decreased LVPW, which was more obvious during systole. In mice treated with DNhSUN1_201aa (Construct G), left ventricular dilation and thinning of the heart wall occurred earlier than in other DNhSUN1 variants (DNhSUN1_255a / Construct E, DNhSUN_334a / Construct D2, DNhSUN1_457aa / Construct A), which correlated with decreased cardiac function and early onset of DCM in mice treated with AAV delivering DNhSUN1_201aa.

[0595] Thus, AAV encoding DNhSUN1_201aa, DNhSUN1_255a, DNhSUN1_334aa or DNhSUN1T457aa was found to treat Lmna deficiency-associated DCM. DNhSUN1_201aa was found to extend lifespan to a lesser extent than DNhSUN1_457aa, whereas DNhSUN_1334aa and DNhSUN_255aa extended lifespan to a greater extent than DNh SUN1_457aa.

[0596] In the second experiment, the efficacy of DNhSUN1_322aa was compared with that of DNhSUN_1457aa. FF:mcm Mice were injected with tamoxifen (TMX) to induce deletion of the Lmna gene. After 17 days of TMX treatment, mice were given a single dose (1x 10 14 vg / kg) encoding DNhSUN1_322aa ( Figure 4 Construct D) or DNhSUN1_457aa ( Figure 4 As a control condition, wild-type mice (WT) or Lmna mice given TMX from day 17 were injected with AAV9 under the control of the cTNT promoter. FF:mcm Mice (DCM) were given a single dose (1x 10 14 vg / kg) of AAV9 encoding GFP. Survival was monitored, cardiac function was assessed by echocardiography, and left ventricular internal diameter (LVID) and left ventricular posterior wall (LVPW) thickness were assessed by ultrasound during diastole (d) and systole (s).

[0597] The results are as follows Figures 6A to 6D shown.

[0598] Fig. 6AThe results showed that treatment with AAV encoding DNhSUN1_322aa or DNhSUN_1457aa prolonged median lifespan compared to DCM control animals, which had an average survival of 39 days. All mice in the groups given AAV encoding DNhSUN1_322aa or DNhSUN_1_457aa were still alive at day 170.

[0599] Figure 6B Echocardiographic analysis showed that 17 days after AAV9 administration (i.e., day 31 after TMX administration), Lmna mice treated with AAV9 delivering the 322aa or DNhSUN1_457aa variants had improved cardiac function compared with mice (DCM) treated with AAV9-cTNT-GFP. FF:mcm The shortening fraction (FS) and ejection fraction (EF) were significantly improved.

[0600] Figure 6C and 6D The results showed that Lmna DCM mice had increased LVID and decreased LVPW, which was more pronounced during the systolic phase. AAV9-cTnT-DNhSUN1-treated animals survived longer than DCM control animals, had increased LVID, and had stable LVPW without a decrease.

[0601] Therefore, AAV encoding DNhSUN1_322aa or DNhSUN1_457aa was found to be able to treat Lmna deficiency-associated DCM.

[0602] References

[0603] Burke, B., and CL Stewart. 2013. The nuclear lamins: flexibility in function. Nat Rev Mol Cell Biol. 14:1324. doi:10.1038 / nrm3488.

[0604] Crisp, M., Q. Liu, K. Roux, JBRattner, C. Shanahan, B. Burke, PDStahl, and D. Hodzic. 2006. Coupling of the nucleus and cytoplasm: role of the LINCcomplex. J. Cell Biol. 172: 41-53. doi: 10.1083 / jcb.200509124.

[0605] Gurusaran,M.,and O.R.Davies.2021.A molecular mechanism for LINCcomplex branching by structurally diverse SUN-KASH 6:6 assemblies.eLife.10:e60175.doi:10.7554 / eLife.60175.

[0606] Jahed,Z.,D.Fadavi,U.T.Vu,E.Asgari,G.W.G.Luxton,andM.R.K.Mofrad.2018a.Molecular Insights into the Mechanisms of SUN1Oligomerization in the Nuclear Envelope.Biophysical Journal.114:11901203.doi:10.1016 / j.bpj.2018.01.015.

[0607] Jahed,Z.,U.T.Vu,D.Fadavi,H.Ke,A.Rathish,S.C.J.Kim,W.Feng,M.R.K.Mofrad,and V.M.Weaver 2018b.A molecular model for LINC complexregulation:activation of SUN2 for KASH binding.MBoC.29:2012-2023.doi:10.1091 / mbc.E18-04-0266.

[0608] Lee,Y.L.,and B.Burke.2018.LINC complexes and nuclearpositioning.Seminars in Cell&Developmental Biology.82:67-76.doi:10.1016 / j.semcdb.2017.11.008.

[0609] McCarty,D.M.2008.Self-complementary AAV Vectors;Advances andApplications.Molecular Therapy.16:1648-1656.doi:10.1038 / mt.2008.171.

[0610] Nie,S.,H.Ke,F.Gao,J.Ren,M.Wang,L.Huo,W.Gong,and W.Feng.2016.Coiled-Coil Domains ofSUN Proteins as Intrinsic Dynamic Regulators.Structure.24:80-91.doi:10.1016 / j.str.2015.10.024.Sosa,B.A.,A.Rothballer,U.Kutay,andT.U.Schwartz.2012.LINC complexes form by binding of three KASH peptides todomain interfaces of trimeric SUN proteins.Cell.149:1035-1047.doi:10.1016 / j.cell.2012.03.046.

[0611] Wang,W.,Z.Shi,S.Jiao,C.Chen,H.Wang,G.Liu,Q.Wang,Y.Zhao,M.I.Greene,andZ.Zhou.2012 Structural insights into SUN-KASH complexes across the nuclearenvelope.Cell Res.22:1440-1452.doi:10.1038 / cr.2012.126.

[0612] Xu,Y.,W.Li,H.Ke,and W.Feng.2018.Structural conservation of theautoinhibitory domain in SUNproteins.Biochem.Biophys.Res.Commun.496:1337-1343.doi:10.1016 / j.bbrc.2018.02.015.

[0613] Zhou,Z.,X.Du,Z.Cai,X.Song,H.Zhang,T.Mizuno,E.Suzuki,M.R.Yee,A.Berezov,R.Murali,S.-L.Wu,B.L.Karger,M.I.Greene,and Q.Wang.2012.Structure ofSad1-UNC84 Homology(SUN)Domain Defines Features of Molecular Bridge inNuclear Envelope.J.Biol.Chem.287:5317-5326.doi:10.1074 / jbc.M111.304543.

Claims

1. A nucleic acid encoding a LINC complex inhibitory polypeptide, wherein the LINC complex inhibitory polypeptide comprises: (i) an inhibitory region comprising an amino acid sequence corresponding to the α3 helix of the CC2 region and the SUN domain of a protein containing a SUN domain, and (ii) an endoplasmic reticulum retention motif; And the LINC complex inhibitory polypeptide does not comprise the amino acid sequence of any one of SEQ ID NO:43, 45 or 58.

2. The nucleic acid of claim 1, wherein the inhibitory region of the LINC complex inhibitory polypeptide consists essentially of: (i) an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 66; (ii) an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO:94; or (iii) an amino acid sequence that has at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 65; or (iv) an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 63; or (v) an amino acid sequence that has at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 64; or (vi) an amino acid sequence having at least 80% amino acid sequence identity with the amino acid sequence of SEQ ID NO:

67.

3. The nucleic acid of claim 1 or claim 2, wherein the LINC complex inhibitory polypeptide comprises or consists essentially of: (i) an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 72; (ii) an amino acid sequence that has at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO:95; or (iii) an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 71; or (iv) an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 69; or (v) an amino acid sequence that has at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO:70; or (vi) an amino acid sequence having at least 80% amino acid sequence identity with the amino acid sequence of SEQ ID NO:

73.

4. The nucleic acid of any one of claims 1-3, wherein the LINC complex inhibitory polypeptide comprises a signal peptide.

5. The nucleic acid according to any one of claims 1 to 4, wherein the nucleic acid is a vector suitable for delivering a nucleic acid encoding a LINC complex inhibitory polypeptide for gene therapy.

6. The nucleic acid of claim 5, wherein the vector is an adeno-associated virus (AAV) vector.

7. A LINC complex inhibitory polypeptide, comprising: (i) an inhibitory region comprising an amino acid sequence corresponding to the α3 helix of the CC2 region and the SUN region of a SUN domain-containing protein, and (ii) an endoplasmic reticulum retention motif; And wherein the LINC complex inhibitory polypeptide does not comprise the amino acid sequence of SEQ ID NO: 43 or 45.

8. The LINC complex inhibitory polypeptide of claim 7, wherein the inhibitory region of the LINC complex inhibitor polypeptide consists essentially of: (i) an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 66; (ii) an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO:94; or (iii) an amino acid sequence that has at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 65; or (iv) an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 63; or (v) an amino acid sequence that has at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 64; or (vi) an amino acid sequence having at least 80% amino acid sequence identity with the amino acid sequence of SEQ ID NO:

67.

9. The LINC complex inhibitory polypeptide according to claim 7 or claim 8, wherein the LINC complex inhibitory polypeptide comprises or consists essentially of: (i) an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 72; (ii) an amino acid sequence that has at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO:95; or (iii) an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 71; or (iv) an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 69; or (v) an amino acid sequence that has at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO:70; or (vi) an amino acid sequence having at least 80% amino acid sequence identity with the amino acid sequence of SEQ ID NO:

73. 10 . The LINC complex inhibitory polypeptide according to any one of claims 7 to 9 , wherein the LINC complex inhibitory polypeptide comprises a signal peptide.

11. A method for identifying a LINC complex inhibitory polypeptide, comprising: introducing a nucleic acid encoding a candidate LINC complex inhibitory polypeptide, wherein the candidate LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to a SUN domain of a protein containing a SUN domain; and The cells were then analyzed to determine the subcellular localization of the interacting partners of the SUN domain-containing proteins; When a change in the subcellular localization of an interacting partner of a SUN domain-containing protein is detected, a candidate LINC complex inhibitory polypeptide is identified as a LINC complex inhibitory polypeptide.

12. A method for identifying a LINC complex inhibitory polypeptide, comprising: introducing a nucleic acid encoding a candidate LINC complex inhibitory polypeptide, wherein the candidate LINC complex inhibitory polypeptide comprises an amino acid sequence corresponding to a KASH domain of a KASH domain-containing protein; and The cells were then analyzed to determine the subcellular localization of the interacting partners of the KASH domain-containing proteins; When a change in the subcellular localization of an interacting partner of a KASH domain-containing protein is detected, a candidate LINC complex inhibitory polypeptide is identified as a LINC complex inhibitory polypeptide.

13. The method according to claim 11 or claim 12, wherein when an increase in the ratio of interacting partners of the protein containing the SUN / KASH domain localized in the endoplasmic reticulum is detected, the candidate LINC complex inhibitor polypeptide is identified as a LINC complex inhibitor polypeptide.

14. A LINC complex inhibitory polypeptide identified by the method according to any one of claims 11-13.

15. A nucleic acid encoding the LINC complex inhibitory polypeptide according to any one of claims 7 to 10 or claim 14. 16 . A vector comprising the nucleic acid according to claim 15 , wherein the vector is a vector suitable for delivering a nucleic acid encoding a LINC complex inhibitory polypeptide for gene therapy.

17. The vector of claim 16, wherein the vector is an adeno-associated virus (AAV) vector.

18. A cell comprising the nucleic acid according to any one of claims 1-6 or claim 15, the LINC complex inhibitory polypeptide according to any one of claims 7-10 or claim 14, or the vector according to claim 16 or claim 17.

19. A pharmaceutical composition comprising the nucleic acid according to any one of claims 1-6 or claim 15, the LINC complex inhibitory polypeptide according to any one of claims 7-10 or claim 14, the vector according to claim 16 or claim 17, or the cell according to claim 18.

20. A method for use in medical treatment or prevention using a nucleic acid according to any one of claims 1 to 6 or claim 15, a LINC complex inhibitory polypeptide according to any one of claims 7 to 10 or claim 14, a vector according to claim 16 or claim 17, a cell according to claim 18 or a pharmaceutical composition according to claim 19.

21. A method for treating or preventing laminopathy using a nucleic acid according to any one of claims 1 to 6 or claim 15, a LINC complex inhibitory polypeptide according to any one of claims 7 to 10 or claim 14, a vector according to claim 16 or claim 17, a cell according to claim 18 or a pharmaceutical composition according to claim 19.

22. Use of a nucleic acid according to any one of claims 1-6 or claim 15, a LINC complex inhibitory polypeptide according to any one of claims 7-10 or claim 14, a vector according to claim 16 or claim 17, a cell according to claim 18 or a pharmaceutical composition according to claim 19 in the preparation of a medicament for treating or preventing laminopathy.

23. A method for treating or preventing laminopathy, comprising administering to a subject a therapeutically or prophylactically effective amount of a nucleic acid according to any one of claims 1-6 or claim 15, a LINC complex inhibitory polypeptide according to any one of claims 7-10 or claim 14, a vector according to claim 16 or claim 17, a cell according to claim 18, or a pharmaceutical composition according to claim 19.

24. Use of a nucleic acid, a LINC complex inhibitory polypeptide, a vector, a cell or a pharmaceutical composition according to claim 21, the use according to claim 22 or the method according to claim 23, wherein the laminopathy is characterized by one or more of myopathy, cardiomyopathy, dilated cardiomyopathy, muscular dystrophy, cardiac myodystrophy, skeletal muscular dystrophy, progeria, neuropathy, lipodystrophy, skeletal dysplasia, lipodystrophy, leukodystrophy or skin disease.

25. Use, purpose or method of a nucleic acid, a LINC complex inhibitory polypeptide, a vector, a cell or a pharmaceutical composition according to any one of claims 21 to 24, wherein the laminopathy is associated with a LMNA mutation.

26. Use, purpose or method of a nucleic acid, LINC complex inhibitory polypeptide, vector, cell or pharmaceutical composition according to any one of claims 21 to 25, wherein the laminopathy is selected from: Hutchinson-Gilford Progeria Syndrome; Dilated Cardiomyopathy; Muscular Dystrophy, Congenital, Lmna-Associated; Emery Dreifuss muscular dystrophy type 2, autosomal dominant; muscular dystrophy; mandibular dysplasia with lipodystrophy type a; dilated cardiomyopathy, 1a; Charcot-Marie-Tooth disease; limb girdle muscular dystrophy; dilated cardiomyopathy with hypogonadism; Emery Dreifuss muscular dystrophy type 3, autosomal recessive; lipodystrophy, familial partial, type 2; Emery Dreifuss muscular dystrophy; Charcot-Marie-Tooth disease, axonal, type 2b1; heart-hand syndrome, Slovenian type; senility; familial partial lipodystrophy; restrictive skin disease, lethal; arrhythmogenic right ventricular cardiomyopathy; dental disease; heart disease; Werner syndrome; hypertrophic cardiomyopathy; left ventricular nonfilling; atrioventricular block; calcifications; acroosteolysis; autosomal dominant acrocardia; diabetes mellitus, non-insulin-dependent; osteoporosis; atrial fibrillation; atrial standstill 1; acanthosis nigricans; cardiac conduction defects; ventricular tachycardia with catecholaminergic polymorphism; mandibular dysplasia, deafness, anterior features, and lipodystrophy syndrome; sick sinus syndrome; Pelger-Huet anomaly; Charcot-Marie-Tooth disease, axonal, type 2e; congenital generalized lipodystrophy; restrictive cardiomyopathy; Congenital fiber-type disproportion; Congenital generalized lipodystrophy, type 1; Myofibrillar myopathy; Familial partial lipodystrophy, type 1; axonal neuropathy; atypical Werner syndrome; ovarian cystadenoma; Fanconi anemia, complement group a; BMI quantitative trait locus 11; skin diseases; myotonic muscular dystrophy 1 case; neuromuscular diseases; craniofacial dysmorphism syndrome; Bethlem myopathy 1; acquired generalized lipodystrophy; dilated cardiomyopathy, 1e; Congenital generalized lipodystrophy, type 4; Undifferentiated pleomorphic sarcoma; familial partial lipodystrophy, type 3; muscular dystrophy, congenital carnosine deficiency, 1a; proximal spinal cord muscular atrophy; dystrophic polysaccharide disorder, type B, 5; congenital muscular dystrophy, 1b; Reynolds syndrome; Wiedemann-Rautenstrauch syndrome; Emery Dreifuss muscular dystrophy 1, X-linked; congenital generalized lipodystrophy, type 2; monogenic diabetes mellitus; dilated cardiomyopathy, 1d; myopia, proximal and ophthalmoplegia; muscle tissue diseases; familial partial lipodystrophy, type 4; Dilated cardiomyopathy, 1 hour; second-degree atrioventricular block; median neuropathy; intrinsic cardiomyopathy; female genital prolapse; complete systemic lipodystrophy; myotonic muscular dystrophy; emergency; ulnar nerve injury; Acrocarpal muscular dystrophy type 1b; Lmna-related dilated cardiomyopathy; pelvic muscle wasting; Generalized lipodystrophy-associated progesterone syndrome; muscle disorders; Dilated cardiomyopathy, 1b; autosomal genetic disease; Familial isolated arrhythmogenic ventricular dysplasia, right dominant; Familial isolated arrhythmogenic ventricular dysplasia, biventricular type; Familial isolated arrhythmogenic ventricular dysplasia, left dominant; Lmna-related progeria of the carpel syndrome; and autosomal semidominant severe lipodystrophy layer disease.

27. A method for treating or preventing a disease characterized by hyperlipidemia using a nucleic acid according to any one of claims 1 to 6 or claim 15, a LINC complex inhibitory polypeptide according to any one of claims 7 to 10 or claim 14, a vector according to claim 16 or claim 17, a cell according to claim 18 or a pharmaceutical composition according to claim 19.

28. Use of a nucleic acid according to any one of claims 1 to 6 or claim 15, a LINC complex inhibitory polypeptide according to any one of claims 7 to 10 or claim 14, a vector according to claim 16 or claim 17, a cell according to claim 18 or a pharmaceutical composition according to claim 19 in the preparation of a medicament for treating or preventing a disease characterized by hyperlipidemia.

29. A method for treating or preventing a disease characterized by hyperlipidemia, comprising administering to a subject a therapeutically effective amount or a prophylactically effective amount of a nucleic acid according to any one of claims 1-6 or claim 15, a LINC complex inhibitory polypeptide according to any one of claims 7-10 or claim 14, a vector according to claim 16 or claim 17, a cell according to claim 18, or a pharmaceutical composition according to claim 19.

30. Use of a nucleic acid, a LINC complex inhibitory polypeptide, a vector, a cell or a pharmaceutical composition according to claim 27, the use according to claim 28 or the method according to claim 29, wherein the disease characterized by hyperlipidemia is selected from atherosclerosis, cardiovascular disease, stroke and familial hyperlipidemia.